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ABSTRACT 
Mycobacterium tuberculosis (M.tb) causes approximately 2 million deaths a year. There 
have been few new drugs developed to treat the disease and treatment courses are often 
complex owing to the emergence of drug resistance and the HIV epidemic. It is unknown 
whether lesions in human tuberculosis (TB) are hypoxic, nor whether this influences disease 
pathology.  Human TB is characterized by extensive lung destruction driven by host MMPs 
particularly collagenases such as MMP-1.  This thesis describes the investigation of hypoxia 
in patients with the specific tracer [18F]-Fluoromisonidazole (FMISO).  [18F]FMISO 
accumulated in regions of TB consolidation and around pulmonary cavities, demonstrating 
for the first time severe hypoxia in man. Dynamic imaging and Patlak Ki mapping showed 
heterogenous levels of oxygenation within and between patients.  In M.tb-infected human 
macrophages, hypoxia (1% pO2) upregulated MMP-1 gene expression 2,800-fold, driving 
secretion and caseinolytic activity.  Dimethyloxalyl glycine (DMOG), a small molecule 
inhibitor which stabilizes HIF-1α, similarly upregulated MMP-1.  Hypoxia did not affect 
mycobacterial replication.  Hypoxia increased MMP-1 expression in primary respiratory 
epithelial cells via TB-dependent networks.   HIF-1α and NF-κB regulated increased MMP-1 
activity in hypoxia. Furthermore, M.tb infection drove HIF-1α accumulation even in 
normoxia, and epithelioid macrophages and multi-nucleate giant cells in human TB lung 
biopsies expressed HIF-1α.  HIF-1α blockade including by targeted siRNA inhibited TB-driven 
MMP-1 gene expression and secretion.  Human TB lesions are severely hypoxic and M.tb 
directly drives HIF- 1α accumulation, thereby synergistically increasing collagenase activity 
leading to cavitation and disease transmission. 
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CHAPTER 1:  INTRODUCTION 
1.1 Background 
Tuberculosis (TB) is an infection caused by Mycobacterium tuberculosis (M.tb).  Tuberculosis 
is a major global health burden and is the second leading cause of death from an infectious 
disease after the human immunodeficiency virus (HIV).  In 2011,  1.4 million people died 
from TB and there were an estimated 8.7 million new cases of TB globally [1]. It is estimated 
that 13% of these incident cases is co-infected with HIV [2].  In 1993, TB was declared a 
global health emergency by the World Health Organisation [1].   This declaration reflects the 
main global challenges to the control of TB which include insufficient measures to detect, 
prevent and treat TB, as well as the lengthy antibiotic course required to treat active TB 
resulting in non-adherence and development of multi-drug (MDR) and extensively-drug 
(XDR) resistant strains [3].   
1.1.1 The global burden of tuberculosis 
The global burden of disease caused by TB can be measured in terms of incidence (defined 
as the number of new and relapsed cases in a set time period, usually one year), prevalence 
(defined as the number of cases of TB at a given point in time) and mortality (defined as the 
number of deaths over a defined period, usually one year).  The results of these analyses are 
detailed in the most recent report of the World Health Organisation Global Tuberculosis 
Report 2012. 
In 2011, there were an estimated 8.7 million incident cases of TB (range 8.3-9.0 million) 
globally.  Most of the estimated cases occurred in Asia (59%) and Africa (26%).  Despite 
significant improvements in global surveillance for TB a significant proportion of disease is 
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under-reported.  As such, the exact incidence remains uncertain.  Of the estimated 8.7 
million incident cases in 2011, 1.0-1.2 million (12-14%) were among people co-infected with 
HIV.  The highest proportion of co-infected cases was in the African region where 39% of TB 
cases were estimated to be HIV positive [1]. 
 
Figure 1:  Estimated global incidence of TB (Adapted from Global Tuberculosis Report 2012, WHO) 
 
Globally, incidence rates of TB have remained relatively stable between 1990-2001 and, 
between 2010 and 2012, the global incidence of disease fell by 2.2% [1].  The latest 
assessment of what are considered to be High Burden Countries indicates that the incidence 
of TB is falling in most countries. 
The prevalence of TB can only be measured indirectly in most countries but the global 
prevalence of TB was estimated to be 12 million in 2011 (range, 10-13 million).  The 
prevalence rate has decreased by 36% since 1990.  At present many countries do not 
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accurately record cause of death according the International Classification of Disease (ICD-
10).  The inclusion of data from China and India in the WHO 2011 report has significantly 
improved reporting but  direct measurement of TB deaths according to this classification are 
only available for 120 countries.  Given these figures only account for approximately 46% of 
death globally, mortality rates are based predominantly on estimated data.  Globally, 
mortality rates (excluding deaths from HIV positive persons) have fallen by 41% since 1990. 
1.1.2 The threat of drug-resistant tuberculosis 
Whilst the rates of tuberculosis globally have fallen, the emergence of drug-resistant TB (DR-
TB) represents a significant threat to the global control of the disease.  In 2011, 3.7% of new 
cases and 20% of previously treated cases were estimated to have multi-drug resistant TB.  
Of these cases, 60% were identified to be in India, China and the Russian Federation.  
Worryingly, the number of reported cases of MDR-TB represented only 19% of the 
estimated 310 000 cases of MDR-TB reported TB patients with pulmonary TB.  Additionally, 
extensively drug-resistant disease (XDR-TB) has been identified in 84 countries globally.  The 
average proportion of MDR-TB cases with XDR-TB is 9.0% (6.7-11.25) and is increasing 
particularly in High Burden Countries.  It is clear therefore that significant advances are 
required in order to detect, report and treat drug-resistant disease. 
1.1.3 TB in the United Kingdom 
Rates of TB within the UK continue to rise with almost 9000 cases reported in 2011.  This 
represents a rate of 14.4 per 100,000 however rates have stabilised since 1995.  Of these 
cases, the majority were reported from urban centres and in individuals from high burden 
countries and those with social risk factors for developing TB.  The incidence of drug-
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resistant cases has continued to rise within the UK and in 2011 8.4% of TB cases were 
resistant to any first-line drug, an increase of 26% compared to 2010.  The proportion of 
isoniazid resistant and multi-drug resistant cases increased in 2011 by 7.6% and 1.6% 
respectively.  With regards to XDR-TB, six cases were reported in 2011 representing 25% of 
all cases reported since 1995.  Whilst rates of TB have started to stabilise in the UK, the 
trends in drug-resistant disease are concerning.  Further and continued efforts are required 
therefore to reduce the incidence of disease and contain the onset of drug-resistant disease. 
 
1.2 TB pathogenicity 
TB is spread from person to person by the inhalation of infection airborne particles 
containing the M.tb bacilli.  Upon inhalation, the infectious bacilli are phagocytosed by 
macrophages which then transit into deeper tissues.  There the infected macrophages 
recruit additional macrophages and other immune cells to form tightly aggregated immune 
structure called granulomas, the pathological hallmark of TB.  The infection can then remain 
dormant for many years, but with viable bacilli remaining within macrophages.  Occasionally 
(approximately 5% of cases), infection with TB results in an acute symptomatic pulmonary 
infection or, “primary progressive TB” but most individuals develop asymptomatic or “latent 
disease” [4]. 
The exact reason why TB re-activates are not clearly understood but some of the associated 
risk factors include HIV infection, advanced age, malnutrition, immunosuppression 
(including corticosteroids, chemotherapy and anti-TNF-α therapies) and other inheritable 
abnormalities in cytokine production (principally IFN-γ and IL-12.  Under such circumstances, 
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granuloma centres may necrotise spilling viable infectious bacilli into the airways and 
facilitating their spread.  TB can then present in a number of ways.  Commonly, this includes 
pulmonary infection, cervical lymphadenopathy, pleural disease, disease of the central 
nervous system (CNS) and disseminated infection (miliary TB).  Left untreated, TB infection 
has a 50% mortality rate but with significantly higher rates encountered in CNS and miliary 
disease. 
Whilst it is possible to treat TB using chemotherapy, treatment is both lengthy and complex.  
Individuals are required to take a combination of 3-4 drugs for a period of at least 6 months 
which leads to low patient compliance.  Furthermore, the emergence of MDR and XDR-TB 
means that treatment can be extended to 2 years and beyond.  There have been no new 
drug treatments developed for TB in the past 25 years and the currently used vaccine 
(Bacille Calmette-Guèrin or BCG) has been shown to be of limited effectiveness due to high 
variability in effectiveness (0-80%) [5].  It is clear therefore, that as well as the development 
of effective vaccines and novel treatment strategies, a greater understanding of the 
pathogenicity of TB is needed.   
1.2.1 TNF 
TNF is essential for the control of M.tb in humans and in experimental animals [6].  The 
predominant activities of TNF in immunity to TB are to contribute to the activation of 
macrophages for killing of intracellular mycobacteria and to modulate apoptosis of infected 
cells [7].  In particular TNF can act with IFN-y to activate macrophages for optimal control of 
M.tb growth.  Excess TNF also contributes to the immunopathology of M.tb [8] indicating 
that optimal immunity with minimal tissue damage is an important element of the biology 
of TNF in TB.  The critical role of TNF in control of M.tb  infection in humans has been  
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illustrated by the increased rate of reactivation of active TB in subjects with latent TB who 
received anti-TNF therapy for conditions such as rheumatoid arthritis or Crohn's disease [9].  
Screening for latent TB infection is now recommended patients being considered for this 
treatment [10]. 
1.2.3 IFN-γ 
IFN-γ is essential for the control of M.tb infection [11].  Whilst IFN-γ is known to exert its 
effects through broad transcriptional programmes and the induction of cytokines, the 
effector mechanisms downstream of IFN-γ signalling responsible for the restriction of 
mycobacterial infection are still to be elucidated.  IFN-γ stimulates macrophages to produce 
reactive oxygen intermediates as well as reactive nitrogen intermediates, both of which 
have been implicated in intracellular growth inhibition and/or mycobacterial killing.  
Additionally, IFN-γ stimulates macrophages to increase the expression of MHC class II 
molecules, thus leading to increased antigen presentation and further amplification of the 
immune responses.  In humans, lack of appropriate IFN-γ responses results in increased 
susceptibility to severe systemic infection with mycobacterial species that do not usually 
cause significant disease in immunocompetent individuals [12, 13] 
1.2.4 TB granulomas 
The granuloma is the hallmark of tuberculosis and is composed of an organised aggregate of 
macrophages.  Macrophages within granulomas exhibit several phenotypes, including 
mature macrophages, differentiated or epitheloid macrophages, foamy macrophages and 
multinucleated giant cells (MGCs) which form by fusion of the plasma membrane of multiple 
macrophages. Traditionally, granuloma formation was believed to be initiated by T 
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lymphocyte recruitment toward infected macrophages. The ability to visualise granuloma 
formation in transparent zebrafish infected with M.marinum has however provided exciting 
insights into the possible mechanisms governing granuloma initiation, recruitment and 
integrity.  Research by Davis et al. revealed that macrophages are able to initiate 
granulomas prior to the appearance of T lymphocytes [14].  Similarly, in vitro granulomas 
models using human peripheral blood cells, confirm that macrophages alone are able to 
form epitheliod granulomas containing MGCs [15, 16].  After infection of the macrophage, 
evidence from the zebrafish model demonstrates that bacteria are released in to the 
extracellular space through the death of the macrophage.  Mycobacteria are then rapidly 
ingested by the surrounding macrophages thereby promoting expansion of the pathogen 
population.  This process is mediated by the EsxA/ESAT-6 protein which induces the 
expression of MMP-9 to promote the recruitment of uninfected macrophages to the site of 
infection [17]. 
In addition to macrophages, human granulomas contain dendritic cells, B cells and T 
lymphocytes, the latter of which is considered essential for the maintenance of organised 
granulomas and the control of mycobacterial progression after the acute phase of infection.  
Evidence from several animal models demonstrates hypoxia as well as an acidic 
microenvironment within these chronic granulomas.   Hypoxia has been shown to induce 
the gene expression of several hundred genes, under the control of the dosR/dosS regulon, 
which favour pathogen survival and a shift towards reduced metabolic activity [18].  
Because this metabolic adaptation is thought to favour a state of mycobacterial latency, this 
is an area of great interest particularly with respect to the development of new drugs and 
vaccines [19].  Interestingly, the discovery of actively replicating subpopulations in some 
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models of mycobacterial persistence[20] have challenged some of these long-held views of 
non-replicating persistence.   
 
1.3 Clinical features of pulmonary tuberculosis 
Following initial infection with M.tb, some individuals progress rapidly to active disease, 
usually referred to as primary or progressive TB, which is more common in children but also 
affects adults  [21].  The majority of individuals will contain the initial infection and develop 
latent disease, with latently infected individuals having a 5-10% lifetime risk of developing 
active TB, termed reactivation or post-primary TB.   
1.3.1 Latent TB 
The majority of patients infected with M.tb (32% of the global population) are 
asymptomatic and have no clinical evidence of disease.  These individuals with latent 
infection are able to maintain the disease in a quiescent form.  This latent state is thought to 
be maintained by an active immune response in the host initiated by the infecting M.tb 
bacilli, permitting host controlled persistence of the organism [22]. 
1.3.2 Active TB 
Active TB encompasses a heterogenous range of presentations and forms of disease.  TB is 
predominantly a disease of the lungs with pulmonary disease accounting for approximately 
70% of cases, although M.tb can disseminate to other organs in the body including lymph 
nodes, bone and meninges, and cause extra-pulmonary disease [21].  Extrapulmonary 
tuberculosis occurs in 10-43% of patients, depending on race or ethnic background, age, 
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presence or absence of underlying disease, genotype of the M.tb strain, and immune status 
[23]. The clinical signs and symptoms of tuberculosis are often non-specific.  In adults, up to 
5% of cases of active disease may be completely asymptomatic [24] Patients with primary 
tuberculosis are often asymptomatic but may develop a symptomatic pneumonia.  
Individuals with primary progressive disease may present with, cough, haemoptysis and 
weight loss and is most commonly seen in children and young adults.  Patients with post-
primary disease most commonly experience a chronic productive cough and marked weight 
loss and often experience low-grade pyrexia, dyspnoea and fatigue.  Symptoms are often 
insidious and persist from weeks to months [25]. 
1.3.3 HIV co-infection 
HIV co-infection poses special challenges to the clinical management of patients with active 
tuberculosis.  The risk of active tuberculosis increases soon after infection with HIV and the 
manifestations of pulmonary tuberculosis are similar to those of HIV-negative individuals.  
At CD4 counts of less than 200, the presentation of TB may be atypical, with subtle 
infiltrates, pleural effusions, hilar lymphadenopathy, and other forms of extrapulmonary TB 
in up to 50% of patients.  At CD4 counts of less than 75, pulmonary findings may be entirely 
absent, manifested as a non-specific chronic febrile illness with high early mortality [26]. 
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1.4 Tuberculosis diagnosis 
1.4.1 Latent infection 
Screening and treatment for latent M.tb infection is indicated in the groups in which the 
prevalence of latent infection is high [27].  These include: 
- Foreign born persons from regions in which tuberculosis is endemic 
- Those in whom the risk of reactivation is high e.g. patients with HIV infection or 
diabetes and persons receiving immunosuppression 
- Recent and close contacts of individuals of patients with tuberculosis [28-30] 
Latent TB infection can be diagnosed with either a tuberculin skin test (TST) or an 
interferon-gamma release assay (IGRA).  The TST was first described by Koch in 1890 and 
developed by Mantoux in 1907.  The test relies on the principle of delayed hypersensitivity 
to recruit memory T cells to the site of intradermal injection of purified protein derivative 
(PPD) of Mycobacterium bovis.  It is less expensive than an IGRA and in patients with culture 
confirmed TB, has similar levels of sensitivity (75-90%).  TSTs have several disadvantages 
including cross-reactivity of PPD with non-tuberculous mycobacteria and the BCG vaccine.  
Other limitations include false-negative results in immunocompromised patients, young 
persons and older persons [31].   
IGRA testing is based on the assessment of the release of interferon (IFN)-γ by CD4 cells.  
Currently, two standardised IGRAs have been developed to measure IFN-γ responses to 
infection in blood samples; QuantiFERON-TB GOLD test (Cellestis) and T-SPOT TB (Oxford 
Immunote) assay.  QuantiFERON uses ELISA to measure the amount of IFN-γ released in 
response to in vitro stimulation of whole blood with M.tb antigens and T-SPOT uses ELISA to 
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count the number of IFN-γ producing cells on precoated plates.  Both assays use highly M.tb 
specific antigens such as early secreted antigen 6 (ESAT 6) and culture filtrate protein 
(CFP10) which are not present in BCG or most environmental mycobacteria thus providing 
specificity available with TST.  The sensitivity and specificity of IGRAs vary according to the 
population being tested but a recent comprehensive review calculated the pooled 
sensitivity of QFT-GOLD and TB-SPOT to be 83% and 90% respectively with a specificity of 
99% and 88% respectively [32] 
1.4.2 Active infection 
Worldwide, acid-fast bacilli (AFB) sputum smear microscopy is the most widely used method 
for identifying tuberculosis cases [33, 34].  The main advantages of microscopy are that the 
test is inexpensive and rapid.  Major disadvantages include low sensitivity and specificity, 
particularly in HIV-positive individuals and the absence of drug susceptibility information. 
 
Figure 2: Ziehl-Neelsen stained sputum slide showing acid-fast bacilli.   
Adapted from http://biomedfrontiers.org/diabetes-2014-1-4/ 
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M.tb culture therefore remains the recognised gold standard for confirming diagnosis of 
tuberculosis.  In recent times, liquid-based culture technologies have resulted in faster and 
more sensitive.  Compared to solid-culture on Lowenstein-Jenson medium which requires 
approximately 4-6 weeks for detectable growth and a further 2-3 weeks for species specific 
identification, these newer methods allow recovery of mycobacterial species from 2 weeks 
from clinical specimens.  Culture-based methods suffer from a number of disadvantages 
including the need for biosafety category 3 facilities and extensive training of personnel, 
particularly when liquid culture technologies are used. 
The development of molecular methods, typically involving PCR, has allowed the rapid 
identification of M.tb with a number of commercially developed tests available.  The pooled 
sensitivity of these test has been calculated as approximately 95% for smear-positive 
samples and approximately 75% for smear negative samples, while their performance for 
extrapulmonary specimens is usually much lower [35, 36] 
The Xpert MTB/RIF assay is a PCR-based test which has been developed as a point-of-care 
TB diagnostic test [37].  Xpert MTB/RIF has a sensitivity of 98-100% in smear-positive 
respiratory specimens and 57-83% in smear-negative specimens.  
1.4.3 Drug-resistant tuberculosis 
Whilst conventional drug-sensitivity testing (DST) on Lowenstein-Jensen medium requires 2-
4 weeks from primary culture, broth-based fully automated culture systems report results 
within 5–8 days from a primary culture.  Such systems are now routinely used for first- and 
second-line anti-TB DST of M.tb in developed countries [38]. 
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The emergence of MDR-TB has led to the development of novel methods to facilitate the 
rapid diagnosis of drug-resistant TB.  In resource-poor settings, a number of inexpensive, 
non-commercial  phenotypic methods have been developed to assess DST with high levels 
of agreement with conventional DST.  The microscopic observation drug susceptibility 
(MODS) test in which sputum is directly inoculated into Middlebrook 7H9 broth containing 
first-line anti-TB drugs, and the cording growth of M. tuberculosis is detected by an inverted 
microscope, exhibits ≥95% agreement with conventional DST for INH, RIF and MDR-TB  [39].  
The nitrate reductase (NR) assay is able to detect ≥95% of MDR-TB and XDR-TB samples by 
detection of pink-red colour due to the reduction of nitrate to nitrite by viable M.tb [39].  
Molecular methods detect resistance-associated mutations in the target genes of M.tb and 
can yield results within 1-2 days.  Identification of the 81-bp RRDR of the rpoB gene present 
on 90-95% of RIF-resistant strains allows the identification of most MDR-TB strains as 85-
90% of RIF-resistant M.tb isolates are also resistant to INH [40].  The ability of Xpert 
MTB/RIF assay to rapidly diagnose M.tb as well as identify drug resistance has resulted in 
endorsement by the WHO and represents a potential key tool in tackling drug-resistant 
disease globally [1]. 
 
1.5 The matrix metalloproteinase (MMPs) family 
Metalloproteinases are endopeptidases that contain an active site Zn2+ and are divided into 
subfamilies based on evolutionary relationships and structure of the catalytic domain.  The 
metzincin subfamily of metalloproteinases are characterised by 3-histidine zinc-binding 
motif and a conserved methionine turn following the active site.  The members of the 
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metzincin family are the reprolysins or ADAMS (A Disintigrin And Metalloproteinase), 
serralysins, astacins and matrixins (MMPs). 
Initially described in the  involuting tail of tadpoles by their ability to degrade collagen, a 
total of 25 vertebrate MMPs have be described of which 24 are found in humans [41].  
MMPs are translated as an inactive enzyme which required cleavage to its active form.  All 
MMPs contain a conserved pro and catalytic domain, with the exception of MMP-23.  The 
prodomain is approximately 80 amino acids and contains the consensus sequence PRCXXPD.  
The catalytic domain contains three conserved histidines in the sequence HEXXHXXGXXH, 
which ligate the active Zn2+ site.  With the exception of MMP-7, -23 and -26, MMPs have a 
flexible proline-rich hinge region and a hemopexin-like C-terminal domain, which functions 
in substrate recognition.  Other domains are restricted to subgroups of enzymes.  MMPs 
share a strikingly similar 3-D structure as well as gene arrangement suggesting that they 
originated from a common ancestor gene.  At least eight of the known human MMP genes 
(MMP-1, -3, -7, -8, -10, -12, -13, and 20) are clustered on chromosome 11 at 11q21-23.  
Other MMP genes are scattered among chromosomes 1, 8, 12, 14, 16, 20, and 22 [42].  
MMP gene expression and secretion can be triggered by a variety of factors including 
growth factors, cytokines, physical stress, oncogenic cellular transformation and 
components of infectious pathogens among others [43].  Various factors can activate MMPs 
via the conformational change that disrupts the Cys-Zn 2+ binding (cysteine switch) and leads 
to intermediate activation followed by autocatalytic cleavage of the propeptide from the 
core protein that renders the enzyme fully active [44].  
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Figure 3:  Schematic structure of major MMP groups.  Adapted from Parks et al.  Matrix 
metalloproteinases as modulators of inflammation and innate immunity, Nature Reviews 
Immunology 4, 617-629 (August 2004) 
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MMPs can be broadly defined by their substrate specificity into the following groups 
Name Alternative name ECM Substrate Other substrates 
Collagenases    
MMP-1 Collagenase-1 Type I, II, III collagen, aggrecan  
MMP-8 Collagenase-2 Type I, II, III collagen, aggrecan  
MMP-13 Collagenase-3 Type I, II, III collagen, aggrecan   
Gelatinases    
MMP-2 Gelatinase-A BM, Type IV, V and XI collagen, 
gelatin, aggrecan, laminin 
CCL-7, CXCL12, β-amyloid 
MMP-9 Gelatinase-B BM, Type IV, V and XI collagen, 
gelatin, fibronectin, laminin  
Latent TGFβ &VEGF, α1-
proteinase inhibitor, CXCL8, 
CXCL1, 4 & 11, β-amyloid 
Stromelysins    
MMP-3 Stromelysin-1 Fibronectin, laminin, Type IV 
collagen, aggrecan 
Latent TGFβ, E-cadherin, IL-
1β, β-amyloid 
MMP-10 Stromelysin-2 Laminin ProMMP-1, 7, 8 & 9 
MMP-11 Stromelysin-3 Type IV collagen, aggrecan, 
laminin 
Apoptosis 
Elastases    
MMP-7 Matrilysin Elastin, gelatin, fibronectin, 
Type IV collagen, aggrecan, 
laminin 
E-cadhrin, syndecan-1, 
pro=defensins, FasL, latent 
TNFα, CXCL1 
MMP-12 Metalloelastase Type V collagen, laminin, 
elastin, fibronectin 
Latent TNFα, CXCL11, α1-
proteinase inhibitor, CXCL1, 
3, 5, 6 & 8, CCL2, 7, 8 & 13 
Membrane-type    
MMP-14 MT1-MMP Type I, II, III collagen, laminin, 
aggrecan 
ProMMP-2, syndecan-1, 
SLPI, DR-6, CCL7 
 MMP-15 MT2-MMP Fibronectin, aggrecan, laminin, 
perlecan 
ProMMP-2, antiapoptotoc 
 MMP-16 MT3-MMP Type III collagen, fibronetin, 
gelatin, laminin, vibronectin 
ProMMP-2 
MMP-24 MT5-MMP Proteoglycans ProMMP-2, cadherins 
GPI anchored    
MMP-17 MT4-MMP Gelatin ProMMP-2, ADAMTS4 
MMP-25 MT6-MMP Type IV collagen, gelatin, 
fibronectin, fibrin, laminin 
α1-proteinase inhibitor, 
ProMMP-2 
Others    
MMP-19 RASI1 Type IV collagen, aggrecan, 
laminin, fibronectin, gelatin 
T-cell development, IGFB-3 
MMP-20 Enamelysin Type V collagen, aggrecan, 
amelogen, ameloblastin 
 
MMP-21  Gelatin  
MMP-28 Epilysin Casein  
 
Table 1:  Summary of major MMP groups and published substrates 
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1.5.1 MMPs in health and disease 
MMPs have been implicated in a number of disease processes which involve aberrant ECM 
turnover such as arthritis, tumour invasion and malignancy.  However, as well as their role in 
ECM remodelling, MMPs perform multiple roles in the normal immune response such as 
facilitating leukocyte recruitment, cytokine and chemokine processing and defensin 
action[45]. Typically, MMPs are not expressed in normal healthy tissue but can often be 
detected in repair or remodelling processes, as well as in diseased or inflamed tissues. They 
are released from a broad range of cells at sites of infection, including leucocytes 
(monocytes, macrophages, lymphocytes and neutrophils), fibroblasts and epithelial cells, 
and play a number of physiological roles in the normal immune response to infection 
including remodelling of the extracellular matrix, facilitating cell migration, processing 
cytokines, and activating defensins [45]. However, excess MMP activity may lead to tissue 
destruction and immunopathology that favours pathogen dissemination or persistence by 
breaking down barriers to spread or by creating an immunoprivileged site that is poorly 
accessed by host immune cells [46].  To prevent this, MMP production is tightly regulated. In 
addition to control on the transcriptional level, MMPs are compartmentalized and secreted 
as pro-enzymes that require proteolytic cleavage. What is more, upon activation, they are 
controlled by tissue inhibitors of metalloproteinases (TIMPs) which bind MMPs in a 1:1 
manner to prevent enzymatic activity MMP activity is controlled at the transcriptional level 
as well as by compartmentalisation and secretion as pro-enzymes requiring proteolytic 
cleavage [47].  The balance of MMPs to TIMPs therefore determines matrix turnover, where 
either an excess of MMPs or a deficit of TIMPs may result in ECM degradation. 
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1.5.2 Regulation of MMP activity 
Under physiological conditions the activity of MMPs is tightly regulated to prevent excessive 
proteolytic activity and tissue destruction. As with other proteinases, the action of MMPs 
can be regulated at the level of gene transcription, translation and secretion of latent 
enzyme, proenzyme activation, and inactivation by endogenous inhibitors.   
Proenzyme activation 
In addition to the “cysteine switch” mechanism, several MMPs contain a RXXR or RRKR  
sequence between the pro- and catalytic domains.  These function as a target sequence for 
pro-protein convertases or furins; this is known as a furin cleavage site.  Not all MMPs are 
activated in this manner, for example, proMMP-2 is known to be activated by active MMP-
14 through its cell surface interaction [48].  Currently the mechanism of activation in some 
MMPs is not fully described and remains the subject on ongoing investigation both within 
our group and by others.   
Compartmentalisation 
Compartmentalisation is an important regulatory control mechanism which prevents the 
indiscriminate release of proteinases.  Typically, proteinases such as MMPs are anchored to 
the cell membrane, thereby maintaining a high enzyme concentration locally and targeting 
their catalytic activity to specific substrates in the pericellular space 
Endogenous inhibitors of MMPs 
MMPs activities are inhibited by two major types of endogenous inhibitors: α2-
macroglobulin and Tissue Inhibitors of Metalloproteinases (TIMPS). 
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α2-macroglobulin 
Human α2-macroglobulin is a plasma glycoprotein of 725 kDa comprising of four identical 
subunits of 180kDa.  It acts by trapping the proteinase whilst in their fluid phase within the 
macroglobulin. The complex is then rapidly cleared by endocytosis via the receptor low 
density lipoprotein related protein-1. 
TIMPS 
TIMPs are selective inhibitors of MMPs consisting of 184-194 amino acids.  They comprise 4 
main classes TIMP-1, TIMP-2, TIMP-3 and TIMP-4 which can be subdivided into an N-
terminal and C-terminal subdomain.  Each domain contains three conserved disulphide 
bonds and the N-terminal domain folds as an independent unit with MMP inhibitory 
activity.  TIMPs inhibit all known MMPs although TIMP-1 has only limited inhibitory activity 
against MT1-MMMP, MT3-MMP, MT%-MMP and MMP-19.  TIMP-1 null mice and TIMP-2 
null mice do not exhibit obvious abnormalities.  TIMP-3 null mice develop emphysema-like 
alveolar damage [49] and faster apoptosis of mammary epithelial cells after weaning [50] 
indicating that TIMP-3 is a major regulator of MMP activity in vivo. 
1.5.3 MMPs and cytokines 
Several studies have indicated that MMPs can directly or indirectly affect the activity of 
various cytokines that function in inflammation and repair processes, including interferon-β, 
vascular endothelial growth factor (VEGF), epidermal growth factors, fibroblast growth 
factors and transforming growth factor-β [51].  Similarly, IL-1β, a potent pro-inflammatory 
cytokine, requires proteolytic processing by IL-1β-converting enzyme (ICE) for activation has 
been shown to be modulated by MMPs.  At least three members of the MMP family, MMP-
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2, -3 and -9 can cleave and activate the IL-1β precursor.  Furthermore, after activating IL-1β, 
MMP-3 degrades the biologically active cytokine [52], which can also be inactivated in vitro 
my MMP-1, -2 and -9 [52].  These data indicate a dual role for MMPs in biphasic modulation 
of inflammatory-mediator activity whereby MMPs are involved in both activation and 
inactivation 
 
1.6 MMPs and their role in TB pathogenicity 
In order to exert its pathogenic effects M.tb must drive destruction of the extracellular 
matrix and destroy its fibrils to allow transmission.  Increasing evidence is implicating MMPs 
activity in the TB-related tissue destruction with MMPs being the only enzymes capable of 
destroying all components of lung fibrillar collagen at neutral pH.  Initial studies of M.tb 
pathogenicity and MMPs demonstrated that mycobacterial lipoarabinomannan (LAM), a 
major antigenic wall component of M.tb increases MMP-1 and MMP-9 in the human THP-1 
cell line [53].   Virulent M.tb up-regulates MMP-1 more potently than the weakened vaccine 
strain M.bovis BCG in primary human macrophages [54] whilst examination of lung 
specimens from Tb infected patients indicate that MMP-1 is expressed and secreted in 
macrophages around the granuloma.  Additionally, both MMP-1 and MMP-9 were found to 
be up-regulated in primary human lung cells stimulated with filtered, conditioned media 
from M.tb-infected monocytes (CoMTb).  These results were not seen with direct infection 
indicating that MMPs are up-regulated via a monocyte-dependent network that involves 
both host and pathogen derived soluble factors [55-57].  Much of the investigation of MMPs 
and Tb pathogenicity has focused on clinical disease and more recently on novel animal 
models in which to study the disease.  Elevated MMP-9 levels have been found in the 
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pleural fluid and serum of Tb infected patients [58] whilst elevated levels of MMP-1 and 
MMP-3 have been found in the sputum and bronchoalveolar lavage (BAL) samples of Tb 
infected patients, irrespective of HIV status [59].  In terms of extra-pulmonary disease, 
elevated levels of MMP-9 have been demonstrated in the cerebrospinal fluid and brain 
tissue of patients with tuberculous meningitis [60].  In addition, it has been shown that CNS 
tuberculous disease causes a down-regulation of glial MMP-2 secretion via TNF-α, NF-КB, 
p38 and caspase 8 dependent network [61]. 
Until recently, the study of MMPs and TB pathogenicity in animals has been somewhat 
limited due to the lack of good models in which to study the disease.  The mouse for 
example, does not express MMP-1 nor does it form cavitatory disease.  This has been 
overcome by the recent development of MMP-1 transgenic mice.  Within these mice it has 
been demonstrated that, M.tb infection increased MMP-1 expression, resulting in alveolar 
destruction in lung granulomas and significantly increased collagen breakdown [59].  It has 
also been shown that MMPs  may play a major role in the induction of tuberculous 
granuloma formation [17].  In these studies which utilise Mycobacterium marinium (Mm) to 
infect transparent zebrafish larvae, the widely accepted model of the granuloma as an 
immunoprotective mechanism to curtail and encase mycobacteria has been challenged [62].  
Recently it has been shown that ESAT 6 from TB drives epithelial cell MMP-9 secretion 
which then regulates a cytokine gradient for monocyte recruitment to the granuloma. [17].  
In this study the early granuloma was shown to expand bacterial numbers with MMP-9 
promoting granuloma formation and virulence as well as accelerating macrophage 
recruitment to the granuloma. 
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There is mounting evidence for the role of MMPs in TB pathogenicity and increasingly, a 
better understanding of MMP activity is starting to challenge some of the accepted models 
of granuloma formation, tissue destruction and disease transmission. 
 
1.7 Hypoxia and its role in innate immunity 
In a given environment, oxygen availability is usually defined as anaerobic or anoxic (no 
available oxygen), hypoxic (reduction in available oxygen compared to atmospheric 
pressure) or normoxic (atmospheric pressures of usually 21% O2 at sea level or an O2 [pO2] 
partial pressure of 159mmHg).  The oxygen percentage in healthy tissue ranges from 2.5-9% 
O2 but markedly decreases in tumours, wounds and sites of infection to levels of ≤1% O2 [63-
65].  In the healthy human lung, alveolar pO2 is approximately 100-110mmHg (~14% O2).  
Local hypoxia found in inflamed and infected sites relates to a number of factors; decreased 
perfusion secondary to microvascular injury and thrombosis associated with the metabolic 
activities of the infectious pathogen and the recruited inflammatory cells. 
The principle cells of the innate response to inflammation are cells of the myeloid lineage, 
monocytes/macrophages and neutrophils.  These cells phagocytose invading 
microorganisms and release numerous antimicrobial molecules and pro-inflammatory 
mediators.  Phagocytic cells must therefore be adapted to generate energy and function 
effectively in oxygen-deprived areas.  In recent times, these adaptive responses have been 
demonstrated to be orchestrated by the transcription factor hypoxia-inducible factor or HIF  
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1.8 Hypoxia-inducible factor (HIF) 
HIF is a heterodimeric helix-loop-helix transcription factor, the expression of which is 
controlled by both oxygen and iron [66].  HIF-1 was discovered by the identification of a 
hypoxia response element (HRE; 5’-RCGTG-3’) in the 3’ enhancer gene for erythropoietin 
(EOP), a hormone that stimulates erythrocyte proliferation and undergoes hypoxia-induced 
transcription [67, 68].  HIF is comprised of a constitutively expressed β-subunit and an 
oxygen-dependant α-subunit.  HIF-1β is also known as the aryl hydrocarbon nuclear 
translocator (ARNT), which was originally identified as a binding partner of the aryl 
hydrocarbon receptor [69]. These proteins belong to the basic helix-loop-helix-Per-ARNT-
Sim (bHLH-PAS) protein family.  The bHLH and PAS motifs are required for heterodimer 
formation between the HIF-1α and HIF-1β subunits, and the downstream basic region is 
responsible for specific binding to the HRE DNA sequence.  Three forms of HIF have been 
identified, HIF-1α, HIF-2α and HIF-3α and all are known the respond to changes in available 
cellular oxygen [70]. 
 
Figure 4:  Domain structure of human HIF-α and HIF-1β.  Adapted from Ke, Q. and Costa, M.  
Hypoxia Inducible Factor-1.  Mol Pharmacol. 2006 Nov; 70(5):1469-80 
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In comparison the HIF-1α which is universally expressed, HIF-2α is predominately expressed 
in the lung, endothelium and carotid body [71].  HIF-3α was discovered later and is also 
expressed in a wide variety of tissues [72].  In addition, a splice variant of HIF-3α, inhibitory 
PAS (IPAS) which is found predominantly in the Purkinje cells of the cerebellum and corneal 
epithelium, was subsequently discovered [73].  HIF-α (HIF-1α, HIF-2α, HIF-3α and IPAS) 
contains an oxygen-dependent degradation domain (ODDD) that mediates oxygen-
regulated stability through the hydroxylation of two proline (P) residues and the acetylation 
of a lysine (K) [74].  HIF-1α and HIF-2α contain two transactivation domains; N-TAD and C-
TAD.  The C-TAD in particular has been shown to interact with co-factors such as CBP/p300 
to activate gene transcription [75] 
1.8.1 Regulation of HIF 
The transcription and synthesis of both HIF-1α and HIF-1β are constitutive but HIF-1α 
protein has a short half-life (t=2-5mins) and is highly oxygen sensitive.  In normoxia, HIF-1α 
protein is rapidly degraded resulting in little or no detectable HIF-1α protein.  Thus the 
stability and transactivational function of HIF is controlled principally at the post-
transciptional level by hydroxylation, ubiquitination, acetylation and phosphorylation [76]. 
In normoxia, the HIF α-subunits are unstable as cells continually synthesised and degraded.  
This process is primarily regulated by a family of prolyl hydroxylases called PHD1, PHD2 and 
PHD3 [77, 78].  Under normoxic conditions, PHDs catalyse the Fe(II)-dependent 
hydroxylation of specific prolyl residues within the oxygen-dependent domain of HIF-α.  
Once hydroxylated, the von-Hippel-Lindau (pVHL) tumour suppressor protein binds to α-
subunits and identifies them for ubiquitination and proteosomal degradation [79].  A further 
level of control is provided by asparaginyl hydroxylase factor inhibiting HIF (FIH).  FIH 
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inhibits p300-CREB-binding protein (CBP)-mediated transcriptional co-activation of the HIF 
genes. 
Under low oxygen levels (hypoxia), PHD activity decreases.  This results in stabilisation of the 
α-subunits which translocate to the nucleus and heterodimerises with the β-subunit along 
with co-factors p300/CBP.  The resultant HIF complex binds to core pentanucleotide 
sequences known as hypoxic-response elements (HREs) in the promoter regions of target 
genes. 
Besides hypoxia, HIF has also been shown to be regulated by oxygen-independent 
mechanisms.  Cytokines, growth factors, environmental stimuli and other signalling 
molecules have been implicated in regulating HIF in normoxic conditions [80-83]. 
HIF signalling pathway is considered to be the master regulator of both immune cell 
function and survival [79].  HIF is present in all mammalian cells and is known to regulate 
the expression of several hundred genes which function in a variety of host cellular and 
systemic responses to low oxygen levels.  It has been shown to influence metabolism, 
angiogenesis, vascular tone, cell differentiation, and apoptosis as well being involved in 
cancer and many other physiological conditions such as inflammation and infection.  
Recently, HIF has been shown to act as the master regulator of macrophage and neutrophil 
inflammatory and innate immune function [84]. 
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Figure 5:  Schematic representation of HIF-1 regulation in normoxia and hypoxia.  Adapted from 
http://journals.cambridge.org/fulltext_content/ERM/ERM7_06/S1462399405009117sup007.htm 
1.8.2 HIF and innate immunity
It has been shown that hypoxia increases phagocytic rates in a HIF-dependent manner [85, 
86]and that macrophages from mice deficient in HIF-????????????? ?????????????????????????
Gram-negative and Gram positive bacteria when compared to macrophages from wild-type 
littermates[86].  Conversely, activation of the HIF pathway through deletion of the VHL-
tumour suppressor protein or pharmacological inducers supported myeloid cell production 
of defence factors and improved bactericidal capacity.  HIF-1 has been shown to induce 
????????????? ???????????????????? ??????????????????????????????????? ?????????????? [87] as 
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well as inhibiting neutrophil apoptosis via NF-КB activity [88], thereby prolonging the 
effective window for these cells to participate in phagocytic killing. A striking and perhaps 
unexpected finding is that bacterial exposure is a stronger stimulus for HIF-1α activation 
than hypoxia itself [86].  Several clinically important bacterial species such as Group A 
Streptococci (GAS), methacillin-resistant S.aureus and Salmonella species can induce HIF-1α 
with HIF-1α stabilisation demonstrated even at normoxia.  These findings indicate the 
complex nature of HIF signalling and the need for further analysis of its pathways as well as 
its role in innate immunity. 
In addition to oxygen-dependent activation pathways, HIF can also be induced by 
inflammatory cytokines, growth factors and bacterial products at normoxic conditions, 
although the underlying molecular pathways are not fully elucidated.  Pro-inflammatory 
cytokines TNFα and IL-1β have been shown to increase accumulation and transcriptional 
activity of HIF-1α.    The fact that HIF can be activated in response to inflammatory cytokines 
indicates HIF may play an important role in inflammation. 
In addition to cytokines, bacteria and bacterial products such as LPS also stimulate HIF 
activity under normal oxygen levels.  Several pathways have been reported to be involved in 
this process including NF-κB [79, 84, 89], ROS [90], and PHDs [91].   
The finding that bacteria can be stronger activators of the HIF pathway rather than hypoxia 
in addition to the demonstration of bacteria-induced HIF protein stabilisation in normoxia 
has been the subject of much investigation.  Recently, the mechanistic explanation for these 
phenomena has been found to reflect a close, synergistic relationship between HIF and the 
central regulator of innate immunity, NF-κB. 
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1.8.3 NF-κB in innate immunity 
NF-κB is a dimeric transcription factor composed of subunits from two subfamilies: the NF-
κB subfamily comprised of p50 and p52 and the Rel subfamily comprised of Rel A, also 
known as p65, Rel B and c-Rel.  All NF-κB subunits have Rel homology domains that facilitate 
DNA-binding and dimerisation but only the Rel proteins have C-terminal transactivation 
domains [92]. As a result, all NF-κB subunits with the exception of Rel B can form homo- or 
heterodimers resulting in a high degree of combinatorial diversity but only dimers 
containing Rel proteins can act as transactivators.  Currently, the p50/p65 heterodimer 
represents the most abundant of the Rel dimers [92].   
 
NF-κB influences gene expression events that impact cell survival, differentiation and 
proliferation in addition to its pivotal role in innate immunity.  For this reason, the activity of 
NF-κB is tightly regulated at multiple levels.  The principal mechanism for regulating NF-κB is 
through the inhibitory IκB proteins (inhibitor of NF-κB), and the kinase that phosphorylates 
IκBs, namely, the IκB kinase (IKK) complex [93].  The IKK complex consists of two catalytic 
subunits (IKKα and IKKβ) and one regulatory subunit (NEMO).  This signalling pathway 
through the heterodimeric IKK complex is known as the canonical NF-κB signalling pathway 
[94].  An alternative noncanonical pathway also exists which is mediated through activation 
of IKKα homodimers [95] A number of post-translational modifications also modulate the 
activity of the IκB and IKK proteins as well as NF-κB molecules themselves [92]. 
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1.8.4 Regulation of NF-κB by hypoxia 
Hypoxic activation of NF-κB has been identified in a wide array of cells types and has been 
the subject of intense investigation.  Most notable, key inflammatory genes including TNFα, 
IL-6 and MIP-2 have been shown to be directly activated by hypoxia in an NF-κB-dependent 
manner.  Although the exact mechanisms involved have not been fully elucidated, the 
hypoxia sensitive component appears to be at the level of (or upstream) of the IKK complex, 
as evidenced by demonstration of IKKβ activation in cells exposed to hypoxia [84, 91].  A 
possible explanation linking HIF and NF-κB regulation is through the oxygen-sensing prolyl 
hydroxylase (PHDs) enzymes which also regulate HIF.  Evidence from Cummins et al. 
demonstrates that inhibition of the PHDs leads to increased NF-κB signalling by inhibition of 
IKKβ [91].  
 
1.8.5 HIF and NF-κB interdependence 
A number of studies have indicated that significant cross-talk occurs between HIF and NF-
κB.  TNFα-induced HIF-1α stimulation requires NFκB at the level of HIF-1α protein 
stabilisation without affecting its mRNA level [96, 97].  Similarly, IL-1β acts on HIF-1α protein 
stability by triggering NFκB activity and inhibiting VHL-mediated protein degradation [96].  
More recently, an in vivo study by Ruis et al demonstrated that NF-κB upregulates HIF-1α 
through transcriptional upregulation and furthermore showed that basal NF-κB is a 
prerequisite for constitutive HIF-1α expression [84].  A further level of support for HIF and 
NF-κB cross-talk is the finding that HIF can alter NF-κB signalling by upregulating p65 and 
IKKα in neutrophils [88].  
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1.9 Hypoxia and tuberculosis 
It is evident from a variety of human, animal and in vitro studies, that oxygen tension is 
intimately associated with the outcome of M.tb infection.  A growing body of research 
demonstrate that M.tb growth, metabolic and transcriptional profile are acutely sensitive to 
varying levels of oxygen in vivo and in vitro [18, 98].   Tuberculous granulomas have long 
been considered the hosts defence mechanism against the bacteria.  By encasing the bacilli, 
the granuloma restricts access to oxygen and exposes the organism to an acidic 
environment as well as other immune effectors, such as nitric oxide.  This hypoxic 
environment does not necessarily lead to eradication of the bacillus.  Several studies 
indicate that hypoxia causes Tb to enter a state of bacteriostasis or slow growing replication 
which can last the lifetime of the host [99].  In this model of latency, these mycobacteria are 
viewed as the seeds of reactivation which under certain permissive conditions, for example 
HIV infection, will then progress to cause active disease.  
1.9.1 Oxygen status and reactivation  
Several indirect observations have supported the view that Tb infections are preferentially 
associated with the most oxygen-rich sites in the body [100].  In humans, reactivation from 
latency most commonly occurs within the upper lobes of the lungs, an area shown to be the 
single most oxygenated region in the body.  Similarly, quadrapeds such as rabbits and cows 
develop Tb infection in the dorsal portion of the lungs, a region corresponding to the most 
oxygen-rich site of the animal [101]. Strikingly, if M.tb infected rabbits are maintained in an 
upright position for 11 hrs a day, the Tb lesions are found to be predominantly in the apical 
lung zones [102]. It has long been postulated that reduced oxygen tension is associated with 
inhibition of M.tb growth.  In the pre-antibiotic era, one of the most effective treatments for 
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pulmonary tuberculosis involved the use of artificial pneumothorax, a process in which the 
affected lung is temporarily collapsed thereby restricting the supply of both blood and 
oxygen.  Maintaining infected animals at reduced oxygen tension slows disease progression 
and results in reduced pathology [103].  Similarly, human epidemiological studies indicate 
that rates of Tb transmission and/or disease decrease at higher altitudes where oxygen 
tensions are lower [104].  Despite the mainly observational evidence from human studies, it 
is interesting that no study of tissue oxygen tension has been undertaken in humans.  
Currently, our understanding of tissue oxygenation and hypoxia is based on animal models 
of TB infection, many of which indicate that TB granulomas are in fact profoundly hypoxic. 
 
1.9.2 Investigation of hypoxia in current animal models of TB infection 
Several animal models are currently used to study TB infection.  These include mice, 
zebrafish, guinea pig, rabbit and non-human primates.  Whilst a number of studies have 
been undertaken to examine the presence of hypoxia within these models, it is not until 
recently that specific animal models have been developed to assess the impact of hypoxia 
on the immunopathology of TB infection. 
Hypoxia and the mouse model of TB infection 
Mice, most notably BALB/c mice, are the most commonly used animal model to study M.tb 
infection.  The advantages of this model include low cost and space requirements, 
availability of inbred strains and immunological reagents.  Unfortunately, caseation and 
cavitation, two hallmarks of human TB associated with dramatic changes in oxygen tension 
are almost never seen in infected mice [59].  Granulomas in mice are generally small and 
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poorly differentiated and studies by Aly et al. and Via et al. indicate that TB lesions in mouse 
lungs are not hypoxic [105, 106].  More recently, several groups have sought to utilise 
C3HeB/FeJ (Kramick) mice to more closely represent human phenotypic changes.  In this 
setting, M.tb infection results in the formation of caseous necrosis within granulomas with 
surrounding regions of hypoxia, as demonstrated by positive staining for the hypoxia tracer 
pimonidazole (Pimo) [107, 108].  Interestingly, C3HeB/FeJ mice demonstrate reduced 
responsiveness to pyrazinamide and moxifloxacin when compared with BALB/c mice and 
different.  There is also evidence that hypoxia within granulomas of C57BL/6 mice might 
alter host immune responses resulting in the upregulation of the serine proteases cathepsin 
G, neutrophil elastase and proteinase 3 [109].  Interestingly, when C57BL/6 mice are 
infected with M.tb by dermal inoculation, they appear to develop a phase of latent disease, 
a phenomenon not seen in BALB/c mice.  As such, this mouse model has the potential to 
offer a novel mechanism by which to assess new vaccines and anti-tuberculosis 
chemotherapy. 
Hypoxia and the zebrafish model of TB infection 
Zebrafish are sensitive to infection with Mycobacterium marinarm (Mm) whose embryo 
stage is transparent allowing for the live imaging of early TB infection and granuloma 
formation[17].  Currently the limited immunological reagents means oxygen tension in 
zebrafish lesions has not been reported.  There has however been recent investigation of 
HIF signalling in Mm infection in zebrafish which demonstrates that HIF-1α signalling occurs 
in early Mm infection and that activation of this pathway aids host clearance of Mm 
infection [110].  Additionally, the antimicrobial effect of HIF-1α stabilization, and HIF-2α 
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reduction, were demonstrated to be dependent on inducible nitric oxide synthase (iNOS) 
signaling at early stages of infection. 
Hypoxia and the guinea pig model of TB infection 
Guinea pigs are exquisitely sensitive to M.tb infection and as such do not undergo a latent 
phase.  Mature lesions develop caseous necrosis which are positive for the hypoxia marker 
pimonidazole hydrochloride (PIMO) [106].   
 
Figure 6:  H &E stain of caseous necrosis (G) and PIMO stain (H) in a guinea pig.   Via et al. Infect 
Immun. 2008 June; 76(6): 2333–2340. 
 
Guinea pigs have been widely used to model TB infection and represent an attractive model 
in which to study tissue hypoxia.  Unfortunately, their use is limited by the space and 
moderate cost requirements as well as the relative lack of immunological reagents.  
Hypoxia and the rabbit model of TB infection 
Like the guinea pig, rabbits develop hypoxic lesions around areas of caseous necrosis.  
Rabbits however are resistant to infection with Mycobacterium tuberculosis and are instead 
infected with Mycobacterium bovis, to which they are highly sensitive.  Necrotic granulomas 
Chapter 1:  Introduction 
47 
 
are positive for PIMO whilst rabbits kept at 95% O2; 5% CO2 i.e. hyper-oxygenated, 
demonstrate decreased PIMO uptake compared to rabbits housed at 21% O2; 5%CO2 [106].  In 
addition, direct measurement of granulomas using a PO2 probe placed into visible 
granulomas revealed mean (± SE) pO2 measurements of 2.66 ± 0.70 mm Hg compared to 
59.46 ± 5.03 mm Hg in grossly normal lung tissue (P<0.001) [106]. 
Non-human primate 
Primates develop TB disease in remarkably similar way to humans with evidence of a latent 
phase as well as caseous necrosis and hypoxia within pulmonary lesions [111].  Unlike the 
rabbit and guinea pig, immunological reagents are plentiful but the high costs involved as 
restricted the use of this model for studying TB.  In addition to demonstrating evidence of 
hypoxia in the rabbit and guinea pig, Via et al. demonstrate evidence of PIMO activation in 
100% of necrotic granulomas in M. tuberculosis-infected cynomologous macaques [106].   
Given this body of evidence, it is surprising that the nature of oxygen tension and its 
relevance to disease activation has never been adequately investigated in humans.  This is 
likely to be due in part to the invasive nature of many of the tools used to assess hypoxia.  
Polarograpy using a pO2 probe requires an accessible site and the endogenous hypoxia 
tracer pimonidazole needs to be administered intravenously prior to an invasive biopsy.  
Investigators therefore have sought to utilise in vitro systems, transcriptional analysis of 
human TB granulomas, and M.tb genome sequencing to better understand pathogen and 
host responses to hypoxia. 
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1.10 In vitro systems of hypoxia 
1.10.1 The Wayne model 
The most widely accepted in vitro system of hypoxia is the Wayne model which, despite 
improvement, is still troubled by issues of reproducibility [112].  In this model, a sealed 
standing culture of M.tb with a defined volume of air above it is allowed to incubate over a 
period of days.  By defining and restricting the volume of air available, a self-generated 
oxygen gradient is produced which slowly depletes the bacteria of oxygen.  The concomitant 
shift in M.tb physiology produces two distinct states of non-replicating persistence (stages 1 
and 2) [99].  These stages reflect discrete metabolic and drug-susceptibility states compared 
with log phase growth.  As might be expected, the synthesis of proteins is markedly reduced 
in this system [113].  This is however accompanied by the increased expression of certain 
genes namely the alternative sigma factors sigB, sigE and sigH.  Alternative sigma factors 
drive broad changes in transcription and may help drive the adaptation to hypoxia [114, 
115].   
1.10.2 The defined hypoxia model 
This model allows researchers to determine the atmospheric conditions and maintain them 
throughout the course of an experiment, usually within an incubator or dedicated hypoxia 
workstation.  Use of this approach has determined that bacterial replication is halted at 
oxygen tensions of 1% or less but the bacteria remain viable supporting the theory of non-
replicating persistence [116, 117]. 
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1.10.3 Transcriptional analysis 
Analysis of the initial transcriptional response to hypoxia indicates approximately 100 genes 
with altered expression and nearly all the up-regulated genes were found to be under the 
control of the two-component transcriptional regulation system DosR/DosS, or DosR 
regulon [18]. Of the characterised genes which are down-regulated, many are involved in 
protein synthesis, lipid synthesis and aerobic metabolism, indicating a shift to reduced 
metabolic activity.   Interestingly, the expression of DosR regulon genes is not synonymous 
with the “dormancy response” of M.tb.  Evidence from several groups shows that the DosR 
regulon is induced during stages of active growth [118] and that loss of DosR results in only 
mild phenotypic changes in many models of latency [119].  The DosR regulon may therefore 
participate in a more focussed manner to promote survival during periods of extended 
respiratory, nitrosative and redox stress.  
Evidence from transcriptional profiling of human TB granulomas again supports the finding 
of altered transcriptional responses which favour bacterial survival.  Using RNA-RNA in-situ 
hybridisation, Fenhalls et al. demonstrate upregulation of icl, narX, and Rv2557 and Rv2558, 
within the lymphocyte “cuff” directly surrounding the necrotic center [120].  These four 
genes have all been implicated in bacterial persistence and concur with data from in vitro 
studies using the Wayne model. 
In a recent systems analysis of M.tb regulatory and metabolic networks using ChIP-Seq, key 
transcription factors induced by hypoxia and subsequent re-aeration were further 
investigated.  In addition to the key role of DosR, the gene Rv0081 was found to act as the 
central mediator of the initial response to hypoxia whereas a larger stimulon termed the 
enduring hypoxic response (HER) is induced in later hypoxia [121].  In addition the negative 
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transcriptional regulator KstR which control a large regulon mediating cholesterol 
degradation and lipid and energy metabolism was found to significantly impact on this 
network [122].  Collectively, the data reveals in interconnected subnetwork linking hypoxic 
adaptation, lipid and cholesterol degradation, and lipid biosynthesis in the pathogen 
response to hypoxia but do not address hypoxia in the host. 
 
1.11 Hypoxia and MMPs 
Hypoxia is present in several disease processes which involve pathophysiological 
mechanisms related to hypoxia-induced extracellular remodelling.  These include chronic 
obstructive pulmonary disease (COPD), atherosclerosis and arthritis [123, 124].  In relation 
to vascular remodelling, overexpression and activation of MMPs strongly correlates with 
clinical manifestations of atherosclerosis [125].  In patient samples, levels of active 
intraplaque MMP-9 were found to be higher in unstable coronary plaques and were found 
to be strongly associated with unstable angina compared with stable coronary plaques 
[126].   
Hypoxia and HIF-1α have been implicated in a wide range of malignant disease processes.  
HIF-1α overexpression is found in a number of cancers including ovarian, breast, lung, head-
and-neck and gastric cancers amongst others [127-129]. HIF is correlated with p53 
accumulation and cell proliferation suggesting a role for HIF-1α in cancer progression.  
MMPs contribute to invasion and metastasis of tumour cells by degrading the basement 
membrane and ECM, which then enables migration and spread of cancer cells.  Several 
studies indicate increased HIF-1α mediated MMP activity in malignancy.  In human breast 
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cancer, hypoxia and HIF-1α upregulate MMP-9 expression and promotes tumour invasion 
[130].  Similarly, hypoxia increases MMP-2 expression in oesophageal cancers via a HIF-1α 
mediated pathway and contributes to hypoxia-induced invasion and metastasis [131]. 
Recent studies investigating the role of hypoxia in inflammation indicate that changes in 
oxygen levels affect MMP activity and a number of key regulators of MMP expression 
including the transcription factors NF-КB and AP-1, have been linked to HIF [84].  It has been 
shown that the hypoxic environment of the rheumatoid synovium promotes MMP-1 and 
MMP-3 gene expression and secretion thereby contributing to direct tissue destruction 
observed in the disorder [132].  In the context of Tb infection, little is known of the impact 
of oxygen levels on MMP expression and activity.  Moreover the role of hypoxia during 
active Tb infection has not been elicited with most research focusing on latent disease.  In 
fact, whist animal studies indicate that Tb granulomas are hypoxic, there has been no 
research performed to determine whether human lesions are hypoxic. 
 
1.12 The radiological manifestations of pulmonary TB 
Historically, pulmonary tuberculosis has been divided into primary and post-primary 
infection.  It can be difficult to distinguish between the two radiologically (as well as 
clinically) as there tends to be a large amount of overlap between the two.  The main 
imaging modality used globally, if this is available, is a plain chest radiograph.  In the 
developed world computerised tomography (CT) is increasingly being used.  Nuclear 
medicine techniques are occasionally used but are mostly employed when the diagnosis is 
debated. 
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1.12.1 Primary tuberculosis 
At radiology, primary TB manifests itself as four main entities: parenchymal disease, 
lymphadenopathy, miliary disease and pleural effusion.  
Parenchymal disease 
Typically, parenchymal disease manifests as dense, homogenous parenchymal consolidation 
in any lobe.  Its appearance is often indistinguishable from that of bacterial pneumonia, 
however it can be differentiated from bacterial pneumonia on the basis of radiographic 
evidence of lymphadenopathy and lack of response to conventional antibiotics [133]. 
Lymphadenopathy 
Radiographic evidence of lymphadenopathy is seen in up to 96% of children and 43% of 
adults [133].  Lymphadenopathy is typically unilateral and right sided, involving the hilum 
and right paratracheal region, although it is bilateral in about one third of cases.  Nodes 
greater than 2cm in diameter with low attenuation at its centre, secondary to necrosis at CT 
are highly suggestive of active disease [134].   
Miliary disease 
Miliary disease affects 1-7% of patients with TB.  The classic radiographic findings are of 
evenly distributed small 2-3mm nodules.  These are sometimes interspersed with focal or 
diffuse consolidation where the nodules have coalesced.   
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Pleural effusion 
A pleural effusion is seen in approximately one quarter of patients with a proven diagnosis 
of TB [135].  It is often the only manifestation of TB and is usually unilateral.  Ultrasound 
scanning often reveals a complex septated effusion 
1.12.2 Post primary TB 
As already discussed, significant radiological overlap occurs between the features of primary 
and secondary TB.  Post primary disease can manifest as parenchymal disease, airways 
involvement and pleural extension. 
Parenchymal disease 
Typically, parenchymal disease occurs as patchy, poorly defined consolidation, particularly 
in the apical and posterior segments of the upper lobes.  Additionally, cavitation, the 
hallmark of postprimary TB is seen in approximately 50% of patients [136].  Cavities are 
usually multiple and occur within areas of consolidation. 
                  
Figure7:  A.) Plain chest x-ray demonstrating left upper lobe cavity B.) Normal chest x-ray. 
Adaptedfrom http://www.sharinginhealth.ca/pathogens/bacteria/mycobacterium_tuberculosis.html 
A
 
 
 
B 
Chapter 1:  Introduction 
54 
 
 
   
Figure 8:  A. High resolution CT scan showing apical consolidation and cavitation of pulmonary 
tuberculosis.  B.  Normal CT chest for comparison. 
http://main.rudn.ru/_new/russian/win/tub1/tubeng2012/02_diag/02_09_rentgen/02_09_07_caver
na/02_09_08_4%20CT-scan/CT-scan.htm 
 
Airways disease 
Airways disease may be seen on CT as tree-in-bud opacification[136].  This finding 
represents endobronchial spread of infection and indicates active disease.   Other airways 
changes include bronchial stenosis leading to lobar collapse and obstructive pneumonia. 
Pleural extension 
Pleural effusions are seen in about 18% of individuals with postprimary TB.  The pleura may 
become thickened and may progress to a tuberculous empyema and ultimately a 
bronchpleural fistula.  Residual pleural thickening and calcification may occur. 
 
 
 
A
 
 
 
 
 
 
B 
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1.13 Nuclear medicine imaging of TB 
Nuclear medicine techniques are frequently employed in the investigation of pyrexia of 
unknown cause, of which tuberculosis often forms part of the differential diagnosis.  Several 
techniques are available including Galium-67 citrate, Indium 111-labelled autologous 
leucocyte scintigraphy and fluorodeoxyglucose positron emission tomography (FDG-PET).  
Both Gallium-67 and Indium 111 have a sensitivity of approximately 76% in detecting 
extrapulmonary tuberculosis but neither are specific for detecting TB compared with other 
infective causes [137, 138].  Similarly, FDG-PET has a high sensitivity for TB lesions but its 
uptake is increased in malignant disease as well as other granulomatous lesions.  One study 
indicates that it might be possible to distinguish between TB and malignant lesions by using 
carbon-11 choline PET.  In this study, the standardised uptake value (SUV) of C11-choline was 
found to be high in malignant lesions and low in TB lesions whereas all lesions were found to 
have high uptake with FDG-PET [139].  
 
1.14 Assessment of tissue oxygenation 
The measurement and assessment of tissue oxygenation has been primarily influenced by 
the field of tumour biology.  Tumour hypoxia has long been recognised to confer poorer 
prognosis and poorer response to therapy[140].   Many therefore have sought to elucidate 
the role of oxygen in solid tumours in order to improve cancer therapy.  Various methods to 
assess the level of oxygenation have been developed including invasive measurement using 
pO2 electrodes and fibre-optic probes, immunohistochemical detection of exogenously 
administered drugs that label hypoxic tumour cells and of proteins overexpressed in 
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response to hypoxia as endogenous markers.  More recently, non-invasive imaging tissue 
techniques have been established to allow assessment of tissue hypoxia, disease 
progression and treatment responsiveness. 
1.14.1 pO2-polarography 
Several groups have attempted to measure tissue oxygenation using a directly inserted pO2 
probe.  In particular, head and neck and cervical cancers have been studied due to their 
relatively accessible site. This method uses a very fine 300 µm cathode needle, which is 
inserted into the site of interest and a current generated by ionisation of oxygen is 
measured to provide an estimate of oxygen concentration at the site of insertion [141].  This 
method has been validated and is considered the gold standard of hypoxia measurement by 
the American Cancer Institute [142].  
1.14.2 Exogenous hypoxia markers 
Currently, pimonidazole (Pimo) is considered to be the “standard” exogenous hypoxia 
marker [143].  The binding of Pimo to thiol containing proteins has been shown to 
dramatically increase below in oxygen concentration of 10 mmHg [144].    At present, Pimo 
is injected intravenously prior to an invasive biopsy and immunohistochemical staining 
being carried out.  The small patient numbers within the published data means the 
prognostic role of Pimo is unknown [145]. Furthermore the need for invasive biopsies has 
limited the clinical application of Pimo. Its utility therefore remains mainly primarily in 
laboratory research as a marker of severe tissue hypoxia.  
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1.14.3 Non-invasive imaging probes for hypoxia 
Several non-invasive methods to detect tissue hypoxia have been developed including 
functional imaging modalities such as  positron emission tomography-computed 
tomography (PET-CT), single-photon emission computed tomography (SPECT) and magnetic 
resonance imaging/magnetic resonance spectroscopy (MRI/MRS) and surrogate markers of 
hypoxia, for example carbonic anhydrase IX (CA-IX).    
1.14.4 PET-CT and SPECT 
PET-CT and SPECT permit the non-invasive in vivo assessment of tissue hypoxia by 
measuring the spatiotemporal distribution of hypoxia specific tracers. 
1.14.5 [18F] fluoromisonidazole FMISO 
Nitroimidazoles have long represented an attractive therapeutic agent in tumour biology 
because of their unique behaviour in hypoxic environments arising from their high electron 
affinity.  The past 40 years has seen the development and therapeutic trials of this group as 
chemical modifiers that increase the sensitivity of hypoxic tissues to radiation or 
chemotherapeutic agents, and as bioreductive prodrugs, or hypoxia selective cytokines.  
These agents have since been adapted for the labelling procedure of hypoxic cells in vivo.  
 [18 F]fluoromisonidazole (FMISO) is a lipophilic compound that enters the cell by diffusion.  
Once inside the cell, the nitro group is reduced by a series of nitroreductase enzymes which 
include cytochrome p450 reductase, xanthine oxidase and oxdioreductase.  In the presence 
of high intracellular oxygen, the resulting radical anion is converted back to the intact nitro 
group and the compound will leave the cell via diffusion [146] and return into the 
circulation.  Under hypoxic conditions a sequence of single electron reductions takes place, 
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leading to irreversible covalent binding to intracellular macromolecules[147].  FMISO is then 
irreversibly trapped within the hypoxic tissue. Whilst several radionucleotide hypoxic tracers 
exist, [18F]FMISO represents the most widely investigated and validated of this group.  In 
vivo investigation of rat rhabodomyosarcoma found significant correlation between the 
hypoxic volumes identified by [18F]FMISO PET and the volumes detected by Pimo.[148].) In 
studies of the correlation between concentrations of titrated misonidazole ([3H]MISO) and 
oxygen pressures using EMT6/Ro multicell spheroids, accumulation of MISO near the central 
necrosis was observed where oxygen tensions lower than 10mmg were measured[149].  
Interestingly, no [3H]MISO was detected in the area of central necrosis but since MISO 
requires intact nitroreductase enzyme activity, this is perhaps not a surprising finding. There 
have been numerous human studies conducted to evaluate the relationship between tissue 
pO2 and FMISO uptake[150].  These have confirmed a strong correlation between tissue 
pO2 and [18F]FMISO uptake irrespective of the method used to assess tissue pO2 [151].   
Thus far no study has been able to demonstrate a direct linear relationship between pO2 
measurement and amount of FMISO taken up by tissues.  It is therefore not possible at 
present to measure the pO2 of tissues using this non-invasive method. 
1.14.6 Other 2’-nitroimidazole based hypoxia tracers 
Since the advent of [18F]FMISO, several other fluorinated and iodinated agents which utilise 
the nitroimidazole basic structure as its base have been developed.  These include 18F-
fluoroazomycinarabinofuranoside (18F-FAZA) and its iodinated counterpart 123I/124I-IAZA.  In 
preclinical trials, 18F-FAZA is more rapidly cleared from the vascular compartment than 
[18F]FMISO resulting in a higher tumour to blood ratio.  This increased ratio enables the 
investigator to more clearly delineate areas of hypoxia from non-hypoxic tissue.  124I-IAZA 
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exhibited a slightly lower tumour-to-blood ratio compared to [18F]FMISO at three hours but 
the longer physical half-life of the tracer allowed for later time-point imaging [152].  Both 
agents have since been validated in human studies of lymphoma, head and neck tumours 
and lungs tumours but the advantage of these tracers over [18F]FMISO has not been fully 
proven. 
1.14.5 Dithiosemicarbazone compounds 
Dithiosemicarbazone compounds provide investigators with immense flexibility since they 
can be rapidly labeled with a variety of copper isotopes of varying half-lives, including 60Cu (t 
1/2=23.7 min), 61Cu (t 1/2=9.74 min), and 64Cu (t 1/2=12.7 hrs).  Unfortunately, some of these 
tracers have shown quite variable absolute uptakes among different cell lines at the same 
pO2 [153].  These results indicate that whilst tracer uptake in tumours is high in most clinical 
studies, this uptake may not be solely as a consequence of tumour hypoxia.  
1.14.6 Magnetic resonance (MR) techniques 
Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) are tools 
used in a wide variety of clinical settings.  Specialised MRI techniques such as blood oxygen 
level dependent (BOLD)-MRI and Overhauser MRI (OMRI) have been shown to have 
potential to demonstrate tissue hypoxia.  BOLD-MRI uses endogenous signals like 
deoxyhaemoglobin and OMRI uses exogenous paramagnetic contrast agents such as 
triphenyl-methl radicals.  The most widely used MR method to detect tissue hypoxia has 
been fluorine MRS/MRI to assess tumour hypoxia.  It is a sensitive technique and gives a 
measure of interstitial oxygen tension [154]. One of the main disadvantages of this method 
is the false high value of oxygen tension when compared with Eppendorf electrodes [155], 
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something which is difficult to overcome without administering levels of tracer likely to 
cause hepatic toxicity.  BOLD-MRI therefore represents a far more attractive option to 
assess tissue hypoxia as no exogenous marker is required.  Since deoxyhaemoglobin is highly 
sensitive to blood flow, the technique has encountered several obstacles leading to both 
false positive and negative results.  As such a new technique called FLOOD (flow and oxygen 
dependent contract) has been developed and techniques are constantly being designed to 
overcome the issue of in-flow [156]. 
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HYPOTHESIS AND AIMS 
With the background knowledge that hypoxia is present in several animal models of TB 
infections and that hypoxia drives MMP-mediated tissue destruction in other inflammatory 
conditions, my hypothesis is that: 
• Tissue hypoxia increases MMP gene expression and secretion in tuberculosis (TB) 
contributing to inflammation and direct tissue destruction.  
The specific aims of my project are to investigate: 
• The extent of hypoxia in human subjects using PET-CT 
• The effect of hypoxia on MMP/TIMP gene expression and secretion 
• The effect of hypoxia on the transcriptional regulation of MMPs 
• The activation of transcription factors and relevant MMPs in tissue biopsies from TB 
cases 
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CHAPTER 2: METHODS 
 [18F]FMISO PET-CT scans 
Ethical approval for the study was obtained from East London and City Research Ethics 
Committee and Imperial College Healthcare Trust Joint Research Office (Study no. 
10/H0703/43), with further approval by the UK Administration of Radioactive Substances 
Advisory Committee (ARSAC). Patients were recruited by Dr M Belton from Imperial College 
Healthcare NHS Trust with a confirmed microbiological diagnosis of TB, either on acid-fast 
smear and or M.tb culture. All patients had abnormal plain chest radiographs and had 
received less than 2 weeks of anti-TB therapy.   
PET-CT scans were performed on a Siemens mCT (Siemans Medical, Erlangen, Germany) at 
the Department of Nuclear Medicine Charing Cross Hospital, Imperial College NHS Trust, 
London.  [18F]FMISO was synthesized in the Wolfson Brain Imaging Centre, Cambridge 
University.  Patients received 406 ±6 MBq [18F]FMISO intravenously followed by a 90 minute 
uptake period to promote contrast between normoxic and hypoxic tissue on tissue-to-
background (TBR) images, and also to allow the free [18F]FMISO concentration in tissue to 
reach equilibrium with that in blood, a pre-requisite for Patlak plot determination of influx 
rate (Ki) [61]. Immediately following a low dose CT scan for attenuation correction, patients 
underwent a 45 minute single bed position PET scan acquired in list mode.   As Patlak 
analysis requires knowledge of input function to the tissue, three venous blood samples (90, 
135 and 145 minutes post-injection) were taken in order to scale to a population-based 
[18F]FMISO arterial plasma function.  The latter was produced from 6 controls scanned at 
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The Wolfson Brain Imaging Centre, University of Cambridge as part of a study on stroke (PI: 
Prof J-C Baron), which included late venous sampling as part of the study protocol. 
 
[18F]FMISO PET-CT data analysis 
List mode PET data were reconstructed into 9x5min frames using OSEM [62] (8 subsets, 4 
iterations, 5mm FWHM 3D Gaussian post-smoothing filter) into a 168x168x74 array with 
voxel dimensions 4.07 x 4.07 x 3.00mm.  Corrections were applied for randoms, dead time, 
normalization, scatter, attenuation, sensitivity and decay.  To reduce the impact of patient 
motion during PET acquisition, the last 8 frames of the dynamic PET image series were non-
rigidly registered to the first frame using symmetric normalization (SyN) with mutual 
information as the similarity metric  [63].  All PET frames were then registered to CT using 
affine transformation.  The last three of the registered frames (120-135mins post injection) 
were converted to a TBR image through normalization with the radioactivity concentration 
in a bilateral lateral muscle region assumed to represent normoxic tissue.  All 9 frames were 
used to produce a Ki map using Patlak plot analysis.  Regions of interest (ROI) were defined 
on the TBR images and ROI values were determined by placing the ROIs on the TBR and Ki 
maps.  
Cell culture 
A549 cells 
Lung adenocarcinoma A549 cells (ECACC 86012804) were cultured in RMPI 1640 (Invitrogen, 
UK) with 10% fetal calf serum (FCS), 2 mM glutamine, and 10 mg/ml ampicillin. Subculture 
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was performed by washing the cell monolayer twice with 10ml of warmed HBSS, adding 5ml 
of trypsin for 2 mins and then neutralising with 5ml of RPMI 1640.  Cells were then seeded 
at 2-4,000cells/cm2 for further passaging or 35-50,000 cells/cm2 depending on the type of 
experiment being undertaken.  Experiments were performed on cells between passage 8-16 
and all experiments were performed in RPMI 1640 with 2 mM glutamine, and 10 mg/ml 
ampicillin (no FCS added).   
Normal Human Bronchial Epithelial cells (NHBE) 
NHBE cells were purchased form from Lonza as cryopreserved cells and were regenerated 
and maintained according to supplier’s instructions.  In brief, NHBEs were cultured in T75 
tissue culture flasks in 15ml basal cell epithelial growth medium (BEBM) supplemented with 
52 μg/ml bovine pituitary extract, 0.5μg/ml hydrocortisone, 0.5ng/ml human recombinant 
epidermal growth factor, 0.5μg/ml epinephrine, 10μg/ml transferrin, 5μg/ml insulin, 
0.1ng/ml retinoic acid, 6.5 ng/ml triiodothyronine and 10μg/ml ampicillin.  Medium was 
changed on day 1 and day 3.  Once the cells had reached 80-100% confluence (generally day 
6), to subculture, the cell monolayer was washed twice with 10ml warmed HBSS, trypsin 
was added for 2 minutes and then neutralized with 10ml of trypsin neutralising solution.  
Cells were seeded at a density of 60,000cells/cm2 for experiments. 
Monocyte purification and maturation into macrophages 
Monocytes were isolated from healthy blood donors (UK Blood Transfusion Service) using 
Ficoll-Paque (GE Healthcare, Little Chalfont, UK) density centrifugation and a standard 1 
hour adherence protocol.  In brief, the buffy coat from a single blood donor was diluted 
50:50 with HBSS, 35ml was layered onto 15ml of Ficoll-Paque and centrifuged at 1500 rpm 
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for 30 mins.  The resulting monolayer was then washed with HBSS and spun for 5 mins a 
total of 5 times.  Total monocytes were calculated by counting the number of adherent cells 
in a Neubauer counting chamber after incubation for 5 minutes at 37oC. Cells were 
subsequently plated on to tissue culture plates or 60mm dishes at a density of 250,000 
cells/cm2 resuspended in RPMI 1640 (Invitrogen, UK) containing 2mM glutamine and 
10μg/ml ampicillin.  After 1 hour at 370C in a humidified, 5% CO2 incubator, cells were 
washed a total of 3 times; once with the existing RPMI supernatant and then twice with 1 ml 
of warmed HBSS.  Monocytes were then ready for infection with M.Tb.   
Differentiation into macrophages was carried out over a period of 4 days in medium 
containing 10% FCS and 100ng/ml M-CSF (R & D, Abingdon, UK).  After 4 days in the growth 
factor containing media, the media was changed to RPMI with 10% FCS but no growth 
factors, and 24 hours later the experiment was commenced 
 
TB culture 
The virulent M.tb strain H37Rv Pasteur was cultured in Middlebrook 7H9 broth (BD 
Biosciences) with 10% ADC enrichment medium (BD Biosciences), 0.2% glycerol, 0.02% 
tween 80 and 2.5μg/ml amphotericin for infection of cells.  An optical densitometer 
(Biowave Cell Density Meter: WPA) was used to assess the growth of M.Tb.  On a weekly 
basis, M.tb was subcultured by transferring 100-400μl of ultra-sonicated broth into 2ml of 
fresh 7H9, giving a variety of optical densities (OD) for experiments of the next week.  
Experiments were performed with cultures having an OD of 0.5-0.7, corresponding to 108 
colony forming units/ml (CFU/ml) and the mid-log growth phase. Optical density was 
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correlated with CFU by performing colony counts in triplicate on Middlebrook 7H11 agar 
supplemented with OADC enrichment medium and 0.5% glycerol. 
GFP-Tb 
To construct the GFP-expressing M.tb strain, M.tb was transformed with the dual reporter 
plasmid pSMT3LxEGFP (Fig. 9). This plasmid is based on the pSMT3 Escherichia 
coli/mycobacteria shuttle vector and contains the human codon-optimised and 
fluorescence-enhanced EGFP gene from pEGFP (Clontech, Nottingham, UK) cloned under 
the control of mycobacterial 19 kDa promoter, and the luxAB genes from Vibrio harveyi 
under the control of hsp60 promoter.  Positive clones were selected by growing on plates 
and media supplemented with 50 μg/ml hygromycin (Roche Diagnostics, Mannheim, 
Germany).  
 
Figure 9:  Diagram of GFP-expressing M.tb strain 
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Conditioned media preparation 
Conditioned media from M.tb infected moncytes (CoMTb) was produced in batches by 
infecting monocytes seeded in 3ml RPMI on 60mm dishes (see 4.1.3 above) at a multiplicity 
of infection (MOI) of 1 (which equates to ~70μl of TB broth with an OD of 0.6).  A control 
conditioned media from uninfected cells (CoMCont) was also produced in the same way but 
without the infection step.  After 24 hours, the cell medium culture was harvested, 
centrifuged at 13,000rpm for 5 minutes and filtered to remove infectious material using a 
0.2μm anapore filter (Whatman, UK).  All CoMTb batches were tested by MMP-1 ELISA on 
either A549 or NHBE cells and only those producing a good MMP-1 response were 
subsequently used in experiments.  CoMTb batches were aliquoted and stored at -200C. 
 
Direct infection protocol 
After 5 days maturation, the supernatant from 24 well plates of MDMs was removed and 
replaced with 400μl of macrophage serum free medium (MSFM, Invitrogen, UK) in each well 
prior to infection at a MOI of 1 (~5ml M.tb broth).  Cells were incubated at 370C for 2 hours 
after which non-phagocytosed M.tb was removed by suctioning the supernatant and 
replacing with 400μl per well of fresh medium.  Cell supernatants for analysis were 
harvested at 72 hours and spun at 13,000 rpm for 5 minutes using a 0.2μm anapore filter 
(Whatman, UK).  Samples were then stored at -200 C.  Direct infection of samples for HIF-1α 
Western Blot analysis was performed in the same way but without replacing the 
supernatant at 2 hours. 
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CoMTb experiment protocol 
Experiments involving A549 cells were performed using RPMI 1640 and those involving 
NHBE cells used BEBM supplemented as per the manufacturers’ instructions (see above).  
Experiments were performed 24 hours after the seeding of tissue culture plates at the 
appropriate density.  These were 70% for transfection experiments and 80-100% for all 
other experiments.  Apart from dose-response experiments, all studies were performed 
using CoMTb at a 1:5 dilution.  Previous kinetic experiments of the JSF laboratory have 
shown that the 72 hour time point is the appropriate time to harvest supernatants for MMP 
secretion quantification.  
 
LDH cytotoxicity assay 
The cytotoxic impact of hypoxia on cultured cells was assessed by measurement of lactate 
dehydrogenase (LDH) in cell culture supernatants.  LDH levels are measured using 
Cytotoxicity Detection Kit (Roche Applied Sciences) according to the manufactures 
instructions.  Briefly, cell culture supernatants were harvested at 72 hours along with 
supernatants from unstimulated cells (low control) and those having undergone complete 
chemical lysis (high control) with 5µl 1% triton X per well.   A reaction mixture of 250µl of 
reconstituted bottle 1 (catlaysis) and 11.25ml of bottle B (dye solution) was prepared and 
100µl added per well to a 96 well tissue culture plate.  100µl each of samples and controls 
were then added to each well followed by 50µl of Stop solution.  The plate was then shaken 
at a speed of 500rpm for 10 seconds and the samples analysed immediately on Bio-Orbit 
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1253 luminometer (Labtech International) at 490nm, with a reference wavelength over 
600nm. 
LDH cytotoxicity of experimental samples were calculated using the following equation 
Cytotoxicity= exp. Value-low control    x100 
                        high control-low control 
 
 
Colony counting 
Following 72 hours of infection with M.Tb, MDMs were lysed with 100µl of sterile 0.1% 
Triton X and 2µl of the lysate diluted with 198µ of 7H9 Middlebrook 7H9 broth (BD 
Biosciences) with 10% ADC enrichment medium (BD Biosciences), 0.2% glycerol and 0.02% 
tween 80.  5µl of serial 1 in 10 dilutions were then plated (in triplicate) onto 7H11 agar 
plates Middlebrook 7H11 agar (BD Biosciences) with 10% OADC enrichment medium (BD 
Biosciences) and 0.005% glycerol and colony counting performed between 2 and 3 weeks 
after initial plating based on the assumption that one colony represented a single Tb bacilli. 
 
Generation of hypoxia 
All cells were incubated at 37˚ in a humidified atmosphere containing either 5% CO2 
(normoxia) and the required oxygen level.  Initial experiments were either performed using 
a dedicated hypoxic chamber (kindly loaned by Patrick Maxwell, UCL) adapted from an 
anaerobic jar (Oxoid) or a hypoxic incubator (Galaxy CO14S, New Brunswick).   
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Figure 10: Oxoid hypoxic chamber. Prior to each incubation, the chamber was secured in a 
horizontal position. Plates were loaded along with a T-25 flask containing sterile water to ensure 
sufficient humidification. After sealing, the chamber was evacuated (-0.6 Bar) and filled with a 
hypoxic gas mixture (1% O2, 5% CO2) (repeated 3x as per manufacturer’s instructions) and placed in a 
standard incubator set to 37°C.? 
 
Subsequently, a custom designed hypoxia workstation was built and approved for use with 
Containment Level 3 pathogens (Coy Laboratories).  Prior to commissioning the workstation, 
a mock up to the exact proposed dimensions was made out of cardboard.  This was then 
placed within the Class I cabinet and airflow testing performed to ensure that the 
workstation did not interfere with airflow.  The cabinet was made from acrylic which could 
withstand formaldehyde fumigation in the event of a large spill of M.tb however small spills 
were managed as others in the CL3 with alcohol decontamination.  The design of the 
workstation incorporated an airlock facility as well as a temperature controlled humidified 
incubator allowing the handling and manipulation of cells without any exposure to ambient 
air.    Stable O2 and CO2 levels were maintained through sensors which continuously 
monitored and adjusted gas levels.  The workstation was commissioned by a Coy approved 
engineer who ran temperature and humidity testing and compared these to a control CO2 
incubator in the CL3 to ensure that comparable environments were present in both.  In 
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addition, CO2 and O2 levels were measured using gas sampling meters.  Sensors were 
calibrated once per month according to the manufacturers’ instructions. 
 
 
Figure 11:  Technical drawings of specially commissioned hypoxia workstation designed to fit 
within Class I cabinet in the CL3 facility of the JSF laboratory 
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Figure 11 continued 
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HIF-1α stabilisation 
The pan hydroxylase inhibitor 2-oxoglutarate dimethyloxalylglycine (DMOG) was used to 
inhibit HIF prolyl and asparaginyl hydroxylases (PHD1/2/3 and FIH respectively).  By blocking 
the activity of these hydroxylases, DMOG stabilises HIF-1α and activates the HIF system.  
Cell viability at the completion of experiments (72 hrs) was assessed by trypan blue 
exclusion assay 
 
Enzyme Linked Immunosorbent Assay (ELISA) 
MMP and TIMP levels in cell culture medium were measured by ELISA (R&D Systems, UK) 
according to the manufacturer’s instructions. Briefly, a 96-well plate was coated with the 
appropriate capture antibody and incubated at room temperature (RT) overnight. Wells 
were then blocked for 1h using 0.5% BSA in PBS. Standard curve (loaded in duplicate) and 
supernatants from 72h-conditioned cell culture ware added at the appropriate dilution to 
each well and incubated for 2h hours at RT. Biotinylated detection antibody was then added 
and incubated for 1 hour at RT followed by HRP-conjugated streptavidin, incubated for 
20min. The substrate tetramethylbenzidine (TMB) was added to the wells, and the reaction 
terminated using 1M H2SO4.  MMP-1, MMP-3, MMP-9 and TIMP-1 levels were quantified by 
measuring optical density at 450nm, with a 540nm reference wavelength. 
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Fluorokine ® MAP Assay (Luminex xMAP® analysis) 
Luminex analysis (R&D systems, UK) is a microparticle based multiplex immunoassay for the 
accurate quantification of human MMPs 1, 2, 3, 8, 9, 12 and 13 in various sample types 
(serum, plasma and cell culture supernatants).  This assay provides simultaneous 
quantification of these MMPs in a single small volume.  MMPs 1, 3 and 7 were measured 
according to the manufacturers’ instructions.  In brief, MMP specific antibodies are 
purchased pre-coated onto colour-coded microparticles or beads.  Microparticles, standards 
and samples are pipette into 96 well luminex plates and shaken at a speed of 500rpm for 2 
hours to allow the immobilised antibodies (on the suspended beads) to capture the MMP of 
interest.  After washing away any unbound substances, biotinylated antibodies specific to 
the MMPs of interest are added and shaken for a further 2 hour at 500rpm.  Finally, 
streptavidin PE (phylocoerythrin) were added to generate a signal and the beads 
resuspended and read using a Luminex® dual laser analyser.  The first laser classifies the 
bead and determines which MMP is being detected whilst the second determines the 
magnitude of the PE derived signal, which is directly proportionate to the amount of MMP 
bound.  In addition to MMP analysis, 30-plex analysis of a broad spectrum of cytokine, 
chemokines and growth factors was performed using the Luminex platform in collaboration 
with other members of the JSF group. 
 
Zymography 
Zymography is a substrate-based SDS-PAGE electrophoresis, using 11% polyacrylamide gels 
and is used to detect MMPs by the degradation of their preferential substrate as well as by 
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their molecular weight.  Proteins are separated in a denaturing in an SDS-PAGE containing a 
specific substrate that is co-polymerised with the acrylamide.  Following electrophoresis, the 
gel is washed with Triton X-100 which restores enzyme structure and proteolytic activity.  
The renatured MMPs in the gel digest the substrate when incubated in appropriate 
activation buffer i.e. collagenase buffer.  This enzyme activity is then seen as white bands on 
Comassie stained gels.  Densitometric image analysis is   performed by digital image 
acquisition (UVP) followed by band quantification with NIH Image version 1.61 (Scion 
Image). 
 
Casein zymography 
Casein zymography to analyse MMP-1 concentrations was performed as previously 
described (Leber et al, 1997). Briefly, 20μl aliquots of cell culture supernatant with 5x 
loading buffer (0.25 M Tris pH 6.8, 50% glycerol, 5% SDS, bromophenol blue) were run on 
11% acrylamide gels impregnated with casein (Invitrogen) at 125V for 2 hours (buffer 25 
mM Tris, 190 mM glycine, 0.1% SDS). After incubation in 2.5% Triton X-100 (Amresco 0694-
1L) for 1 hour with agitation and two brief washes in collagenase buffer (55 mM Tris base, 
200 mM sodium chloride, 5 mM calcium chloride, 0.02% Brij, pH 7.6), gels were incubated 
for 40 hours in fresh collagenase buffer at 37°C. Caseinolytic activity was detected by 
staining the gels with 0.1% Coomasie blue (Pharmacia Biotech, Sweden) in 1:4 acetic acid: 
water for 1 hour with agitation and then destaining for 15 min with 1:3:6 acetic acid: 
methanol: water. All experimental samples were run in parallel with 10 ng recombinant 
MMP-1 (Merck) to standardize between gels. 
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Gelatin zymography 
Gelatin zymography was performed for the detection of MMP-9.  20μl aliquots of cell 
culture supernatant mixed with 5x loading buffer (0.25M Tris pH 6.8, 50% glycerol, 5% SDS, 
bromophenol blue) were run on 11% acrylamide gel impregnated with 0.1% gelatine 
(SIGMA G2500) at 180V for 3-4 hours (buffer 25mM Tris, 190 mM glycine, 0,1% SDS).  After 
incubation in 2.5% Triton X-100 (Amresco 0694-1L) for 1 hour with agitation (to remove the 
SDS), the gel was rinsed twice in 1x low salt collagenase buffer (55mM Tris base, 200mM 
NaCl, 5mM CaCl2, 0.02% Brij-35, pH 7.6) prior to incubation at 370C for 16 hours in fresh 
collagenase buffer.  The following day, gelatolytic activity was detected by a single step 
stain/de-stain method using 0.02% Comassie blue (Pharmacia Biotech, Sweden) in 1:3:6 
acetic acid: methanol: water.   
 
Anti-HIF-1α Western blotting 
Cells were initially washed with 1ml sterile PBS and then lysed in SDS sample buffer 
(62.5mM Tris, 2% SDS, 10% glycerol, 50mM DDT, 0.01% bromophenol blue).  For MDMs 
directly infected with M.Tb, samples were spun at 13,000 rpm for 5 mins then filtered 
through a 0.2μm anapore filter (Whatman) to ensure the removal of any infectious material.   
Sample could then be safely removed from the CL3 facility.  20µl samples were heat-
denatured at 70°C for 10min and separated on a NuPAGE Bis-Tris 4-12% gel (Invitrogen) at 
200V (Running buffer: 50mM MOPS, 50mM Tris, 0.1% SDS, 1mM EDTA) for 1h. Gels were 
electro-transferred to a nitrocellulose membrane (Amersham, UK) and blocked for 1h with 
5% milk protein, 0.1% Tween-20. The membrane was probed with anti-HIF1α Ab (1:1,000 
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dilution) (BD Biosiences, UK) overnight, washed, and incubated with goat anti-mouse IgG 
horseradish peroxidase (HRP)-conjugate secondary Ab (1:1,000 dilution) (Jackson 
ImmunoResearch)  for 1h. Loading control was performed using the rabbit-anti p38 Ab 
(1:1,000 dilution) (Cell Signalling Technology) and goat anti-rabbit IgG HRP conjugate 
(1:1,000 dilution) (Cell Signalling Technology) Luminescence was detected with the ECL 
system (Amersham) according to manufacturer’s protocol. 
 
Transformation of competent E.Coli with MMP-1 promoter constructs 
10 µl of plasmid DNA was added to chilled sterile polypropylene tubes containing 100 µl of 
competent E.coli cells (Invitrogen).  Cells were gently mixed using a pipette tip and placed 
on ice for 30 mins.  In order to assess transformation efficiency, 5 µl of control DNA was 
added to an additional chilled polypropylene tube containing competent cells.  Cells were 
then heat shocked in a 42oC water bath for 45 secs and immediately placed on ice for 2 
mins.  0.9ml of SOC medium (Invitrogen) was added to each tube and cells were then 
incubated in a shaking incubator (at 225rpm) at 37 0C to allow expression of antibiotic 
resistance.  After 1 h the contents of each tube was diluted 1:10 and 1:100 with SOC 
medium and plated on 15% LB agar plates containing 0.1mg/ml ampicillin. Plates were 
incubated overnight at 370C until colonies developed.  A single colony from each plate was 
selected and used to inoculate a starter culture containing 5ml of sterile LB media (Sigma) 
and 0.1 mg/ml ampicillin.  The starter culture was placed on a shaking incubator 150rpm at 
370C for 8 hours to allow the E.coli cells to reach late logarithmic phase.  400µl of each 
started culture was then added to 200ml LB media and placed in a shaking incubator for 16 
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h at 370C.  E.coli cells were harvested by centrifugation in a 50ml falcon at 6000g for 15 mins 
at 40C following which supernatants were drained and discarded.   Cell pellets were frozen 
and stored at -20 0C if not proceeding immediately to DNA plasmid purification.    
Alkaline Lysis and plasmid DNA purification 
Alkaline lysis and plasmid DNA purification was performed using the Qiagen Maxi Kit® 
according to the manufacturers’ protocol.  In short, bacterial pellets were resuspended in 
8ml buffer P1 containing 100 µg/ml RNase A solution and mixed by pipetting until no clumps 
remained.  8ml of buffer P2 was then added and the cells suspension gently mixed by 
inversion of the falcon 4-6 times.  The suspension was then allowed to incubate at room 
temperature for 5 mins after which 8ml of chilled buffer P3 was added.  Following gentle 
mixing, the lysate was placed on ice for 20 mins.  The lysate was then centrifuged at 
13000rpm for 30mins at 40C after which the supernatant containing the plasmid DNA was 
promptly removed and placed in a 50ml falcon and centrifuged at 13,000rpm for a further 
15 mins at 40C.  Supernatants were immediately placed in the Qiagen tips-500 equilibrated 
with 8ml buffer QBT and the column allowed to empty by gravity.    The tip was washed x2 
with 25ml buffer QC and the plasmid DNA then eluted with 12ml buffer QF into a clean 50ml 
centrifuge tube.  8.5ml of isopropanol was then added to the eluted DNA in order to 
precipitate the DNA.  The DNA was then centrifuged immediately at 12,000rpm for 30 mins 
at 40C and the supernatant carefully decanted.  The DNA remaining pellet was washed with 
4ml of 70% ethanol and centrifuged at 12,000rpm for 10 mins after which the supernatant 
was removed and the pellet allowed to air dry.  The dried pellet was resuspended in 500 µl 
TE buffer (pH 8.0) and DNA OD 260/280 measured for quantitation. 50 µl aliquots were then 
stored at -800C for subsequent use. 
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Promoter-reporter assay 
A549 cells were seeded in 12-well plates at 160,000 cells/well in RPMI 1640 containing 2 
mM glutamine, 10% FCS, and 10 µg/ml ampicillin. Cells were transfected 24 h later in serum-
free medium with 0.8 µg of MMP-1 promoter DNA inserted into the firefly luciferase 
expression plasmid pGL2-basic (gift from Dr. I. Clarke, University of East Anglia, East Anglia, 
U.K.) and 0.08 µg of control reporter plasmid, pRL-TK, constitutively expressing low level 
Renilla luciferase activity, suspended in 2.4 µl of FuGene 6 (Roche). After 12h, cells were 
stimulated with CoMTb at a 1:5 dilution in the presence or absence of 0.25mM DMOG (4h 
pre-incubation period). After another 24h, cells were washed with 100µl of sterile PBS, lysed 
in 100µl of Passive Lysis Buffer (Promega) and frozen at -80°C. Luciferase activity of extracts 
was measured using the Dual-Luciferase Reporter Assay System (Promega) analyzed with 
the Bio-Orbit 1253 luminometer (Labtech International). Renilla luciferase activity was used 
to normalize firefly activity to control for transfection efficiency. The following construct 
were used: -4372 (WT), -3830, -2942, -2001, -1551, -1194, -517 (Figure 12). 
 
 
Figure 12:   MMP-1 promoter truncation constructs. HIF-1, AP-1 and NF-κB binding sites are 
indicated 
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RNA extraction (early experiments) 
RNA was extracted from cultured cells using Qiagen RNeasy® Mini Kit and according to the 
manufacturers’ protocol.  Cell-culture medium was completely aspirated and discarded after 
which 175μl of precooled (40 C) Buffer RLN was added.  Cells were gently scrapped, 
transferred to a microcentrifuge tube then incubated on ice for 5 mins.  The lysate was then 
centrifuged at 40 C for 2 mins at 300 x g.  The supernatant from this tube was then 
transferred to a new centrifuge tube and the centrifuge heated to 20-250 C.  600μl of Buffer 
RTL was added to the supernatant and then briefly vortex to ensure complete mixing.  430μl 
of ethanol (96-100%) was added to the homogenised lysate and mixed by pipetting.  Up to 
700μl of the sample was transferred to an RNeasy spin column placed in a 2ml collection 
tube and centrifuged for 15 s at ≥10,000rpm.  The flow-through was then discarded and this 
step repeated with the remaining sample.  700μl Buffer RW1 was then added to the RNeasy 
spin column and centrifuged 15 s at ≥10,000rpm to wash the spin column and the flow-
through discarded.  Next, 500μl Buffer RPE was added to the RNeasy spin column and 
centrifuged 15 s ≥10,000rpm and the flow-through discarded.  This step was then repeated 
a second time.  Finally, the RNeasy spin column was placed in a 1.5ml collection tube and 
30-50μl RNase free water was added directly to the spin column membrane.  The sample 
was centrifuged for 1 min at ≥10,000rpm to elute the RNA.  Samples were stored at -800 C if 
not proceeding immediately to cDNA synthesis. 
 
cDNA synthesis (early experiments) 
cDNA synthesis by reverse transcription, using the extracted RNA as a template, was 
performed as a prerequisite for Quantitative Real Time PCR. For each sample a volume of 
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RNA equivalent to 250ng, 500ng, 1µg was diluted up to 11µl with RNase-free water. 1 µl of 
random primers (Invitrogen) was added to each sample. The samples were heated at 65˚C 
for 10 minutes. A mastermix containing 5x 1st strand buffer, 10mM dNTPS, DTT, RNase OUT 
and Superscript III (Invitrogen) in the correct proportions was made. The samples were 
placed on ice for 1 minute. 8µl of the mastermix was added to each sample. And they were 
incubated at 50˚C for 1 hr, then 75˚C for 15 mins. If not proceeding to RT-PCR straight away 
the cDNA samples were stored at -20˚C.  
 
RNA extraction (2011 onwards) 
RNA was extracted from cultured cells using PureLink RNA® Mini Kit (Invitrogen) and 
according to the manufacturers’ protocol.  Cell-culture medium was completely aspirated 
and discarded after which cells were washed with 1ml of sterile PBS and 1ml of trizol was 
added.  Cells were gently scraped and transferred to microcentrifuge tubes and 200µl of 
chloroform added per sample.  Samples were shaken vigorously by hand and incubated at 
room temperature for 2 mins.  Samples were then centrifuged at 12,000g for 15 mins at 40C 
and the colourless upper phase (350µl) transferred to a sterile RNase free microcentrifuge 
tube.  350µl of 70% ethanol was added to the samples which were then vortexed and 
inverted until all visible precipitate had dispersed.  Samples were then transferred to a spin 
cartridge placed in a 2ml collection tube and centrifuged at 12,000g for 15 secs at room 
temp following which the flow through was discarded. 700µl of buffer I was added to the 
spin cartridge and centrifuged at 12,000g for 15 secs and the flow through discarded. 500µl 
of buffer II was then added to the cartridge and centrifuged for 15 sec and the flow through 
discarded.  This step was then repeated with a further 500µl of buffer II.   The spin cartridge 
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was then centrifuged at 12,000g for 1 min to dry the membrane after which the RNA bound 
to the cartridge membrane was eluted with 30µl of RNase free water.  The spin cartridge 
was centrifuged for 1 min at 12,000g at room temperature and this step was then repeated 
with the same 30µl of RNase free water to increase the RNA yield.  RNA concentrations 
were then determined using the nanodrop and stored at -80oC.  
 
cDNA synthesis (2011 onwards) 
cDNA synthesis by reverse transcription, using the extracted RNA as a template, was 
performed as a prerequisite for Quantitative Real Time PCR.  cDNA synthesis was performed 
using QuantiTect Reverse Transcriptase Kit (Qiagen) according to the manufacturers’ 
protocol.  RNA samples were diluted to an RNA equivalent value to the quantity required up 
to 12µl RNase free water and incubated on ice.  2µl of gDNA wipeout buffer was added to 
each sample to remove genomic DNA.  Samples were heated to 42oC for 2 min and 
immediately placed on ice.  A reverse transcriptase mastermix was made from Quantiscript 
Reverse Transcriptase, Quantiscript RT buffer 5x and RT primer mix in the correct 
proportions, mixed and incubated on ice.  6µl of reverse transcriptase mastermix was added 
to each sample and the tubes gently flicked and briefly spun to mix and the mastermix 
placed on ice.  The samples were then heated to 42oC for 15 min and then immediately 
heated to 95oC for 3 min.  If not proceeding immediately to RT-PCR, cDNA was stored at -
20oC 
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RT-PCR 
cDNA was prepared at a 1:50 dilution in RNase free water.  Five standards were prepared 
using the sample with the highest expected level of the gene of interest and serial 1:5 
dilutions.  The gene of interest was normalised to 18s however since this time the JSF group 
have moved to β-actin as its primary reference gene.  A mastermix was prepared with 
specific probes (0.5 μl FAM for MMP-1 from Sigma; 0.125μl for 18S from Applied 
Biosystems) and primers (0.25μl for MMP-1 and 0.125μl for 18S) , Brilliant II 12.5μland 
nuclease free water up to a volume of 15μl.   15μl mastermix was mixed with 10μl of 
standard or sample then 15μl added to the wells of Framestar 96-well plates which was 
then centrifuged at 300rcf for 5 mins at 4 degrees.  The plate was centrifuged at 300 rcf for 
5 minutes at 4˚C. RT PCR was performed on a Stratagene Mx3000Pro machine with an initial 
10 minute denaturation step at 95˚C followed by 50 cycles at 95˚C for 30 seconds then 60˚C 
for 1 minute.  MMP-1 gene expression was normalised to 18s.  Data was expressed as fold 
change compared to control. 
 
siRNA  
Monocytes were isolated and differentiated into MDMs.  MDMs were transfected using 
DharmaFECT 3 transfection reagent with either non-targeting control siRNA or HIF-1α siRNA 
smartpool (Dharmacon, FisherScientific, Loughborough, UK), according to the supplier’s 
instructions.  Transfection medium was replaced with RPMI at 8hrs and cells allowed to rest 
for 16hrs, at which time the MDMs were infected with M.tb H37Rv (MOI= 1).  Cell culture 
supernatant and cell lysates were harvested for HIF-1α and MMP-1 mRNA and protein 
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secretion analyses.  To access transfection efficiency, MDMs were also transfected with 
25nM FAM conjugated non-targeting control siRNA, detached from the plates with cell 
dissociation buffer (Gibco, Invitrogen) and analysed by flow cytometry (FACSCalibur, BD 
Biosciences).  Transfection efficiency was 80.4%. 
 
Figure 13:  FACS analysis of siRNA transfection efficiency of primary human MDMs with FAM NT 
siRNA 
Confocal microscopy 
Primary human monocytes were matured to macrophages in 4-well Permanox plastic 
chamber slides (Thermo Fisher Scientific Inc. UK).  Cells were fixed for 3 days following 
infection with 4% paraformaldehyde in PBS for 30 minutes. Cells were permeabilized with 
0.5% saponin and blocked with 1% BSA for 1 hr.  Cells were incubated with anti-MMP-1 
primary Ab (1:200, Abcam, UK) overnight, washed and incubated with goat anti-mouse 
secondary Ab (1:100, Abcam, UK) and labelled with FITC for 2 hrs.  Nuclei were visualized 
using DAPI.  The images were scanned under an x60 oil immersion objective and to avoid 
bleed-through effects, each dye was scanned independently by a Leica TCS SP5 equipped 
with an argon-krypton mixed gas laser. Image analysis was with Leica confocal software 
(Leica Microsystems, Germany) and Image J v1.48a.  
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Immunohistochemistry 
HIF-1α immunohistochemistry was performed on formalin-fixed, paraffin-embedded lung 
biopsies from six patients with culture-proved M.tb infection and six non-infected control 
samples.  Immunohistochemistry staining was performed using Bond III fully automated 
staining system with the Bond Polymer Refine Detection system and associated reagents 
(Leica Microsystems, Newcastle-Upon-Tyne, UK).  Antigen retrieval was carried out using 
Epitope retrieval pH 6 (ER1) at 100°C for 30mins.  The antibody HIF1-α (Abcam AB1) was 
applied for 30mins at a dilution of 1/500.  The detection system uses DAB as chromogen and 
section were counterstained with haematoxylin.   
 
Statistical analysis 
Statistical analysis of the data was carried out using Prism GraphPad software. The main 
statistical test used was a one-way ANOVA, for comparison of multiple groups, with Tukey 
correction for multiple comparisons. The student t-test was used for direct comparison of 
two groups, where relevant.  Unless stated otherwise, all experiments were performed in 
triplicate  and performed at least twice.  A p value ≤ 0.05 was considered significant. 
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CHAPTER 3:  INVESTIGATION OF HYPOXIA IN HUMAN PULMONARY 
TB USING PET-CT 
Introduction 
Radiological imaging of pulmonary TB has been performed in several modalities including 
plain x-rays, CT scanning and nuclear medicine techniques such as FDG-PET.  In the clinical 
setting, plain CXR is the most commonly used radiological technique used to monitor both 
disease progression and response to treatment.  CT is frequently employed in the developed 
world to aid with diagnosis and monitor treatment, particularly in cases of drug-resistant 
disease.  The role of FDG-PET in the diagnosis of M.tb infection has been limited by its 
inability to reliably distinguish between M.tb infection and lung malignancy [157, 158].   
The imaging of hypoxia in patients with TB, pulmonary or extra-pulmonary, has not 
previously been performed.  Similarly, no studies to confirm the presence of hypoxia, by any 
modality, in TB patients have been undertaken.  Of the methods available to measure tissue 
oxygenation, imaging with the hypoxia tracer 18F-FMISO using PET-CT was considered to be 
the most appropriate for my study.  The use of pO2 polarography requires an accessible site 
to insert the probe and pimonidazole requires an invasive excision biopsy, neither of which 
is appropriate in pulmonary disease.  The decision to use the tracer 18F-FMISO was based 
on two fundamental principles, 1.)  18F-FMISO is the most extensively studied hypoxia tracer 
with no known harmful side-effects in humans, 2.) The half-life (t1/2) of 18F-FMISO is 110 
mins meaning that that most of the tracers will have dispersed by the end of the study.  This 
means that at the end of the study, an individual can continue with their daily activities with 
minimal disruption.  It also meant the period of isolation from children and/or pregnant 
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women was only 24 hrs from the start of the study, which is equivalent to a standard FDG 
PET-CT study. The t1/2 of 18F-FMISO was also an important consideration as the tracer was 
produced by the Wolfson Brain Imaging Institute, University of Cambridge and then 
transported an a specially designed vehicle to Charing Cross Hospital.  A tracer with a 
shorter t1/2 would have decayed en-route and not been suitable for use. 
The protocol for the study and methods of data analysis are contained within the Methods 
section of this thesis. In order to cause the least disruption to the patient, our protocol 
involved late PET-CT imaging (90 minutes after administration of [18F]FMISO).  This allowed 
for patients to be scanned at the earliest time that the tracer is known to have reached 
equilibrium in the blood.  In addition, our patients had x3 venous samples from a single 
cannula performed as opposed to the arterial blood samples of other [18F]FMISO studies, 
which can be significantly more uncomfortable for patients.  Samples were then scaled 
according to a population-based [18F]FMISO arterial plasma input function scale produced 
from n=6 controls scanned at Wolfson Brain Imaging Centre, University of Cambridge as part 
of a study on stroke (PI: Prof J-C Baron); which included late venous sampling as part of the 
study protocol.  
 The study was approved by East London and City Research Ethics Committee and Imperial 
College Healthcare NHS Trust Joint Research Office.  The study was also approved by UK 
Administration of Radioactive Substances Advisory Committee (ARSAC). Patients were 
recruited from Imperial College Healthcare NHS Trust during the period Jan 2011-Jan 2013.  
PET-CT scan were conducted within the department of Nuclear Medicine at Charing Cross 
Hospital.  Patients were recruited according to the following inclusion and exclusion criteria 
and asked to sign a consent form prior to their participation in the study. 
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Inclusion criteria Exclusion criteria 
Confirmed diagnosis of pulmonary TB (either 
smear or culture) 
Prisoners, patients unable to give consent, 
children under the age of 18 years 
Evidence of one or more radiographic 
abnormalities associated with TB e.g. cavities, 
nodules, consolidation, fibrosis or calcific 
changes 
Patients with pre-existing lung disease of any 
aetiology 
Treatment naïve or within 4 weeks of having 
commenced anti-TB medication 
Individuals with a history of previously treated 
TB 
HIV negative Individuals with a past history of clastrophobic 
anxiety disorder 
 
Table 2:  Patient criteria for recruitment to clinical study 
Patients with HIV infection were excluded as TB infection in HIV co-infected individuals shows 
different clinical features to HIV negative patients.  In particular, these patients do not develop 
cavitatory lung disease.  Pregnant women were excluded because of the potential teratogenic 
effects of radiation to a developing fetus.  Finally, the initial exclusion excluded smokers from the 
study and this might act as a hypoxia confounder.  As the recruitment process progressed it became 
evident that smokers formed a significant proportion of the TB population and such an exclusion was 
not reflective of the general TB population.  Smokers and ex-smokers were therefore included in the 
study along with non-smokers. 
Results 
In total, six patients were the recruited to the study however, PET-CT scans were only 
performed in five individuals.  This was because of failure of production of [18F]FMISO on 
one occasion meaning there was insufficient yield available to perform the scan.  Despite 
the inclusion criteria detailing that patients should not have received four or more weeks of 
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anti-TB medication, all patients underwent their scan within 14 days of commencing 
treatment with 4 of the patients being scanned within 8 days. 
Clinical and laboratory data collected at the start of the study are recorded in Table 3 and 
Table 4.  Antibiotic sensitivity results were verified by the UK National Reference laboratory 
(Health Protection Agency) and were added later (usually 6-8 weeks after commencing 
treatment). 
Data from the scans along with gamma counts of the three blood samples were transferred 
to the Wolfson Brain Imaging Institute, University of Cambridge where they were analysed.  
The amount of uptake of [18F]FMISO in a specific region of interest (ROI) was measured at 
the end of the scan i.e. 145 minutes after injection of the tracer and recorded as the 
standardised uptake value (SUV).  The same frames then underwent Patlak analysis to 
perform Ki mapping where Ki represents the rate of influx of tracer and is a more specific 
marker of hypoxia.  It was possible to undertake Patlak analysis since the study protocol was 
designed in such as way so as to allow a total of nine five minute dynamic acquisition 
windows to be performed.  During the dynamic acquisition windows, the influx and efflux of 
tracer were measured and the background blood levels of [18F]FMISO digitally subtracted.  
This data was then used to produce Ki images which demonstrate the trapping of tracer 
within regions of severe hypoxia (pO2<10mmHg). 
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Patient 1Paatient 
1 
 
Patient 2 
 
Patient 3 
 
Patient 4 
 
Patient 5 
 
Sex (M/F) 
 
M 
 
F 
 
F 
 
F 
 
F 
 
Age (years) 49 22 31 37 62 
 
Country of origin Romania Mongolia Nepal Philippines Morocco 
 
Height (cm) 178 160 153 157 156 
Weight (kg) 64 53.2 44.9 45.3 48 
 
Duration of symptoms  6 months 3 months 1 month 1 month 1 month 
 
Symptoms 
Cough 
Weight loss 
Fever 
Haemoptysis 
GI symptoms 
Lethargy 
 
+ 
+ 
+ 
+ 
- 
- 
 
+ 
- 
+ 
- 
- 
- 
 
+ 
+ 
+ 
- 
+ 
- 
 
+ 
+ 
+ 
- 
- 
- 
 
+ 
- 
+ 
- 
- 
+ 
 
Smoking status  Current 
30 pack years 
 
Never Never Never Never 
CXR  
Consolidation 
Cavitation 
Fibrosis 
 
+ 
+ 
- 
 
+ 
+ 
- 
 
+ 
- 
+ 
 
+ 
+ 
- 
 
+ 
+ 
- 
 
Sputum smear AFB +++ AFB +++ AFB + AFB + AFB +++ 
 
 
Days to M.tb culture 
positivity 
 
Antibiotic sensitivity 
 
3 days 
 
 
Fully sensitive 
 
7 days 
 
 
Resistant 
isoniazid + 
streptomycin 
 
26 days 
 
 
Fully 
sensitive 
 
7 days 
 
 
Resistant 
rifampicin, 
isoniazid + 
prothionomide 
 
 
5 days 
 
 
Fully sensitive 
 
Table 3:  Patient demographics, chest radiograph and microbiology results 
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Patient 1 1Patient 
1 
 
Patient 2 
 
Patient 3 
 
Patient 4 
 
Patient 5 
Haematology 
Hb (g/dl) 
WCC (x109g/l) 
Neutrophil (x109g/l) 
 
Biochemistry 
Na (mmol/l) 
K+ (mmol/l) 
Urea (mmol/l) 
Cr (µmol/l) 
 
CRP (mg/l) 
 
Liver function 
Bilirubin (µmol/l) 
ALT (IU/l) 
ALP (IU/l) 
Total protein (g/l) 
Albumin (g/l) 
 
HIV status 
 
Vitamin D (nmol/l) 
 
 
10.8 
7.5 
6.0 
 
 
129 
4.0 
3.5 
52 
 
189 
 
 
10 
39 
135 
62 
39 
 
Negative 
 
26.0 
 
 
 
 
10.2 
7.7 
4.4 
 
 
141 
4.1 
3.5 
53 
 
10.6 
 
 
n/a 
n/a 
n/a 
n/a 
n/a 
 
Negative 
 
28.6 
 
 
10.1 
10.4 
7.3 
 
 
134 
4.8 
2.4 
55 
 
150 
 
 
6 
13 
95 
70 
27 
 
Negative 
 
24.3 
 
 
 
12.7 
16.4 
12.8 
 
 
132 
4.0 
3.1 
65 
 
69 
 
 
11 
29 
114 
72 
24 
 
Negative 
 
25.9 
 
 
10.4 
10.7 
8.7 
 
 
132 
4.0 
8.1 
97 
 
312 
 
 
12 
<6 
113 
75 
49 
 
Negative 
 
  14.9 
      
      
Table 4:  Blood analysis at time of presentation     n/a, not available 
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Patient 1 
Results from Patient 1 revealed evidence of high uptake of [18F]FMISO throughout both lung 
fields at 145 minutes (SUV).  In particular, uptake in the left upper lobe and right upper lobe 
were extremely high (Figures 14 and 15).  Once Patlak analysis was performed, high Ki areas 
were seen in the right upper lobe and sporadically within the left upper lobe.  Interestingly, 
when the changes present in the left lung were analysed most of the regions of high SUV did 
not correlate with high Ki mapping (Figure 15).  This discordance can be explained by 
analysing the Time Activity Curves (TAC) along with SUV and Ki mapping (Figure 16).  It is 
expected that blood [18F]FMISO levels should decrease over time as the tracer decays.  As 
such, the TAC in a region of interest will have the same shape of curve if the tracer is 
decaying and not accumulating in that area.  The TACs for Patient 1 show that the curves for 
the left upper and left lower lobes follow the same curve for blood [18F]FMISO levels.  It is 
likely therefore that the changes seen in most of the left lung are due to hyperperfused, 
normoxic lung tissue.  In direct contrast, the changes in the right upper lobe demonstrate 
high SUV, high Ki and increasing TAC of [18F]FMISO indicating accumulation of [18F]FMISO 
and hence severe hypoxia.  The co-registered PET-CT images did not show any significant 
emphysema in this patient therefore the smoking status of this patient was not a 
confounder. 
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Figure 14:  18F-FMISO PET-CT images of right upper lobe lesion in Patient 1.  Standardised uptake 
values (SUV) of 18F-FMISO were assessed for the region of interested (ROI) 145 mins post-injection 
of tracer (A).  CT and PET images were fused to allow spatiotemporal assessment of tracer uptake.  
The same ROI and frame was analysed using Ki mapping (B) to identify evidence of trapping of 18F-
FMISO and thus severe hypoxia.  (White arrows=regions 18F-FMISO trapping; blue 
arrows=movement artefact 
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Figure 15:  18F-FMISO PET-CT images of posterior aspect of left lower lobe lesion in Patient 1.  (A)  
Standardised uptake value of the left lower lobe lesion demonstrated high uptake of 18F-FMISO at 
145 mins post injection. (B)  Ki modelling demonstrates no significant trapping of tracer, indicating 
pO2 levels of >10mmHg.   
White arrows=regions of 18F-FMISO uptake; blue arrows=movement artefact 
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Figure 16:   Time Activity Curves and PET-CT images for Patient 1.  (A)  TACs for the left upper lobe, 
left lower lobe and heart have the same shape as blood levels of FMISO indicating equilibrium has 
been reached.  In direct contrast, the right upper lobe region shows TAC increasing with time 
demonstrating accumulation of trapped tracer over time.  (B) The high SUV in the anterior left upper 
lobe is not matched by Ki except for 3 small areas indicating most of tracer is not being trapped.   
White arrows=tracer uptake; blue arrow=movement artefact 
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Patient 2 
The results from Patient 2 demonstrated regions of severe hypoxia in the area surrounding 
the right upper lobe cavity (Figure 17B).  This lesion demonstrated variable uptake within 
the surrounding area and hence the ROIs were divided into medial and inferolateral (Figure 
17A).  Both ROI demonstrated increasing TACs whereas the TAC for blood, as would be 
expected, declined.  There was a marked uptake of [18F]FMISO as indicated by SUV at 145 
mins post-injection of tracer.   Ki modelling demonstrated evidence of severe hypoxia in the 
two regions of interest.  Despite a lower concentration of [18F]FMISO, the TAC produced a 
steeper slope in the inferolateral region meaning the Ki was in fact higher.  It is not currently 
possible to correlate Ki with pO2 however it is possible to extrapolate that the degree of 
hypoxia in this region is greater than the medial region.  There was no uptake of tracer 
within the cavity itself and this is an expected finding since [18F]FMISO is trapped through a 
series of reductive steps which only occur in living (non-necrotic) cells.  On this occasion, 
data was analysed on a “non-rigid registration” protocol and this enabled almost complete 
elimination of the movement artefact seen with patient 1. 
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Figure 17:  Time Activity curves and 18F-FMISO PET-CT imaging in Patient 2.  Data from 
Patient 2 demonstrate the presence of severe hypoxia.    (A)  TAC values of 18F-FMISO in the 
right upper lobe lesion increase over time indicating accumulation and trapping of tracer.  
This is in direct contrast to blood levels of 18F-FMISO which, as expected decline over time.  
(B)  SUV values at 145 mins and Ki mapping demonstrate high uptake of tracer and trapping 
of tracer within the region of consolidation surrounding the right upper lobe cavity (high 
uptake is also seen in the liver, the site of metabolism of 18F-FMISO).   
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Patient 3 
Analysis of the data from Patient 3 demonstrated evidence of severe hypoxia within the 
right upper lobe and left lower lobe(Figure 18A and B).  The chest x-ray of this patient 
demonstrated heterogenous changes which were confirmed on CT scan with evidence of 
consolidation, cavities and fibrosis.  Several different ROIs were analysed and concordance 
between SUV and Ki was seen throughout all lesions (Figure 18C).  On this occasion high Ki 
values were seen in small isolated areas of consolidation (Figure 18B) as well as around  
areas of destructive pathology (Figure 18A).  The TAC showed a steady state or increase in 
all ROIs demonstrating accumulation of tracer in direct contrast to the blood values which 
decreased over time (Figure 18C). 
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Figure 18:  Ki mapping and TACs for Patient 3.  Results from Patient 3 demonstrate regions 
of severe hypoxia in TB lesions distributed throughout both lungs. (A)  Ki mapping of lesions 
within the right upper lobe and left lower lobe (B) demonstrate trapping of tracer within 
regions of consolidation and in the area surrounding a pulmonary cavity (upper panel-non-
contrasted CT; middle panel-PET; lower panel-fused PET-CT image).  (C)  TAC for patient 3 
show static or increasing levels of [18F]FMISO in regions of interest.  All regions with high Ki 
values corresponded to high SUV values  
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Standardisation of results 
Following the scans of Patients 4 and 5, attention focussed on how to analyses the data 
from all 5 patients collectively and how to best normalise the findings across the patient 
group.  In particular, it was necessary to determine how best to normalise the data to 
remove the high background seen in the tissues in some of the scans.  In order to achieve 
this, the last three of the registered frames (120-135mins post injection) were converted to 
tissue-to background (TBR) images through normalisation with the radioactivity in a bilateral 
lateral muscle region (assumed to represent normoxic tissue).  Initially, SUV values were 
compared to TBR values to evaluate if the two measurements were concordant.  Mean TBR 
values were demonstrated to correlate with mean SUV across of all regions of interest (ROI) 
within individual lesions across all 5 patients (Figure 19) with TBR values overall measuring 
slightly lower than SUV. 
Average TBR levels (±SD) in the lateral muscle regions were then used to calculate 
background normoxic Ki values for the group.  The upper Ki limit for normoxic tissue was 
calculated as 0.0005 min-1 and subsequent Ki values were considered positive i.e. hypoxic if 
they were greater than this threshold.  Ki mapping of the same ROIs evaluated revealed all 
patients had Ki values greater than background in at least one region of interest except for 
patient 4 whose values were on the limit (Figure 20).  Heterogeneity was seen both within 
individual lesions and across the patient group with the exception of patient 2 who 
demonstrated evidence of hypoxia in all ROIs.  In total, 5 individual lesions (x1 per patient) 
with 21 ROIs were evaluated.  Of these, 11 ROIs had Ki values greater than background and 
were therefore considered hypoxic.   
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Figure 19:  Standardised uptake value (SUV) compared to tissue-to background ratios (TBR) across 
21 regions of interest.  TBR values correlated to SUV across all ROIs in all 5 patients.  TBR values 
were mainly lower than SUV. 
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Figure 20: Standardisation of Ki mapping across all 5 patients (A) TBR values greater than unity are 
found for at least one lesion in all patients (each individual bar represents one region of interest, 
(ROI).  (B)  Regional Ki values demonstrate heterogenous trapping of [18F]FMISO within individual 
lesions and between patients (upper Ki limit for normoxic tissue=0.0005 min-1). 
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Patient 4 
Analysis of data from patient 4 demonstrated the importance of accurate documentation of 
the steps involved in our specific protocol.  Initial analysis demonstrated that the 
radiologically abnormal regions on the CT scan contained regions of severe hypoxia (Figure 
21A).  Subsequent review of the time of administration of the tracer and time of blood 
samples revealed that a discrepancy had occurred.  The outcome of this discrepancy was 
that the peripheral blood values were calculated incorrectly.  Final analysis demonstrated 
high tracer uptake but low Ki values (Figure 21B). 
 
Patient 5 
Following the standardisation of results across the five patients, the results from Patient 5 
were evaluated using TBR and subsequently using TBR to calculate Ki.  TBR demonstrated 
evidence of high tracer uptake in radiologically abnormal areas of lung as well as within 
background tissue. Ki mapping revealed heterogenous changes with hypoxia present in the 
right lower lobe lesion and not in the left sided lesion  (Figure 22).  The results from patient 
5 therefore demonstrated the presence of severe hypoxia with heterogenous changes seen. 
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Figure 21:  PET-CT Results from Patient 4.  (A)  Initial analysis of data from patient 4 demonstrates 
significant tracer trapping and hypoxia (Ki) in the left upper lobe.  (B)  Repeat analysis using adjusted 
blood gamma counts demonstrates high TBR and tracer uptake in this lesion.  Standardisation across 
the 5 patients with a threshold of 0.006 l/min demonstrates no evidence of severe hypoxia on PET-
CT imaging.   
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Figure 22:  PET-CT images from Patient 5.  TBR images show high uptake of tracer in right lower lobe 
and left lower lobe lesion.  Ki mapping demonstrates that severe hypoxia is only present in the right 
sided lesion. 
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Figure 23: Comparison Ki images from Patient 2.   Both SUV and TBR images demonstrate significant 
uptake and trapping of tracer.  (A)  Ki calculated using SUV shows high tracer trapping.  (B)  When 
analysis is performed using TBR to calculate Ki and background threshold of 0.006 l/min is used, 
severe hypoxia is still present in the right upper lobe lesion.  
 
 
Chapter 3:  Investigation of Hypoxia in Human Pulmonary TB using PET-CT 
107 
 
Discussion 
My clinical study is the first to demonstrate the presence of severe hypoxia within 
pulmonary lesions during active tuberculosis infection.  Hypoxia has been demonstrated in 
certain animal models of M.tb infection but the methods used are not suitable for human 
subjects, most notably invasive pO2 probes, excision biopsy or necropsy.   
The results of this clinical study were performed in collaboration with the Department of 
Nuclear Medicine Imperial College and the Wolfson Brain Imaging Centre (WBIC), University 
of Cambridge.  Although studies have been previously been performed at WBIC using 18F-
FMISO to image hypoxia in both animal and human studies, no similar studies have been 
performed in the context of human infection.  Before commencing with the study, a 
protocol was designed taking in to account patient factors, transportation issues and data 
collection and analysis requirements. 
Patient factors included the need to transport the patient in a timely fashion to Charing 
Cross Hospital, minimising the duration of the scan and performing venous blood sampling 
compared the arterial blood sampling that was being conducted in studies at WBIC.  18F-
FMISO kinetics is such that the earliest point that the tracer reaches equilibrium in the blood 
compared to tissues is 45 minutes.   This time-point was therefore selected for my study.  By 
closely examining 18F-FMISO kinetics we were able to limit the tracer uptake duration to 90 
minutes and scan time to 45 minutes (compared to 120 mins and 90 mins respectively in a 
current research study of unconscious stroke patients).  It is possible that an increased 
uptake time might have allowed greater uptake of in hypoxic tissues.  For example the time-
activity curves for patients 2 and 3 suggest that tracer uptake in some lesions were 
increasing with time.  Additionally, arterial blood sampling might have improved peripheral 
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18F-FMISO measurements since a greater number of historical controls are available but 
these factors needed to be balanced with the comfort of the patient. 
Transportation issues were overcome by producing sufficiently large batches of 18F-FMISO 
which allowed for decay of tracer during the 2.5 hour transfer between Cambridge and 
London.  Unfortunately on one occasion the yield of 18F-FMISO was not sufficient to take 
account of this limitation.  Were the scan being performed closer to the site of production, it 
would have been possible to produce a further batch in time.  On this occasion, the scan 
was cancelled and could not be rescheduled.  
Finally, data collection issues were addressed by collecting data in List Mode (a numerical 
format which can be reconstructed into images) which allowed the transfer of large volumes 
of anonymised data.  Venous blood samples were analysed immediately at Charing Cross 
Hospital using standardised gamma counting methods and data transferred to WBIC the 
following day.  On one occasion (patient 4), the time points for collection of blood samples 
was not recorded properly meaning that the analysis was incorrect.  This was subsequently 
rectified but might have been avoided if data collection and analysis were being performed 
on the same site.  
Once a patient had been recruited to the study, the main factors which determined when 
the scan would be performed was the fixed day and time slot within the Department of 
Nuclear Medicine at Charing Cross Hospital and the notice required for production of tracer 
at the WBIC.  This limiting factor resulted in a minimum of 6 days delay in performing the 
scans. My study limited the duration of treatment prior to scanning to less than 1 month 
however ever effort was made to perform the scans as early as possible to reduce the 
impact of anti-TB therapy.  I was able to perform scans in 4/5 patients within 8 days of 
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having commenced anti-tuberculosis treatment.  Current national guidelines recommend a 
2 week isolation period for patients starting anti-TB therapy however many studies 
demonstrate that patients often remain sputum smear positive for longer than this time 
[159, 160].  Several studies demonstrate that sputum conversion rates both on smear and 
culture or often longer than this period [161, 162].  Prolonged conversion times are 
associated with high bacillary counts at diagnosis, lung cavitation and a prolonged period of 
symptoms [161].  Of the 5 patients recruited to my study, 3 were strongly smear positive 
(3+) and median time to culture positivity was 9.6 days (range 3-27 days).  This indicates a 
high burden of disease and likely longer sputum conversion times although it is only possible 
to postulate since this data was not recorded.  The largest human study to examine changes 
in M.tb lesions in the early phase of anti-TB therapy assessed changes in SUVmax by FDG-PET 
in 21 individuals [163].  Scans were performed prior to commencing treatment and after 1 
month.    The median SUVmax at T=0 was 8.6 (range 3.1-15.5) and 1 month median SUVmax 
was 5.3 (range 1-11.9)].   All but 2 patients demonstrated a decrease in SUVmax at 1 month 
with a median decrease of 31%.  Interestingly, of the two patient whose SUVmax did not 
decrease, 1 was shown to have smear positive M.tb at 3 months despite appropriate 
therapy whilst the other was subsequently demonstrated to not to have TB but in fact, 
malignant disease.  This study demonstrates early metabolic changes occurring response to 
anti-TB therapy and given the recent findings linking hypoxia and HIF signalling to metabolic 
responses in inflammation [164], might have been relevant to my study.  Interestingly, a 
prospective pilot study of HIV positive patients examining SUVmax at start of therapy and 
after 4 months found using FDG-PET found no difference between responders and non-
responders [165].  It is possible that earlier anti-TB treatment might have affected my 
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results however the impact of anti-TB therapy on the pulmonary lesions in the patients in 
my study will remain undetermined.   
One possible explanation for the presence of hypoxia in my study might be that hypoxia 
occurs as a consequence of the severe inflammation and consolidation seen in several 
pneumonic processes.  It was not possible to compare the hypoxia in TB patients compared 
to other forms of respiratory infection or bacterial pneumonia since no study of this type 
has yet been performed.  18F-FMISO PET-CT has only been utilised to investigate hypoxia in 
the context of infection in one study.  In this study of 26 patients with nasopharyngeal 
carcinoma, 18F-FMISO PET-CT scans were performed to assess and clinically correlate 
hypoxia in periodontal disease following radiotherapy [166].  The authors of this study 
report high rates of sensitivity and specificity in detecting odontogenic infections but 
interestingly bacterial pathogens were only identified in less than 50% of patients.  
Furthermore, the analysis did not include Patlak Ki evaluation and therefore did not assess 
for possible excess vascular delivery to the region of interest.  Since high tracer uptake 
might represent high tracer delivery secondary to high blood flow, my study used Patlak Ki 
mapping to identify [18F]FMISO trapping and thus specifically regions of hypoxia.  The 
maximum TB lesion Ki value (0.005 min-1) is equal to the highest Ki value in an [18F]FMISO 
study of head and neck cancer by Wang et al [167] which puts the degree of hypoxia in this 
study into context.  As discussed previously, it is not currently possible to provide a direct 
correlation between [18F]FMISO uptake and pO2 but the results confirm evidence of severe 
hypoxia.  Since my study is the first to image hypoxia in the presence of confirmed M.tb 
infection, I was keen to ensure that all possible steps were taken to assess the results using 
both internal and external controls.  My protocol included the measurement of [18F]FMISO 
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levels in peripheral blood thus providing an internal control for any possible movement 
artefact.  In addition the finding of stable or increasing Ki values in lung lesions compared to 
blood values, which declined over time, further supports the finding of tracer trapping 
demonstrated by Ki measurements.  Comparison of abnormal lung lesions compared to 
structurally normal lung demonstrated no uptake of tracer in normal lung tissues in any of 
the five patients, providing a further internal control.  Finally,   peripheral blood 
measurements were scaled to a historical control population of 12 patients in order to 
compare results to external controls.  
My data revealed that heterogeneity existed both within individual lesions and between 
lesions, consistent with the emerging concept of multiple TB microenvironments existing 
within a single patient [168].  Similarly studies conducted in rabbits infected with M.tb 
HN878 and non-human primates infected with M.tb Erdman strain reveals heterogenous 
disease within pulmonary lesions.  Interestingly, when lesions are visualised over time using 
either CT or FDG-PET, temporal-spatial changes are seen with new lesions often appearing 
whilst principal lesions resolve [169, 170].  My results demonstrated that not all lesions are 
hypoxic however, since [18F]FMISO is only taken up in regions of severe hypoxia, it is 
possible that regions of hypoxia existed that were not detected using this probe i.e. greater 
than 1-2% pO2 but less than the 9-10% pO2 present in normal healthy lung tissue.  My study 
did not assess how hypoxic lesions changed during the course of therapy and might be 
considered for future studies assessing TB therapeutics. 
Standardisation of results across the five patients using TBR involved examining at a single 
lung lesion with high SUV and comparing data both within an individual lesion and across 
patients.  Whilst this is a useful method to examine lesions across patients, this method 
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however did not examine multiple lesions within the same patient and might therefore 
underestimate the number of lesions containing hypoxic regions.  It would certainly be of 
interest to determine the extent of hypoxia within different lesions within the same patient 
but this analysis was not undertaken due to time limitations (each patient registration took 
nine days to perform and needed to be performed without compromise to patient 
diagnostic services).  Since Ki mapping performed using SUV revealed multiple lesions within 
a single patient with high Ki values, it is likely that hypoxia exists in several lesions. 
Until now, the study of hypoxia in the context of M.tb infection has focussed on pathogen 
responses to hypoxia which indicate transition to a state of latent disease.  My study is the 
first to demonstrate that hypoxia exists in humans during active M.tb infection.  Research 
demonstrating hypoxia in the context of active infection is emerging but until now has only 
conducted in animal models.  Of note, the presence of hypoxia in these models has been 
shown to affect antimicrobial killing [107, 171].  My clinical research therefore has 
implications not only for furthering our understanding of the disease in humans but also has 
implications for how we study the disease within the laboratory. 
In conclusion, [18F]FMISO PET-CT demonstrates for the first time the presence of severe 
hypoxia within active human pulmonary TB infection.  This novel finding serves not only to 
improve our understanding of the environment in which the infection occurs in humans but, 
provides insights which might aid the development of future new therapies.  
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CHAPTER 4:  HYPOXIA AND MMPs IN RESPIRATORY EPITHELIAL 
CELLS DURING TB INFECTION 
Introduction 
The pulmonary epithelium is the first barrier to M.tb and respiratory epithelial cells are the 
most abundant cells in the lungs covering an alveolar surface area of approximately 70m2.  
Although macrophages are the first immune cells to encounter M.tb in the alveoli and 
secrete a series of inflammatory mediators, signalling also occurs between stromal cells and 
inflammatory leucocytes, often accentuating the host immune response. 
Previous studies from the Friedland group have shown that MMP secretion from normal 
human bronchial epithelial cells (NHBEs) is up-regulated when stimulated with filtered, 
conditioned media from M.tb-infected monocytes (CoMTb)[46].  These results were not 
seen with direct infection with M.tb indicating that MMPs are up-regulated via a monocyte 
dependent network that involves both host and pathogen derived soluble factors[172] 
The in vitro TB network used in my experiments is an established model in the Friedland 
laboratory (description in Methods).  Each individual batch of CoMTb that was generated 
was done so with a batch of conditioned media from uninfected monocytes (CoMCont) from 
the same donor as a control.  Batches were then tested in A549 respiratory epithelial cells 
where cells were stimulated with CoMtb or CoMCont and the supernatants harvested at 72 
hours.  The Friedland group have confirmed that CoMCont does not stimulate MMP 
production from epithelial cells.  A comparative analysis of cytokines and chemokines in 
CoMTb and CoMCont has been performed several times in our department using the 
Luminex multiplex platform.  Table 5 summarises grouped analyses from the Friedland 
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group of batches of CoMTb and CoMCont.  The analysis has also been used to confirm that 
donor-related variability in the cytokine and chemokine profiles of CoMTb is within 
statistically acceptable limits. 
 
Cytokine/chemokine 
CoMCont CoMTb  
p value Mean (pg/ml) SEM Mean (pg/ml) SEM 
GM-CSF 3 0 559.8 374 <0.0001 
G-CSF 3 0 1178 446.2 <0.0001 
IL-1β 131.8 44.5 26274 8815 <0.0001 
IL-6 1 0 41992 14227 <0.0001 
TNFα 1 0 26910 17403 <0.0001 
IFNƴ undetectable N/A Undetectable N/A N/A 
IL-12 2 0 1592 1072 <0.0001 
IL-1RA 505.5 171.1 7970 2032 0.0020 
CXCL-8 27.75 8.9 94865 49375 <0.0001 
MIP-1α 4 0 198693 94784 <0.0001 
MCP-1 7.25 1.25 1426 642.4 <0.0001 
MIG 47 22 147.3 48.2 ns 
IL-17 undetectable N/A undetectable N/A N/A 
 
Table 5:  Summary of principle cytokines and chemokines measured in CoMTb and 
CoMCont.  Primary human monocytes were infected with M.tb MOI=1 and supernatnants 
harvested at 24hrs.  Cytokines and chemokines were analysed by Luminex multiplex 
platform 
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This chapter explores the effect of HIF and hypoxia on MMP activity.  It aims to identify the 
key MMPs affected by hypoxia and the mechanisms which may drive this activity.   
Results 
DMOG increases MMP-1 expression in A549 cells stimulated with CoMTb 
In order to investigate the effect of HIF-1α on MMP expression in respiratory epithelial cells 
stimulated with CoMTb, I initially used the 2-oxyglutarate analogue dimethyoxalyl glycine 
(DMOG) to inhibit the HIF prolyl and asparaginyl hydroxylases and therefore activate the HIF 
system (Fig. 24).  HIF-1α stabilisation by DMOG was confirmed in A549 cells and is discussed 
in Chapter 6 (Fig 25 p117) 
Experiments were initially conducted in A549 cells, a commonly used respiratory epithelial 
cell line which is a widely accepted cellular model in respiratory disease.  HIF-1α stabilisation 
in cells pre-incubated with DMOG caused an increase in MMP-1 secretion in a dose-
response manner (Figure 25A).  Doses above 0.5mM caused significant cell death on trypan 
blue exclusion assay and these results were not included in future experiments.  In CoMTb 
stimulated cells, DMOG 0.25mM also caused a 95-fold in MMP-1 gene expression at 6 hrs 
and and 40-fold increase at 24 hrs (Figure 25B).  By comparison, CoMTb stimulation alone 
causes a 5-fold increase in MMP-1 gene expression at 6 hrs and 10-fold increase at 24 hrs.  
Analysis of the other main MMPs known to be secreted by A549 cells demonstrated that 
DMOG significantly increased MMP-9 secretion in A549 cells (Figure 25D) and that MMP-3 
secretion was unaffected by DMOG (Figure 25C). 
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Figure 24:  Schematic demonstrating blockade of HIF by prolyl hydroxylases (PHD1, PHD2 and 
PHD3) and factor inhibiting HIF (FIH) which binds p300/CBP thereby promoting stabilisation of HIF-1 
and activation of the HIF pathway. 
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Figure 25:  Effect of HIF-1α stabilisation on MMP secretion from CoMTb stimulated A549 cells.  
A549 cells were pre-incubated with DMOG for 2hrs and then stimulated with CoMTb.  Supernatants 
were harvested at 72 hrs and MMPs measured by Luminex.  (A)  DMOG increases MMP-1 secretion 
in CoMTb stimulated cells.  (B)  DMOG increases MMP-1 gene expression at 6 and 24hrs compared 
to CoMTb stimulated cells.  (C)  DMOG does not affect MMP-3 secretion in either control or CoMTb 
infected cells.  (D)  DMOG (0.25mM) causes increased MMP-9 secretion in CoMTb stimulated cells.  
Bars represent mean (+/- SD) of conditions in triplicate and are representative of at least 2 
independent experiments. 
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DMOG decreases TIMP-1 secretion from CoMTb stimulated A549 cells 
One of the ways in which MMP activity is regulated is by the specific tissue inhibitors of 
MMPs (TIMPS) which bind MMPs in a 1:1 manner.  Previous data from the JSF group define 
a matrix destructive phenotype whereby CoMTb stimulation of respiratory epithelial cells 
results in increased MMP activity which is not associated with a corresponding rise in TIMP 
activity [46].  It was important therefore to determine whether DMOG affected TIMP 
activity.  I first performed CoMTb dose-response experiments to confirm the previously 
reported findings by our group.  Compared to control cells, stimulation with CoMTb did not 
affect TIMP-1 secretion (Figure 26A).   These findings remained consistent irrespective of 
the concentration of CoMTb, in particular, TIMP-1 secretion did not increase with increasing 
concentration of CoMTb.  I then assessed the effect of DMOG (0.25mM) on TIMP-1 
secretion in cells stimulated with CoMTb (1:5dilution).  Pre-incubation with DMOG 
decreased MMP-1 secretion in control cells (p<0.01) and also caused a significant decrease 
in MMP-1 secretion in CoMTb stimulated cells (Figure 26B; p<0.001).  Together, these 
results demonstrated that inhibition of the PHDs and FIH with DMOG causes a significant 
increase in MMP-1 and MMP-9 secretion which is not associated with a compensatory 
increase in TIMP-1 secretion. 
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Figure 26:  Effect of DMOG on TIMP-1 secretion in respiratory epithelial cells.  A549 cells were 
stimulated with CoMTb and TIMP-1 levels measured after 72hrs.  (A)  Stimulation of A549 cells with 
CoMTb at increasing concentrations causes no change in TIMP-1 compared to control cells. (B)  Pre-
incubation with DMOG (0.25mM) for 2 hrs decreases TIMP-1 levels in unstimulated cells (p<0.01) 
and in cells stimulated with CoMTb (1:5) (p<0.001).  Bars represent mean (+/- SD) of conditions in 
triplicate and are representative of at least 2 independent experiments. 
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Hypoxia at the level seen in humans increases MMP-1 secretion in A549 cells 
Having established the effect of HIF-1α stabilisation through PHD inhibition, I then sought to 
determine the effect of hypoxia on MMP activity.  In order to do this, I used the fixed model 
of hypoxia where cells were either placed in an adapted Oxoid anaerobic jar filled with a 
calibrated gas mixture of 1% oxygen and 5% carbon dioxide or a hypoxic incubator where 
oxygen levels could be set between 1 and 19% oxygen and CO2 maintained at 5% (see 
Methods).  In these experiments, no pre-incubation in hypoxia took place and cells were 
placed immediately into their respective incubators following stimulation with CoMTb.  
Based on my clinical studies, I initially examined the effect of 1% oxygen on MMP-1 activity 
in A549 cells and then went on to investigate the effect of different oxygen levels.  
Incubating CoMTb stimulated cells (1:5 dilution) cells in 1% oxygen caused a highly 
significant increase in MMP-1 and MMP-9 secretion (Figure 27A and C) compared with cells 
incubated in 21% oxygen.   At lower concentration of CoMTb (1:25 and 1:10), the increase in 
MMP-1 secretion caused by 1% oxygen did not reach statistical significance.   Interestingly, 
when casein zymography was performed, there was evidence of proteolytic activity from all 
samples incubated in hypoxia, even at the lower CoMTb concentrations (Figure 27B).  Casein 
zymography is a semi-functional assay of proteolyic activity and cells incubated in hypoxia 
all showed evidence of retained MMP-1 proteolytic activity.  In comparison, no MMP-1 
proteolytic activity was seen in cells incubated in normoxia.   
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Figure 27:  Hypoxia (1% O2) and effect on MMP-1 and MMP-9 protein secretion from CoMTb 
stimulated A549 cells.  A549 cells were stimulated with CoMTb (1:5) and then incubated at either 
21% O2 or 1% O2.  Cell culture supernatants were harvested at 72 hrs. (A)  1% O2 causes a highly 
significant increase in MMP-1 secretion compared to 21% O2 (p<0.001).  (B)  Casein zymography 
demonstrates that secreted MMP-1 protein from CoMTb stimulated cells incubated in hypoxia is 
proteolytically active.  (C)  Hypoxia causes a highly significant increase in MMP-9 protein secretion 
(p<0.001).  Bars represent mean (+/- SD) of conditions in triplicate.   
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MMP-1 confocal microscopy 
Thus far experiments in A549 cells demonstrated increased MMP-1 secretion from CoMTb 
cells at 72 hours and a significant increase in MMP-1 secretion in the presence of 1% O2.  I 
attempted to visualise MMP-1 from A549 cells using confocal microscopy.  Cells were grown 
in Permanox slides and then stimulated with CoMTb (1:5) and cells fixed at 72 hrs.  No 
MMP-1 staining was seen in these cells at T=0hrs (data not shown).  A small amount of 
MMP-1 staining was seen in control cells (normoxia and hypoxia) at 72 hrs with increased 
staining seen in CoMTb stimulated cells.  Of note, some but not all cells incubated in hypoxia 
demonstrated increased MMP-1 staining within the cytoplasm of the cell (Figure 28). 
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Figure 28:  MMP-1 confocal microscopy of CoMtb-stimulated A549 cells in normoxia and hypoxia.  
A549 cells were stimulated with CoMTb and incubated in either 21% or 1% O2.  Cells were fixed 72 
hrs post stimulation.  Nuclear staining was shown using DAPI.  Increased MMP-1 staining is seen in 
CoMTb-stimulated cells compared with control cells.  More pronounced staining seen in some 
CoMTb-stimulated  cells incubated  in hypoxia and was localised to the cell edge in some instances.  
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Varying degrees of hypoxia differentially affects MMP-1 secretion in A549 
cells stimulated with CoMTb 
I then proceeded to examine the effect of different levels of oxygen on MMP-1 secretion to 
investigate whether there was a level of oxygen which triggered an increase in MMP-1 
secretion.  Experiments performed at 5% oxygen revealed a pattern of increased MMP-1 
secretion which closely resembled MMP-1 secretion at 1% oxygen.  A highly significant 
increase in MMP-1 secretion in 5% oxygen was seen at all CoMTb concentration in a CoMTb 
dose-response manner (Figure 29A; p<0.001)  The results of CoMTb dose-response 
experiments at 10% oxygen compared to 21% oxygen were unexpected and were not 
predicted by my previous DMOG experiments.  Incubating CoMTb stimulated cells at 10% 
oxygen caused a significant decrease in MMP-1 secretion compared to cells incubated in 
21% oxygen (Figure 29B).  My initial concern was that I might have harvested the 
supernatants incorrectly, however multiple repeated experiments at 10% oxygen produced 
the same results of a decreased in MMP-1 secretion. 
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Figure 29:  Effect of varying degrees of hypoxia (5% and 10% O2) on MMP-1 secretion from A549 
cells.  A549 cells were stimulated with increasing concentrations of CoMTb and incubated at either 
in hypoxia or normoxia.  Supernatants were harvested at 72hrs.  (A)  Incubation at 5% O2 resulted in 
a highly significant increase in MMP-1 protein secretion (p<0.001) at all concentrations of CoMTb.  
(B)  Incubation at 10% O2 results in a significant decrease in MMP-1 secretion compared to cells 
incubated at 21% O2.  Bars represent mean (+/- SD) of conditions in triplicate and are representative 
of at least 2 independent experiments. 
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DMOG increases MMP-1 and MMP-9 secretion in primary respiratory 
epithelial cells 
Following on from my work in A549 cells I then progressed to investigating hypoxia in 
primary human bronchial epithelial cells (NHBEs).  Initially I performed a series of DMOG 
dose-response experiments in NHBE cells stimulated with CoMTb (diluted 1:5 as per the 
standard protocol in the JSF laboratory).  Pre-incubation of samples with DMOG prior to 
stimulation with CoMTb resulted in a dose-dependent increase in MMP-1 secretion (Figure 
30A). Increasing the length of pre-incubation with DMOG had no effect on the increase in 
MMP-1 secretion (Figure 30A).  Next, I sought to establish the effect of DMOG (0.25mM) on 
key MMPs known to be up-regulated by the TB networking effect of CoMTb.  Luminex 
analysis demonstrated that HIF-1α stabilisation significantly increased MMP-1 (p<0.001) and 
MMP-9 (p<0.001) secretion in NHBE cells stimulated with CoMTb  (Figure 30B).   
Trypan blue exclusion assay performed at 72 hours demonstrated significant cell death at 
0.5 and 1.0mmol concentrations of DMOG and is the most likely explanation for the 
decrease in MMP-9 secretion seen above 0.25mM (Figure 31A).  Subsequent dose-response 
experiments using lower concentrations of DMOG once again confirmed the significant 
increase in MMP-9 in cells  pre-incubated with DMOG and stimulated with CoMTb (Figure 
31B; p<0.05). Gelatin zymography (Figure 31C) demonstrated the proteolytic activity to be 
increased in both the DMOG samples and CoMTb stimulated cells.  The addition of DMOG to 
CoMTb stimulated NHBE cells resulted in a large increase in MMP-9 proteolytic activity.  
When the zymogram was analysed by densitometry, this increased proteolytic activity was 
found to be greater than an additive effects of either DMOG or CoMTb alone (Figure 31D). 
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Figure 30:  Effect of DMOG on TB networking effects in NHBE cells stimulated with CoMTb.  NHBE 
cells were pre-incubated with DMOG and then stimulated with CoMTb (1:5).  Supernatants were 
harvested at 72hrs.  (A)  DMOG causes a dose-dependent increase in MMP-1 secretion.  (B)  Length 
of pre-incubation with DMOG (0.25mM) has no effect on the amount of MMP-1 protein secretion.  
(C)  DMOG (0.25mM) causes a highly significant increase in MMP-1 and MMP-9 (p<0.001) protein 
secretion in NHBE cells stimulated with CoMTb compared to CoMTb stimulation alone.  Bars 
represent mean (+/- SD) of conditions in triplicate and are representative of at least 2 independent 
experiments. 
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Figure 31:  Effect of DMOG on MMP-9 protein secretion and proteolytic activity in NHBE cells.  
NHBE cells were pre-incubated with DMOG for 2hrs and then stimulated with CoMTb (1:5).  
Supernatants were collected at 72hrs.  (A)  DMOG (0.25mM) causes increased MMP-9 secretion in 
control unstimulated cells and cells stimulated with CoMTb.  Significant cell death occurs at 
concentrations of 0.5mM and above associated with decreased MMP-9.  (B)  DMOG (0.1mM and 
0.25mM) cause increased MMP-9 protein secretion.  (C)  Gelatin zymography demonstrates 
increased proteloytic activity in cells incubated with DMOG.  (D)  Densitometry of gelatin zymogram 
demonstrates a cumulative effect of CoMTb stimulation and DMOG.   Bars represent mean (+/- SD) 
of conditions in triplicate and are representative of at least 2 independent experiments. 
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Hypoxia (1% pO2) increases MMP-1 secretion in NHBE cells stimulated with 
CoMTb  
I then proceeded to examine the effect of hypoxia on MMP-1 activity in NHBE cells.  
Experiments performed using the fixed model of hypoxia demonstrated that 1% O2 caused a 
significant increase in MMP-1 secretion in CoMTb stimulated cells (Figure 32A; p<0.001).  In 
contrast to the previous A549 experiments, no difference was seen in MMP-1 secretion 
when cells were incubated at 5% O2 (Figure 32B).  Incubation at 10% O2 caused a decrease 
in MMP-1 secretion compared to cells incubated at 21% oxygen but this difference did not 
reach statistical significance (Figure 32C).  In order to assess the dose-response effect of 
oxygen on MMP-1 secretion, I performed parallel experiments where NHBE cells were 
incubated in 1%, 5% or 21% oxygen in the adapted Oxoid jar, hypoxic incubator and 
standard CO2 incubator respectively.  Once again, I was able to confirm that MMP-1 
secretion is only up-regulated in severe hypoxia i.e. 1% pO2 (Figure 32D; p<0.01).  LDH 
cytotoxicity assay confirmed that the increased MMP-1 was not a consequence of hypoxia 
induced cytotoxicity (Figure 32E). 
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Figure 32:  Effect of different oxygen levels on MMP-1 secretion in NHBE cells stimulated with 
CoMTb.  NHBE cells were stimulated with CoMTb and incubated at different oxygen levels.  MMP-1 
levels were measured by ELISA at 72hrs.  (A)  1% O2 causes a highly significant increase in MMP-1 
protein secretion from cells stimulated with CoMTb compared to cells incubated at 21% O2.  (B)  5% 
O2 does not affect MMP-1 protein levels in CoMTb stimulated cells compared to 21% O2.  (C)  MMP-1 
protein levels are unchanged in cells incubated at 10% O2 compared to 21% O2.  (D)  Only severe 
hypoxia (1% O2) causes increased MMP-1 secretion from CoMTb stimulated cells.  (E)  Hypoxia (1% 
and 5% O2) does not increase cells cytotoxicity as measured by LDH release assay.  Bars represent 
mean (+/- SD) of conditions in triplicate and are representative of at least 2 independent 
experiments. 
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DMOG and hypoxia cause increased MMP-1 promoter activity in respiratory 
epithelial cells stimulated with CoMTb 
Having investigated the effect of hypoxia and DMOG on MMP activity in respiratory 
epithelial cells, I then proceed to investigate the mechanisms by which this might occur.  I 
first sought to investigate the effect of hypoxia on MMP-1 promoter activity.  The 
investigation of MMP-1 promoter activity required successful transient transfection of the 
WT-MMP-1 promoter into primary NHBE cells.  Transfection of NHBE cells has been 
successfully performed within the JSF group however all these experiments have been 
performed in normoxia only.  I attempted multiple transfection experiments using NHBEs in 
hypoxia. On all occasions the combination of transfection reagents and hypoxia (1% O2) 
resulted in >50% cell death (assessed by trypan blue exclusion assay).  Consequently, 
transfection experiments were performed using A549 respiratory epithelial cells  
Compared to control cells, CoMTb stimulation caused a significant increase in WT-MMP-1 
activity (Figure 33A; p<0.001).  DMOG (0.25mM) alone did not affect MMP-1 promoter 
activity.   Pre-incubation of cells with DMOG resulted in a significant increase in WT-MMP-1 
promoter activity in CoMTb stimulated cells (Figure 33A; p<0.01).  When DMOG (0.25mM) 
and 1% O2 were compared, 1% O2 was a stronger stimulus for MMP-1 promoter activity 
than PHD inhibition (Figure 33B). 
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Figure 33:  Effect of DMOG and hypoxia on MMP-1 promoter activity in A549 cells.  A549 cells were 
transfected with WT-MMP-1 promoter and then incubated with DMOG or at 1% O2.  Relative 
luminescence was measured at 24hrs by dual luciferase assay.  (A)  DMOG (0.25mM) causes a 
significant increase in MMP-1 promoter activity in CoMTb stimulated cells (p<0.01).  (B)  DMOG and 
hypoxia (1% O2) both increase MMP-1 promoter activity in CoMTb stimulated cells.  Hypoxia is a 
stronger stimulus for MMP-1 promoter activity than DMOG.  Bars represent mean (+/- SD) of 
conditions in triplicate and are representative of at least 2 independent experiments. 
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I next proceeded to further dissect the effect of hypoxia (1% O2) on specific elements within 
the MMP-1 promoter.   In silico analysis of the MMP-1 promoter sequence revealed a 
number of putative hypoxia response elements (HREs) which act as HIF binding sites (Figure 
34A).  Analysis also revealed consensus binding sites of NFКB and AP-1 transcription factors 
which are known to regulate MMP activity and have recently been linked to HIF.  A549 
respiratory epithelial cells were transiently transfected with either WT-MMP-1 promoter or 
MMP-1 promoter truncation constructs and then stimulated with CoMTb in the presence of 
normoxia or hypoxia.   In normoxia, deletions upstream of -2942 resulted in increased 
MMP-1 promoter activity indicating the presence of inhibitory elements (Figure 34B).  In 
contrast, truncations downstream of -2942 had a negative effect on MMP-1 promoter 
activity.  The presence of hypoxia resulted in increased MMP-1 promoter activity, compared 
to normoxia, in deletion constructs upstream of -2001.  Since NFКB is intimately involved in 
the regulation of HIF activity and a consensus NFКB binding site was identified in this 
promoter region, I sought to manipulate this site to dissect its effect on MMP-1 activity.   
Site-directed mutagenesis of the NFКB binding site between -2942 and -2001 resulted in a 
decrease in MMP-1 promoter activity in normoxia (Figure 34C).  Strikingly, mutagenesis of 
the NFКB binding site reduced the highly significant increase in MMP-1 promoter activity 
seen in hypoxia to baseline levels.  Site-specific mutagenesis of the AP-1 site between -2000 
and -1551 did not affect WT-MMP-1 promoter activity in normoxia or hypoxia (34C).   
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Figure 34:  Effect of hypoxia on transcription factors within the MMP-1 promoter.  (A) In silico 
analysis of the MMP-1 promoter reveals putative hypoxic response element (HRE) binding sites as 
well as consensus NFκB and AP-1 binding sites. (B) Relative luminescence data following transfection 
of A549 respiratory epithelial cells with either WT-MMP-1 promoter or a series ofMMP-1 promoter 
deletion constructs in the presence (shaded bars) or absence (solid bars) of hypoxia. The effect of 
hypoxia is absent in constructs from -1551.  (C)  Site-directed mutagenesis of the NFκB binding site 
decreases MMP-1 promoter activity in response to CoMTb in normoxia (solid bars) or hypoxia 
(shaded bars).  Site-directed mutagenesis of AP-1 does not affect MMP-1 promoter activity in 
hypoxia. 
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Chemical inhibition of NFκB leads to decreased MMP-1 secretion in CoMTb 
stimulated cells in hypoxia 
To further investigate the role of NFκB during hypoxia in CoMTb-driven MMP-1 expression, I 
inhibited NFκB activity at two different levels.  Initially, I used SC-514 to inhibit IKK-β activity 
and then used helenalin to inhibit the p65 subunit of NFКB [173].  Inhibition of IKK-β 
resulted in a significant decrease MMP-1 secretion in normoxia in A549 cells stimulated with 
CoMTb.  (Figure 35A; p<0.05).  1% O2 causes a 2.9-fold increase in MMP-1 secretion in 
CoMTb cells compared to 21% and this increase was significantly reduced by SC-514, in a 
dose-dependent manner (Figure 35A; p<0.001).  When cells were treated with DMOG and 
SC-514, CoMTb-driven MMP-1 secretion decreased in a dose-dependent manner (Figure 
35B).  A maximum dose of 50µM was used in this experiment as DMOG (0.25mM) and SC-
514 (100µM) combined caused significant cytotoxicity and cell death. Inhibition of the p65 
subunit of NFКB (RelA) using helenalin resulted in a significant decrease in MMP-1 secretion 
in A549 respiratory epithelial cells (Figure 35C).  Surprisingly, helenalin demonstrated 
greater inhibitory effects on MMP-1 secretion at lower doses with no inhibition of MMP-1 
secretion seen at 10µM.  Collectively, the results of chemical inhibitor studies of NFКB 
indicate that both IKK-β and RelA are required for hypoxic up-regulation of M.tb-driven 
MMP-1 secretion.  
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Figure 35:  Effect of NFκB chemical inhibition on CoMTb-driven MMP-1 secretion.  (A)  Inhibition of 
the IKKβ subunit of NFκB with SC-514 causes a dose-dependent decrease in MMP-1 secretion in 
normoxia and hypoxia (1% O2).  The greatest effect is seen in hypoxia.  (B)  SC-514 decreases MMP-1 
secretion in A549 cells treated with DMOG (0.25mM).  (C)  Helenalin causes decreased MMP-1 
secretion in cells incubated in hypoxia (1% O2).  Bars represent mean (+/- SD) of conditions in 
triplicate and are representative of at least 2 independent experiments. 
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Discussion 
Pulmonary cavitation is fundamental to the global success of M.tb, as it facilitates 
mycobacterial transmission to new hosts. The biochemistry of the lung matrix predicts the 
involvement of MMPs in tissue destruction. Previous studies have shown that a number of 
these enzymes, including MMP-1 and MMP-9, are implicated in M.tb pathogenesis and that 
their expression is up-regulated in lung epithelial cells via a monocyte-dependent network 
that involves both host- and pathogen-derived soluble factors [46, 59].  I have demonstrated 
for the first time that hypoxia and HIF activation (by DMOG), augments this effects and 
cause increased expression of MMP-1 and MMP-9 in respiratory epithelial cells.  This 
increase is not accompanied by an increase in the specific tissue inhibitor of MMP-1 (TIMP-
1).  The results of my cellular experiments demonstrate therefore that hypoxia further 
deviates the secretory profile towards matrix degradation and tissue destruction.   
I found that the increase in MMP-1 and MMP-9 protein seen in hypoxia resulted in 
increased proteolytic activity.  Both casein and gelatin zymography demonstrated evidence 
of increased substrate breakdown in the presence of hypoxia or DMOG.  Interestingly, 
DMOG increased MMP-9 proteolytic activity even in unstimulated cells.  Since zymography 
is a semi-functional assay, other methods to study collagen degradation might have 
included DQ collagen and assessment by confocal microscopy. 
My investigation of MMP-1 by confocal microscopy demonstrated evidence of increased 
MMP-1 staining in some A549 cells stimulated with CoMTb incubated in hypoxia.  I chose to 
visualise MMP-1 at 72 hrs post-stimulation as this is the time-point known to show the 
maximal changes in MMP-1 secretion.  It is possible that performing confocal microscopy 
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earlier, for example at 48hrs might have improved my ability to detect cellular MMP-1, prior 
to secretion of the protein into the cell supernatant.    I attempted to perform dual staining 
for MMP-1 and HIF-1α but found no evidence of HIF-1α staining at 72 hrs.  Again, it is 
possible that the time-point selected was not appropriate and further kinetic experiments 
would need to be performed.  Overall, the results from confocal microscopy compliment my 
experiments examining MMP-1 gene expression and protein secretion but the technique 
does not provide quantitative results beyond direct visualisation of the protein. 
My experiments performed at different levels of oxygen in parallel might be confounded by 
differences between the ambient conditions in each incubator.  I attempted to control for 
these factors by placing temperature and humidity sensors within incubators.  In addition, I 
performed experiments on cells cultured at the same time with sensors set at the same 
level of oxygen e.g.1% O2 to ensure parity between conditions.  Humidity levels in the 
Brunswick Hypoxic incubator were consistently lower than the Oxoid jar or Hypoxia 
Workstation (87% +/- 2%) compared to >95%.  In addition, temperature and humidity levels 
were highly sensitive to opening and closing of the incubator door, therefore experiments 
were designed in such a way as to minimise these factors.  Nonetheless, these differences 
and varying the level of oxygen did not result in an increase in cell cytotoxicity.  Differences 
in ambient conditions therefore are unlikely to have affected my experiments but, an 
improvement to the experimental conditions would be the purchase of a larger incubator 
which would better accommodate repeated opening of the incubator door. 
The decrease in MMP-1 secretion at 10% oxygen compared to 21% oxygen is not accounted 
for in any current literature and is a surprise finding.  It is possible that 10% oxygen is more 
representative of physiological oxygen levels in the lung and adaptive changes have 
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occurred to lessen the tissue destructive effects of the MMPs.  My work focused principally 
on the factors driving MMP expression but did not investigate the features associated with 
10% O2 which lead to a decrease in MMP-1 activity.  Investigation of changes in MMP-1 gene 
expression and MMP-1 secretion kinetics would have been useful but also assessment of 
the chemokine and cytokine profile might have identified potential key regulators.  It would 
have also been useful to look at downstream regulatory pathways such as P38 MAPK to 
assess if these were affected by different oxygen levels.  Such work might provide insights 
into potential therapeutic interventions which result in decreased MMP-1 expression. 
 My findings of hypoxia-driven MMP expression are consistent with findings from the 
hypoxic rheumatoid synovium where hypoxia and HIF have been demonstrated to drive 
MMP-mediated tissue destruction [174].  In addition, HIF-driven MMP expression has been 
described in a number of malignant conditions [130, 175].  HIF-1α stabilisation increases 
MMP-9 activity in breast cancer cell lines [130] and HIF and MMP-9 expression in breast 
cancer is associated with increased metastatic potential and invasiveness [176].  
Since MMP-1 performs the rate-limiting step in the degradation of type I collagen, and that 
it was the most consistently up-regulated MMP in my experiments, I focused on MMP-1 as 
the primary host factor involved in lung tissue damage observed in TB.  I have shown that 
DMOG significantly increases MMP-1 mRNA accumulation in A549 cells stimulated with 
CoMTb.  Additionally, both DMOG and hypoxia up-regulate MMP-1 promoter activity in cells 
transfected with the full-length promoter. 
Having demonstrated that hypoxia potently up-regulates MMP-1, I sought to investigate 
how manipulation of key transcription factors, known to regulate MMPs, might modulate 
MMP-1 secretion in hypoxia.  NF-κB has been shown to be a key regulator of HIF as well a 
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key transcription factor involved in the regulation MMP-1 [61, 177, 178].   By blocking the 
Iκκβ subunit of NF-κB with SC-514, I demonstrated a significant down-regulation of MMP-1 
secretion.  This decrease occurred in normoxia and with DMOG pre-incubation or in 
hypoxia.  Interestingly p65 blockade with helenalin, had no effect in normoxia but caused a 
significant decrease in MMP-1 secretion in cells incubated in hypoxia.  This finding indicates 
that NFκB regulation of MMP-1 activity might involve differing regulatory mechanisms in 
hypoxia compared to normoxia.   
In silico analysis of the MMP-1 promoter sequence revealed a number of putative HREs 
indicating potential involvement of HIF-1 in MMP-1 transcriptional control.  My work 
investigating the role of HIF pathways and MMP activity are described in Chapter 6.  Site-
directed mutagenesis of the HRE’s between -3850 and -1551 however, would have indicated 
if the HIF complex regulates transcriptional activity of MMP-1.  In addition, I would have like 
to have manipulated elements within the MMP-9 promoter to investigate if NF-κB, HIF and 
AP-1 are involved in the transcriptional regulation of MMP-9 in hypoxia. 
My finding of hypoxia-driven MMP expression during TB infection were mimicked by DMOG 
indicating that this pathway in potentially open to therapeutic manipulation.   Previous trials 
of MMP inhibitors have proved unsuccessful due to intolerable side-effects [179]; a more 
targeted approach might therefore improve these therapies.  More recently, the use of 
DMOG to manipulate the HIF pathway has been investigated in animal models of infective 
and inflammatory conditions.  DMOG pre-treatment has been shown to be protective in a 
murine model of colitis [180] and protective against LPS-induced sepsis [181].  DMOG 
therapy is currently being investigated in the context of inflammatory bowel disease [182].  
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My cellular model cannot fully predict MMP responses in vivo, but my finding that DMOG 
potently up-regulates MMP activity might mean that alternative approaches are required.  
One approach might be to overexpress the PHDs and ascertain if this leads to a decrease in 
MMP secretion.  The development of MMP-1 and MMP9 transgenic mice by the JSF group 
means that these studies are now possible and represent potential future avenues by which 
the interplay of hypoxia, the PHDs and MMPs might be explored. 
In summary, my investigation of hypoxia and MMPs in respiratory epithelial cells has 
demonstrated that MMP-1 and MMP-9 are potently up-regulated under hypoxia conditions 
and in response to prolyl hydroxylase inhibition.  My results reveal that hypoxia augments 
the previously described mechanism by which M.tb may drive pulmonary cavitation in the 
lung and thus create a niche within the host for its survival and transmission.
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CHAPTER 5: HYPOXIA AND MMPs IN HUMAN MONOCYTE-DERIVED 
MACROPHAGES 
Introduction 
Macrophages are one of the first host immune cell to encounter M.tb.  Initially macrophages 
phagocytose the bacilli and then proceed to recruit peripheral macrophages and monocytes 
to the site of infection to encase the bacilli.  In data previously published by the JSF group, 
direct infection of monocyte-derived macrophages by M.tb, but not BCG, causes potent up-
regulation of MMP-1 and MMP-7 [183].  Further systematic profiling of all known MMPs and 
the related A disintegrin and metalloproteinases (ADAMs) in primary human macrophages 
infected with M.tb shows up-regulation of MMP-3 and MMP-10 [183].  Finally, analysis of 
MMP-1 and MMP-7 from lung biopsy specimens of TB patients demonstrates expression 
within epitheliod macrophages and Langerhans giant cells within granulomas.  Hypoxia is 
known to influence macrophage function and survival [184, 185] but the effect of hypoxia 
on M.tb-infected macrophages has not been evaluated.   
In this chapter, I have examined the effect of hypoxia and HIF stabilisation on MMP activity 
in MDMs directly infected with M.tb.  This chapter examines the key MMPs affected by 
hypoxia and the mechanisms by which this occurs.  Additionally it explores whether the 
effect of hypoxia on MMP activity is influenced by M.tb phagocytosis and intracellular 
replication.  Finally it also investigates the role of NFκB in hypoxia-driven MMP activity 
during direct infection. 
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Results 
HIF-1α stabilisation with DMOG increases MMP-1 and MMP-3 protein 
secretion in M.tb infected MDMs 
To assess the effect of HIF-1α stabilisation on MMP activity, I initially examined the effect of 
DMOG on MMP-1/-3 and -7, the main MMPs secreted in response to M.tb infection.  The 
investigation of MMP-10 was being conducted by a colleague within the JSF group and 
therefore was not covered in my study.  HIF-1α stabilisation with DMOG caused a highly 
significant increase in MMP-1 secretion in M.tb infected MDMs occurring in a dose-response 
manner (Figure 36A; p<0.001).  Concentrations of greater than 0.5mmol resulted in marked 
cell death, as assessed by trypan blue exclusion assay.  Casein zymography revealed that 
secreted MMP-1 was proteolytically active (Figure 36B).  This increased proteolytic activity 
corresponded with increasing concentrations of DMOG.   
DMOG caused a significant increase in MMP-3 secretion from M.tb infected MDMs although 
no dose-response relationship was identified (Figure 36C).  DMOG did not impact 
significantly on MMP-7 secretion in M.tb infected MDMs except at a concentration of 
0.05mmol where a reduction in MMP-7 secretion was observed (Figure 36D). 
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Figure 36:  Effect of DMOG on MMP secretion from MDMs directly infected with M.tb. MDMs were 
pre-incubated with DMOG (0.05mM, 0.25mM and 0.5mM) for 2 hrs and then infected with M.tb 
(MOI=1).  Supernatants were harvested at 72 hours and MMP-1 levels measured by Luminex. (A)  
DMOG significantly increases MMP-1 secretion in a dose-response manner (p<0.001).  (B)  Casein 
zymography demonstrates that secreted MMP-1 protein is proteolytically active.  (C)  DMOG causes 
a highly significant increase in MMP-3 secretion.  (D)  DMOG has no effect on MMP-7 secretion 
except at a dose of 0.05mM where it causes a decrease in MMP-7 protein levels (p<0.05).  Bars 
represent mean (+/- SD) of conditions in triplicate and are representative of at least 2 independent 
experiments. 
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Hypoxia at the level seen in human disease increases MMP-1 and MMP-7 
secretion in M.tb infected MDMs 
 
I next proceeded to examine the effect of hypoxia (1% O2) on MMP secretion in M.tb 
infected MDMs.  Cells were infected with M.tb H37Rv and placed in the same incubator at 
21% O2 and 5% CO2.  After 2hrs cell culture supernatants were removed and replaced with 
new medium.  MDMs were then incubated at either 21% O2 or 1% O2.  These steps were 
taken with all experiments to ensure try and control for any differences in phagocytosis that 
might occur in hypoxia.  Compared to cells incubated at 21% O2, hypoxia (1% O2) caused a 
significant increase in MMP-1 and MMP-7 secretion in MDMs infected with M.tb (Figure 37). 
Hypoxia did increase secretion of MMP-1 and MMP-7 in uninfected cells but this result did 
not reach statistical significance.  In contrast to cells pre-incubated with DMOG, MMP-3 
secretion was not affected by hypoxia (Figure 37). 
All cells were inspected by light microscopy at 72 hrs and although cells incubated in 
hypoxia appeared more activated i.e. elongated with stellate appearance, not difference in 
cell death was seen (as assessed by trypan blue exclusion assay).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5:  Hypoxia and MMPs in Human Monocyte-Derived Macrophages 
146 
 
 
 
 
 
Figure 37:  Effect of 1% oxygen on MMP secretion from MDMs directly infected with M.tb.  MDMs 
were directly infected with M.tb (MOI=1) and incubated with either normoxia (21% O2) or hypoxia 
(1% O2).  Supernatants were harvested at 72 hrs and MMPs measured by Luminex.  1% O2 causes a 
significant increase in MMP-1 (p<0.05) and MMP-7 protein (p<0.001) secretion compared to cells 
incubated at 21 %O2.  Hypoxia (1% O2) has no effect on MMP-3 protein secretion from M.tb infected 
MDMs.  Bars represent mean (+/- SD) of conditions in triplicate and are representative of at least 2 
independent experiments. 
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Increased MMP-1 secretion in MDMs infected with M.tb is not accompanied 
by a change in TIMP-1 levels 
The concordance between the effect of DMOG and hypoxia on MMP-1 secretion 
determined that subsequent investigations focussed on MMP-1 activity.  In the first 
instance, I looked to compare the effect of hypoxia on M.tb infected MDMs with a control 
stimulus.  LPS is known to stimulate MMP-1 secretion in MDMs [186].  Furthermore, LPS 
activity has been shown to be activated by hypoxia [187].  Compared to control cells 
incubated in normoxia, LPS stimulation (100ng/ml) caused a 2.3 fold increase in MMP-1 
secretion, a result which did not reach statistical significance (Figure 38A; p>0.05).  M.tb 
infection (MOI=1) caused a 20-fold increase in MMP-1 secretion compared to LPS-
stimulated cells. When cells were incubated in hypoxia, M.tb infection caused a 28-fold 
increase in MMP-1 secretion compared to LPS (p<0.001) (Figure 38A).   
Next, I proceeded to examine the effect of hypoxia on TIMP-1 the specific tissue inhibitor of 
MMP-1.  In uninfected MDMs, hypoxia (1% O2) caused a significant increase in TIMP-1 
secretion (Figure 38B).  1% O2 had no effect on TIMP-1 secretion in M.tb infected MDMs 
demonstrating that increased MMP-1 secretion caused by hypoxia was not accompanied by 
a rise in its specific inhibitor.  Casein zymography demonstrated increased caseinolytic 
activity in M.tb-infected MDMs in hypoxia (Figure 38C).  
The results of two independent experiments (single samples run in triplicate) demonstrated 
that the greatest difference in MMP-1 mRNA was seen at 24hrs (Figure 38D).  Hypoxia 
caused at 2800-fold increase in MMP-1 mRNA in M.tb infected MDMs compared to cells 
incubated in normoxia (Figure 38D; p<0.001). 
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Figure 38:  Effect of 1% O2 on MMP-1 and TIMP-1 activity in MDMs.  MDMs were either stimulated 
with LPS (100ng/ml) or directly infected with M.tb (MOI=1).  Supernatants were harvested for MMP-
1 and TIMP-1 protein secretion at 72 hrs.  Cells were lysed at the various time points and RNA 
extraction performed to assess MMP-1 gene expression.  (A)  1% O2 causes a highly significant 
increase in MMP-1 protein secretion from M.tb infected cells compared to LPS and control cells 
(p<0.001).  (B)  1% O2 causes increased TIMP-1 secretion from control cells and has no effect on M.tb 
infected MDMs (p>0.05).  (C)  Casein zymography demonstrates that increased secreted MMP-1 
protein in hypoxia is proteolytically active.  (D)  MMP-1 kinetic experiments show that 1% O2 causes 
increased MMP-1 gene expression, maximal at 24 hrs.  (E)  1% O2 causes a 2,800-fold increase in 
MMP-1 gene expression (p<0.001) at 24 hrs from MDMs infected with M.tb compared to normoxia 
(N=21% O2; H=1% O2).  Bars represent mean (+/- SD) of conditions in triplicate and are 
representative of at least 2 independent experiments. 
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Confocal microscopy demonstrates increased MMP-1 staining in M.tb- 
infected MDMs incubated in hypoxia 
I proceeded to assess MMP-1 activity by confocal microscopy.  Macrophages were matured 
on Permanox chamber well slides as my attempts to mature the cells on glass slides resulted 
in poor cell adherence and fewer cells than seen on standard tissue culture plates.  MMP-1 
staining and confocal imaging has not previously been performed within our group and 
there is no published work in this area so a series of optimisation experiments were 
required to determine antibody concentrations.  MMP-1 staining at t=0 demonstrated no 
MMP-1 staining, either in control or M.tb infected cells (data not shown).  I performed 
MMP-1 staining at 72hrs since this is the time of maximal MMP-1 secretion from MDMs.  
The results of two independent experiments demonstrated increased MMP-1 staining in the 
cytoplasm of MDMs infected with M.tb (Figure 39).  Hypoxia caused increased MMP-1 
staining compared to normoxia in M.tb infected cells.  Interestingly, MMP-1 staining was 
seen in control cells at 72hrs (normoxia and hypoxia) despite no measurable MMP-1 in the 
cell supernatant.  In these experiments the merge images contained the bright field view in 
order to better visualise the morphological changed that occurred during the course of the 
experiment. 
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Figure 39:  MMP-1 confocal microscopy of M.tb infected MDMs in normoxia and hypoxia.  MDMS 
were infected with M.tb and incubated at either 21% O2 or 1% O2.  Cells were fixed and M.tb killed 
with 4% paraformaldehyde prior to permeabilisation and staining for MMP-1.  Nuclei were stained 
with DAPI.  MMP-1 staining is seen in all cells at 72 hrs compared to t=0 (data not shown).  Increased 
MMP-1 staining is seen in M.tb-infected MDMs incubated at 1% O2 compared to control cells and 
M.tb infected cells incubated in normoxia.   
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Incubating M.tb-infected MDMs at varying levels of hypoxia has differential 
effects on MMP-1 secretion 
I next proceeded to investigate the effect of different oxygen levels on MMP-1 secretion.  I 
investigated the effect of 1%, 5% and 10% oxygen in three independent experiments.  In 
keeping with my findings in respiratory epithelial cells, 5% oxygen caused a significant 
increase in MMP-1 secretion (Figure 40B; p<0.05) whilst 10% oxygen caused a decrease in 
MMP-1 secretion compared to MDMs infected with M.tb and incubated at 21% oxygen 
(Figure 40C; p<0.001).  I performed parallel experiments comparing 1%, 10% and 21% 
oxygen and although 10% oxygen did cause a decrease in MMP-1 secretion, this result did 
not reach statistical significance (Figure 41A).  Sub-group analysis demonstrated that the 
decrease in MMP-1 secretion at 10% was statistically significant when compared with 
normoxia alone  (Figure 41B; p<0.01).   
Next I sought to determine if there were any factors which might be associated with the 
changes in MMP-1 secretion at different levels of oxygen.  Light microscopy demonstrated 
little evidence of gross morphological change in the appearance of the cells between 21% 
and 10% oxygen (Figure 41C).  The appearances seen at 1% oxygen of highly activated cells 
were consistent with those seen throughout the course of my cellular experiments.  
Interestingly, I was at this point assisting a colleague in the group and one of the purposes of 
this particular experiment was to investigate the changes in pH of the cell supernatant 72hrs 
post M.tb infection.  At 21% and 10% oxygen, the cell culture supernatant of control cells 
became more alkaline over time (in keeping with the buffering effect of 5% CO2) whereas 
control cells incubated at 1% oxygen remained at pH 7.2.  Strikingly, when cells were 
infected with M.tb, cells incubated at 21% and 1% O2 became markedly acidotic at 6.48 and 
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5.7 respectively (Figure 41D).  M.tb infected MDMs incubated at 10% O2 experienced no 
change in pH during the course of the experiment. 
The mechanisms by which these pH changes occur at different oxygen levels and the effect 
of pH on M.tb-driven immunopathology are now the focus of a clinical research training 
fellowship being conducted within the Friedland group.   
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Figure 40:  Effect of 1%, 5% and 10% oxygen on MMP-1 protein secretion from M.tb infected 
MDMs.  MDMs were infected with M.tb (MOI=1) and incubated with either 21% O2 or hypoxia (1%, 
5% or 10% O2).  Supernatants were harvested at 72 hrs and MMP-1 measured by ELISA.  (A & B) 1% 
and 5% O2 causes a significant increase in MMP-1 protein secretion compared to 21% O2.  (C)  10% 
O2 causes a reduction in MMP-1 secretion compared to M.tb-infected cells incubated at 21% O2.    
Bars represent mean (+/- SD) of conditions in triplicate and are representative of at least 2 
independent experiments. 
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Figure 41:  Investigation of the effect of 10% oxygen compared to 1% and 21% O2 on MMP-1 
secretion, cell morphology and cellular pH.  MDMs were directly infected with M.tb (MOI=1) and 
incubated at 1%, 10% or 21% O2.  MMP-1 protein secretion by ELISA, cell morphology and cell 
culture pH was assessed at 72 hrs. (A)  Compared to 21% and 1% O2, 10% O2 causes a decrease in 
MMP-1 protein secretion but the levels do not reach statistical significance.  (B)  10% O2 causes less 
MMP-1 secretion from M.tb-infected MDMs when compared to 1% O2 only (p<0.01).  (C)  Light 
microscopy reveals no significant morphological changes to account for differences in MMP 
secretion.  (D)  M.tb infection in normoxia and severe hypoxia (1% O2) cause acidification of cell 
culture supernatants at 72 hrs.  pH is unaltered after 72 hrs in MDMs incubated at 10% O2.  
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Investigation of hypoxia on M.tb phagocytosis using GFP-TB 
An emerging body of evidence indicates that myeloid cells adapt to in response to hypoxia 
and that hypoxia increases the phagocytic ability of macrophages.  I therefore proceeded to 
explore if hypoxia might be impacting on the amount of bacilli being phagocytosed following 
direct infection and whether therefore the changes in MMPs might be accounted for by an 
increased percentage of infected macrophages.  
 
I initially investigated M.tb phagocytosis in MDMs using GFP-TB by confocal microscopy.  
Each experimental condition was performed in duplicate.  Cells were fixed at 2hrs post M.tb 
infection and 10 random fields were selected for each experimental conditional.  The 
percentage of MDMs per field containing GFP-TB were counted independently by myself 
and a colleague and the median value between the two assessments was taken was the 
overall percentage.  In this initial experiment, hypoxia resulted in a significant increase in 
phagocytosis of M.tb at 2hrs (Figure 42B).  I then attempted to refine this experiment by 
more accurately counting the number of macrophages using to DAPI to identify the number 
of nuclei and additionally to look at later time points.  My results in MDMs infected with 
GFP-TB and incubated at 21% O2 at 8 hours revealed that not only were individual 
macrophages infected with more than one bacilli but also that distinguishing individually 
infected cells was challenging (Figure 43).  At 24 hours, the GFP signal had marked changed 
and in contrast to the elongated bacilli seen at 8 hrs, the signal had become more diffuse 
and less apparent (Figure 44).  The results in hypoxia could not be analysed since no GFP 
signal was seen either at 8 hrs or 24 hrs.   
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Figure 42:  Effect of hypoxia (1% O2) on phagocytosis of GFP-Tb at 2 hrs.  MDMs were directly 
infected with GFP-Tb (MOI=1).  Cells were fixed and GFP-Tb killed with 4% paraformaldehyde after 
2hrs.  x10 random fields were assessed for each condition by two independent investigators and 
average percentages of intracellular bacilli per field were recorded.  (A)  Representative images for 
permanox wells incubated in normoxia (21% O2) and hypoxia (1% O2).  (B)  Hypoxia increases the 
percentage of intracellular GFP-Tb bacilli 2 hrs post-infection (p<0.05).  Data representative from 2 
independent experiments. 
 
A 
B 
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Figure 43:  Phagocytosis of GFP-Tb at 8hrs in normoxia.  Representative imaged of intracellular 
bacilli 8 hrs post-infection.  (A)  Nuclei are stained with DAPI (far left), GFP-Tb (middle left), 
brightfield (middle right) and merged images (far right).  (B)  Higher powered images reveal that 
individual MDMs are frequently infected with more than one bacilli. 
 
 
 
 
 
 
Chapter 5:  Hypoxia and MMPs in Human Monocyte-Derived Macrophages 
158 
 
 
 
 
Figure 44:  Phagocytosis of GFP-Tb at 24hrs in normoxia.  Representative imaged of intracellular 
bacilli 24 hrs post-infection.  (A)  Nuclei are stained with DAPI (far left), GFP-Tb (middle left), 
brightfield (middle right) and merged images (far right).  (B)  Higher powered images reveal that GFP 
signal is significantly altered 24 hrs post-infection, and becomes more diffuse.   
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Further review of the scientific literature revealed that this result might have been 
predicted.  Green fluorescent protein is a highly fluorescent protein of the bioluminescent 
jellyfish Aequorea vitoria.  This 238 amino-acid is present as a monomer in solution and 
emits green light upon excitation with ultraviolet or blue light [188].  This step 
fundamentally requires molecular oxygen to dehydrogenate the α,β bond of residue 66 and 
is the slowest step in GFP chromophore formation with a time constant of 2 to 4 hrs in vivo 
for wild-type GFP [189].  It is likely therefore that I was able to visualise GFP-TB at my 2 hr 
timepoint and not at 8 and 24 hrs because of this reason. 
An alternative to GFP-TB I considered was auramine-rhodamine staining but given the 
difficultly in quantifying intracellular TB in macrophages, I opted to investigate intracellular 
infection by other methods. 
 
Increased MMP-1 secretion during M.tb infection in hypoxia does not require 
bacterial replication 
My first step was to establish whether hypoxia affected the intracellular replication of M.tb 
within MDMs.  In order to do this, I infected MDMs with M.tb at MOI=1.  In keeping with all 
my previous experiments, cell culture supernatants were replaced at 2 hrs post-infection 
with fresh medium.  This steps is standard to many laboratory infection protocols involving 
bacteria.  It has also been tested many times within the JSF laboratory and shown to 
produce reproducible rates of M.tb infection.  Cells were lysed at 72hrs following incubation 
in either 21% or 1% oxygen.  Colony counting was then performed after 3 weeks.  Hypoxia 
did not affect the number of viable bacilli indicating that hypoxia had no significant effect on 
the intracellular replication of M.tb (Figure 45A).  Since hypoxia had no effect on 
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intracellular replication, I then investigated whether the increase in MMP-1 secretion seen 
in M.tb infected MDMs required the presence of actively replicating mycobacteria.  
Previously published data from the JSF group demonstrates that increased MMP-1 secretion 
is seen when MDMs are stimulated with either uv-killed M.tb and M.tb supernatant, both of 
which contain no live bacteria [59].  Hypoxia (1% O2) increased MMP-1 protein secretion in 
MDMs stimulated with either uv-killed M.tb or M.tb supernatant (Figure 45B; p<0.001).  
Collectively, these results demonstrate that hypoxia upregulates MMP-1 expression in M.tb 
stimulated cells and this process does not require bacterial replication. 
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Figure 45:  Effect of hypoxia (1% O2) on intracellular replication of M.tb and MMP-1 secretion 
following “non-live” M.tb stimulation of MDMs.  MDMs were infected with M.tb (MOI=1).  Cell 
lysates were collected at 72 hrs and plates on 7H9 agar plates.  Colony counting was performed at 3 
weeks.  (A)  Hypoxia had no effect on M.tb CFU’s.  MDMs were stimulated with either M.tb 
supernatant or uv-killed M.tb.  Supernatants were harvested at 72 hrs and MMP-1 protein measured 
by ELISA.  (B)  Hypoxia augments MMP-1 secretion (p<0.001) from MDMs stimulated with “non-live” 
M.tb.  Bars represent mean (+/- SD) of conditions in triplicate and are representative of at least 2 
independent experiments. 
A 
B 
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Inhibition of NFκB causes decreased MMP-1 secretion in M.tb-infected 
MDMs incubated in hypoxia or with DMOG 
My results from respiratory epithelial cells indicated a pivotal role of NFκB during M.tb 
infection in hypoxia.  NFκB is known to critically regulate MMP activity in CNS TB infection 
[61] but there has been no investigation of its role in the presence of hypoxia and M.tb 
infection.  I therefore proceeded to explore if NFκB signalling was important in regulating 
MMP-1 secretion in human MDMs directly infected with M.tb.  In order to this I used the 
chemical inhibitor helenalin, shown to inhibit NFκB in previous work by our group[190].  HIF 
signalling was activated using both DMOG and hypoxia at 1% O2. 
Cells were pre-incubated with DMOG (0.25mM) and helenalin (1.0µM) for 2 hrs and then 
infected with M.tb (MOI=1).  Helenalin caused a decrease in MMP-1 secretion in cells 
treated with DMOG (Figure 46A; p<0.001).)  Dose-response experiments demonstrated this 
finding even at higher doses of helenalin in the presence of DMOG (Figure 46B).  Helenalin 
caused a decrease in MMP-1 secretion from M.tb-infected cells but this decrease was not 
statistically significant (Figure 46B).    
When M.tb infected cells were incubated in hypoxia (1% pO2), helenalin caused a highly 
significant decrease in MMP-1 secretion compared to cells incubated in normoxia (Figure 
46C; p<0.001).  Collectively these results indicate that NFκB signalling might form a key role 
in hypoxia-driven MMP-1 secretion during M.tb infection. 
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Figure 46: Effect of helenalin on MMP-1 secretion in M.tb-infected MDMs treated with DMOG or 
incubated in hypoxia (1% O2).  (A)  Helenalin (1.0µM) decreases MMP-1 secretion from M.tb-
infected MDMs pre-incubated with DMOG (0.25mM).  (B)  p65 subunit inhibition causes decreased 
MMP-1 secretion in M.tb-infected MDMs, but this effect does not reach statistical significance 
compared to DMOG treated cells.  (C)  Helenalin causes a highly significant decrease in M.tb-infected 
MDMs incubated in hypoxia.  Bars represent mean (+/- SD) of conditions in triplicate and are 
representative of at least 2 independent experiments. 
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Discussion 
 
 
The results of my investigation in MDMs showed that MMP-1 gene expression and secretion 
were significantly increased and was functionally active in M.tb-infected human 
macrophages in hypoxia compared to normoxia and, there was no compensatory increase in 
the inhibitor TIMP-1.  Consistent with my findings in respiratory epithelial cells, NF-κB 
signalling pathways were found to regulate MMP-1 secretion in hypoxia.  Additionally, 10% 
O2 causes decreased secretion of MMP-1.  
 
Diverse lines of investigation are implicating MMP-1 as a key protease in TB pathology.  
MMP-1 causes collagen destruction in M.tb-infected transgenic mice [59] and M.tb infection 
upregulates MMP-1 more potently than M.bovis BCG in human macrophages [183]. In 
human TB granulomas, MMP-1 expression is up-regulated 606-fold compared to uninfected 
lung [191].  Similarly, MMP-1 was the most potently upregulated gene in macrophages from 
patients who developed TB compared with those with latent disease [23]. 
 
My results revealed increased protelytic activity in MDMs directly infected with M.tb which 
was markedly increased by both hypoxia and DMOG.  Zymography is a semi-function assay 
of caseinolytic activity and gives an indication of total proteolytic activity. Subsequent to 
these experiments, other techniques have been employed within our group to demonstrate 
collagen breakdown for example using DQ collagen.  Increased collagen degradation is seen 
in neutrophils and monocytes directly infected with M.tb (data unpublished).  Further 
experiments might have included the assessment of collagen degradation using this 
technique both in normoxia and hypoxia and whether this corresponded to infected cells 
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(using auramine-rhodamine to stain M.tb).  Since my experiment involved maturing 
monocytes to macrophages over 5 days, a series of further experiments would be needed to 
assess if maturation on collagen affected this process and additionally, the effect on MMP-1 
secretion.  An alternative approach would be to assess MMP-1 activity in normoxia and 
hypoxia from monocytes.  Since MMP activity is normally measured at 24hrs or less in M.tb 
infection, the effect of seeding on collagen is likely to be reduced.  Hypoxia has been shown 
to prolong monocyte survival and thus might act as a confounder in this experiment [192]  
 
I found divergent MMP-1 and MMP-7 responses in response to DMOG and hypoxia (1% O2).  
Although I did not examine the potential mechanisms by which this process occurs, there is 
evidence that MMP-1 and MMP-7 secretion from macrophages occurs by differing 
processes.  For example, M.Tb, but not important proinflammatory cytokines involved in 
orchestrating the host immune response, increase MMP-1 secretion from macrophages 
whereas MMP-7 expression and secretion can be stimulated by TNF-α alone [183].  In 
addition,  divergent MMP-1 and MMP-7 response occur in response to TNF-α stimulation 
and steroid treatment suggests that the upstream regulation of these MMPs differs [59]. 
 
Although my confocal experiments using GFP-Tb were less successful, owing to the oxygen 
responsive elements of green florescent protein, I demonstrated that not all MDMs became 
infected with M.tb.  It is interesting therefore that the increased MMP-1 staining seen in 
M.tb infection and hypoxia was almost universal.  This demonstrates that direct M.tb 
infection is unlikely to be the only mechanism driving MMP-1 production and that TB-
networks might be exerting an effect.   I showed that increased MMP-1 secretion in hypoxia 
from M.tb-infected MDMs was not dependent on actively replicating bacilli and my findings 
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are supported by recently published data investigating the interaction between 
macrophages and hypoxia.  Nickel et al. demonstrate that hypoxia (1% O2) at increasing 
MOIs does not affect M.tb colony forming units after 4 days of infection.  
 
I attempted to perform HIF-1α staining using confocal microscopy but this was not 
successful.  My initially experiments were performed using antibodies against HIF-1α in 
addition to MMP-1 antibodies.  Care was taken to ensure that there was no cross-reactivity 
between the antibodies and that the colour channels were sufficiently distinct, but I was 
unable to detect HIF-1α staining by confocal microscopy.  One possible explanation is the 
time-point selected.  MMP-1 staining was performed at 72hrs which is the maximal time 
point for MMP-1 protein secretion in MDMs however, since HIF-1α stabilisation frequently 
occurs within hours of exposure to pro-inflammatory stimuli, this time point might have 
been too late.  Recently published data reveals early upregulation of HIF targets genes in 
response to M.Marinum infection in a zebrafish model [110] suggesting I may have selected 
the incorrect time point.  The experiment might therefore have been improved by 
performing HIF-1α kinetic experiment using confocal microscopy as well as assessing HIF-1α 
staining independently of MMP-1 staining. 
 
The role of NFKB was investigated using chemical inhibitors and in consistent with my 
findings in respiratory epithelial cells, NF-κB inhibition decreases MMP-1 secretion in M.tb-
infected cells in hypoxia (or pre-incubated with DMOG).  I only used helenalin to inhibit the 
p65 subunit of NF-κB but would like to have inhibited other subunits.  An alternative 
approach would be to transfect MDMs with NF-κB subunits based on the results of the 
chemical inhibitor experiments.  Transfection of MDMs had not been performed 
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successfully within our laboratory but following the results using HIF-1α siRNA (see Chapter 
6) it would certainly now be possible to undertake these experiments.   
 
I showed that incubating M.tb-infected MDMs at 10% O2 decreased MMP-1 secretion 
compared to incubation at 21% O2.  The finding of neutralisation of pH was extremely 
interesting as M.tb is known to evade host immune cells by effecting mechanisms which 
neutralise pH within phagocytic cells [193].  Research is ongoing in this area within the JSF 
group and might provide insights into the mechanisms by which 10% O2 decreases MMP 
activity, 
 
In conclusion, hypoxia is a positive stimulus for MMP expression in MDMs, potentially 
allowing M.tb, an aerobic bacterium, to escape the hypoxic environment of the granuloma 
and spread to new hosts. 
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CHAPTER 6: HYPOXIA AND THE ROLE OF HIF DURING M.tb 
INFECTION  
Introduction 
Activation of HIF during bacterial infection has been described in several studies with 
increased levels of HIF-1α demonstrated in response to Streptococcus pyogenes, 
Streptococcus agalactiae, Staphylococcus aureus, Salmonella typhimurium and 
Pseudomonas aeruginosa [89].   In addition, HIF stabilisation has been described in a 
number of viral and parasitic infections [64]. 
 
Table 6:  Infectious organisms and effect on HIF.  Adapted Nizet V. Nature Sept 2009: Vol 9. No.9 
Chapter 6:  Hypoxia and the Role of HIF During TB Infection 
169 
 
Interestingly, some studies have shown that bacterial exposure can be a more potent 
stimulus for HIF-1α than hypoxia itself, and bacteria-induced HIF-1α stabilisation can occur 
readily under conditions of normoxia [86].    
Although investigation of HIF activity has been conducted in several infective processes, the 
presence or role of HIF during TB infection has not been previously investigated.  Following 
my finding of severe hypoxia within TB lesions in patients, I investigated the role of HIF-1α 
during Tb infection in vitro and in patients with a confirmed diagnosis of pulmonary M.tb 
infection.  
Results 
M.tb infection drives HIF-1α stabilisation in MDMs 
My initial investigation of HIF-1α activity during M.tb infection involved determining 
whether HIF-1α stabilisation occurred during direct infection of MDMs.  LPS (100ng/ml) was 
used as a positive control since it is known to stabilise HIF-1α maximally at 8hrs in primary 
MDMs [187].  Direct infection with M.tb (MOI=1) caused in HIF-1α stabilisation at 24hrs 
compared to 4hrs with LPS (Figure 47A). This is the first time that M.tb-driven HIF-1α 
stabilisation has been described. I then proceeded to determine the kinetics of HIF-1α 
stabilisation in M.tb infected MDS.  HIF-1α stabilisation occurred maximally at 24hrs and 
declined thereafter (Figure 47B). By comparison, some HIF-1α accumulation was seen in 
control cells from 24hrs which persisted to 72hrs.   
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Figure 47:  HIF-1α western blotting of MDMs directly infected with M.tb.  MDMs were infected 
with M.tb (MOI=1).  Cells were incubated at 21% O2 and 5% O2 and lysed at serial time points to 
determine HIF-1α kinetics.  (A)  M.tb infection drives accumulation from 8 hrs post-infection. 
Maximal accumulation occurs at 24 hrs.  LPS (100ng/ml), used as a positive control, drives HIF-1α 
accumulation from 4 hrs and is more sustained.  (B)  Maximal HIF-1α stabilisation occurs at 24 hrs 
post-infection.  Blots are representative of at least 2 independent experiments  
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DMOG and hypoxia (1% pO2) drive stabilisation of HIF-1α 
I then proceeded to investigate the effect of DMOG and hypoxia (1% O2) on M.tb-driven HIF-
1α accumulation.  Pre-incubation of MDMs with DMOG (0.25mM) for 2 hours prior to M.tb 
infection resulted in an increase in HIF-1α protein compared to DMOG alone (Figure 48A). 
Next I examined the effect of hypoxia (1% pO2) on M.tb-driven HIF-1 stabilization.  Since 
hypoxia driven HIF-1α protein is known to degrade within two minutes of exposure to 
ambient air [194], it was necessary to conduct these experiments within a custom designed 
hypoxia workstation (Coy Laboratories, Michagan, USA) The presence of hypoxia (1% O2) 
caused prolonged and increased HIF-1α accumulation in MDMs infected with M.tb 
compared to cells incubated in normoxia (Figure 48B).   HIF-1α stabilisation occurred as 
early as 4 hours in cell incubated in hypoxia compared to 24hrs in normoxia.  Collectively, 
these results demonstrate that direct M.tb infection results in HIF-1α accumulation in both 
normoxia and hypoxia.   
HIF-1α stabilisation is not specific to M.tb infection 
As part of the investigation of HIF-1α activity in TB infection, I was keen to determine if 
there were any TB specific components driving this stabilisation.  In particular, if these might 
be related to virulence factors ESAT-6 and CFP-10, which are present in M.tb but absent in 
BCG.  MDMs from the same donor were plated and cells infected at MOI=1 with either M.tb 
or BCG.  HIF-1α western blotting demonstrated a faint band corresponding to HIF-1α at 8hrs 
in and 24hrs in M.tb infected cell in normoxia.  By comparison, cells incubated in hypoxia 
demonstrated evidence of HIF-1α stabilisation at 8hrs in both M.tb infected cells and those 
infected with BCG (Figure 48C).     
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Figure 48:  Effect of DMOG and hypoxia (1% O2) on HIF-1α stabilisation in MDMs infected with 
M.tb and BCG.  (A)  MDMs were pre-incubated with DMOG (0.25mM) for 2 hrs and then infected 
with M.tb (MOI=1).  Cells were incubated in normoxia (21% O2).  Lysates were harvested 8 hrs post-
infection. DMOG and M.tb co-infection causes a marked increase in HIF-1α accumulation compared 
to either DMOG or M.tb infection alone.  (B)  MDMs were incubated at either 21% 02 or 1% O2 within 
a hypoxic workstation.  1% O2 causes earlier and more prolonged HIF-1α stabilisation in M.tb 
infected MDMs compared to cells incubated at 21% O2.  (C)  Both M.tb and BCG infection (MOI=1) 
causes stabilisation of HIF-1α in hypoxia (1% 02) 8 hrs post=infection.  Blots are representative of at 
least 2 independent experiments.  
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CoMTb and DMOG cause HIF-1α stabilisation in A549 cells but not NHBEs 
I then proceeded to investigate whether HIF-1α stabilisation occurred as a consequence of 
direct infection alone or also occurred via TB-networking effects.  In A549 respiratory 
epithelial cells stimulated with CoMTb, HIF-1α induction was present in cells from 6 hours 
even in the absence of hypoxia or DMOG exposure (Figure 49A).  As would be predicted, 
DMOG stabilized HIF-1α, but this effect was markedly increased by concurrent stimulation 
with CoMTb.  Investigation in primary cells (NHBEs) produced much less clear results.  
NHBEs exhibited high basal levels of HIF-1α and pre-incubation with DMOG and/or 
stimulation with CoMTb stimulation resulted in reduced HIF-1α levels (Figure 49B).  It is 
possible that the high number of growth factors present supplemented in the NHBE growth 
medium might be driving HIF-1α accumulation therefore the effect of DMOG and/or CoMTb 
are minimal.   
These results confirm that during M.tb infection, HIF-1α stabilization occurs both by direct 
infection in MDMs and via an M.tb networking effect (using CoMTb) in A549 respiratory 
epithelial cells.   
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Figure 49:  Effect of DMOG on HIF-1α accumulation in respiratory epithelial cells stimulated with 
CoMTb.  Respiratory epithelial cells (A549 and NHBEs) were pre-incubated with DMOG (0.25mM) for 
2 hrs and then stimulated with CoMTb (1:5).  Cell lysates were harvested at various time points to 
determine HIF-1α kinetics.  (A)  Both DMOG and CoMTb stimulation cause stabilisation of HIF-1α 
stabilisation in A549 cells.  Maximal accumulation occurs at 6hrs.  Co-stimulation causes a 
cumulative increase in HIF-1α stabilisation.  (B)  NHBE cells display high resting levels of HIF-
1α.   CoMTb and DMOG (0.25mM) cause decreased HIF-1α accumulation at 4 hrs post-
stimulation.  Blots representative of at least 2 independent experiments.  
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Protocol re-optimisation 
At this point during my investigations of HIF-1α, the ECL reagent supplied by GE Healthcare 
was discontinued and replaced with ECL-Prime, a significantly more sensitive reagent.  The 
consequences of this were that although the developing process became more sensitive, 
the assay was frequently too sensitive and detected significant amounts of background 
protein.  Initially, I attempted to shorten exposure time but a reduction from 4 minutes to 2 
seconds still resulted in uninterpretable blots.  Our group tested a number of alternative 
commercially available developing reagents but all proved too insensitive.  After a number 
of re-optimisation experiments involving reducing the amount of protein loaded, diluting 
both the primary and secondary antibodies and lengthening times of protein blocking steps I 
was able to perform western blot analysis of interpretable quality.  Another key factor that 
arose from these optimisation experiments was that HIF-1α is highly sensitive to freeze-
thaw cycles with almost no HIF-1α present following x1 freeze-thaw cycle.  The same was 
not true of subsequent investigation of the PHDs which tolerated up to x4 freeze-thaw 
episodes. 
Role of HIF-2α during M.tb infection is indeterminate 
Having investigated HIF-1α activity in both direct and indirect infection I then proceeded to 
investigate if M.tb infection caused stabilisation of HIF-2α.  I performed multiple 
experiments and western blots to examine HIF-2α activity in MDMs directly infected with 
M.tb.  I was able to detect evidence of HIF-2α activity on one occasion where I detected a 
faint band in hypoxia (Figure 50).  Unfortunately, I was not able to reproduce these results 
on any further experiments despite multiple modifications to my Western blot protocol e.g. 
loading more protein and increasing antibody concentrations.  
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Figure 50:  Effect of hypoxia (1%) on HIF-2α stabilisation in MDMs infected with M.tb.  MDMs were 
directly infected with M.tb (MOI=1) and incubated in either normoxia (21% O2) or hypoxia (1% O2 
hypoxia workstation).  Cell lysates were harvested at various time points to determine HIF-1α and 
HIF-2α kinetics.  Hypoxia causes increased and earlier accumulation of HIF-1α in MDMs infected with 
M.tb compared to cells incubated at 21% O2.  Hypoxia causes a faint band on western blot 
corresponding to HIF-2α from 4 hrs post-infection until 24 hrs post-infection.  Blots from one 
experiment. 
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M.tb infection increases prolyl hydroxylase activity in normoxia and PHD1 
and PHD2 only in hypoxia 
Next I sought to investigate the activity of the prolyl hydroxylases in response to M.tb 
infection both in normoxia and hypoxia.  My aims were to ascertain if the PHD response to 
M.tb were altered compared to control uninfected cells and if so, was this response 
different if the cells were incubated in hypoxic conditions. 
Investigation comparing control cells to those infected with M.tb in normoxia demonstrated 
that cells infected with M.tb demonstrated greater induction of PHD1, PHD2, PHD3 and FIH 
(Figure 51).  Membranes were stripped and re-probed for the PHDs to try and control for 
differences in protein loading.  FIH was run of a separate western blot and may have 
overheated given the bands seen. These differences were seen even at T0 which is 
interesting since the cells were seeded and retrieved from the same tissue culture plate.  
These changes suggest that the PHD response to M.tb infection occurs very rapidly, possibly 
within minutes. 
When responses in normoxia were compared to responses in hypoxia, there was marked 
differences both between control and M.tb infected cells and between each condition in 
normoxia and hypoxia.  Initially comparing the control cells in normoxia to control cells in 
hypoxia revealed that PHD1 activity was relatively unaltered (taking in to account the high 
background interference on the blot).  The activity of PHD2 was markedly increased in 
hypoxia particularly at 24hrs.  By comparison, the activity of PHD3 and FIH were relatively 
unaltered by hypoxic conditions. 
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When HIF-1α levels from M.tb infected cells incubated in normoxia were compared to cells 
incubated in hypoxia there was once again differential expression of PHDs.  PHD1and PHD2 
levels were greater at 24 hrs in M.tb infected cells incubated in hypoxia than cells incubated 
at normoxia.  Levels of PHD3 in M.tb infected MDMs incubated in hypoxia were either 
unchanged or slightly decreased at 24hrs whilst FIH was decreased in hypoxia.  Repeat 
experiments demonstrated the same changes occurring with PHD responses whilst no 
significant difference has noted in FIH activity. 
Collectively, these results demonstrate that in addition to driving HIF-1α stabilisation, M.tb 
infection causes changes in expression of PHD1 and PHD2, with the most significant 
increases occurring in hypoxic conditions. 
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Figure 51: Investigation of effect of hypoxia on prolyl hydroxylase activity in response to M.tb 
infection.  MDMs were directly infected with M.tb (MOI=1) and incubated in either normoxia (21% 
O2) or hypoxia (1% O2, hypoxia workstation).  Cell lysates were harvested at 0, 4, 8 and 24 hrs.   M.tb 
infection causes increased levels of PHD1, PHD2 and PHD3 protein levels on western blot compared 
to control cells.  Hypoxia causes increased protein levels of PHD2 in control cells compared to cells 
incubated in normoxia.  1% O2 causes increased levels of PHD1 and PHD2 in M.tb-infected MDMs 
compared to cells incubated at 21% O2.  Representative blots taken from one experiment performed 
independently on three occasions. 
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HIF-1α inhibition decreases MMP-1 secretion in M.tb infected MDMs 
incubated in hypoxia 
Having demonstrated that M.tb infection drives HIF-1α, I then sought to determine whether 
inhibiting HIF-1α impacted on MMP-1 activity during TB infection.  Initially, I used LW6 
chemical inhibitor (Merck Millipore, UK) to inhibit hypoxia-induced accumulation of cellular 
HIF-1α protein in MDMs directly infected with M.tb.  Although LW6 caused a decrease in 
M.tb driven MMP-1 secretion in human MDMs in normoxia, this result did not reach 
statistical significance (Figure 52; p>0.05).  In contrast, inhibition of HIF-1α activity in 
hypoxia caused a highly significant decrease in MMP-1 expression in a dose-dependent 
manner.  Cell toxicity was assessed by trypan blue exclusion assay and since significant cell 
death was seen at doses >100µmol, these results were excluded from the final analysis.   
Since chemical inhibitors can be associated with non-specific off-target affects, I then 
proceeded to use HIF1α siRNA to inhibit HIF-1α activity.  I was assisted in these experiments 
by my colleague Sara Brilha.  In order to assess transfection efficiency, MDMs were 
transfected with FAM conjugated NT siRNA and analysed by flow cytometry.  Transfection 
efficiency was confirmed as 80.4% (Figure 13).  Knockdown of HIF-1α mRNA was confirmed 
to be 73% in hypoxia compared to M.tb infected cells.  Interestingly, there was little 
upregulation of HIF mRNA by M.tb infection compared to control either in normoxia or 
hypoxia.  This finding suggests that most of the increased HIF-1α activity associated with 
M.tb infection might be occurring at the post-transcriptional level.   
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Figure 52:  Effect of HIF-1α chemical inhibition on MMP-1 secretion in M.tb-infected MDMs.  
MDMs were pre-incubated with LW6 (50 and 100µM) for 2 hrs and then directly infected with M.tb 
(MOI=1).  Cells were incubated in normoxia (21% O2) or hypoxia (1% O2).  Supernatants were 
harvested at 72 hrs post-infection.  Inhibition of HIF-1α decreases MMP-1 secretion in M.tb-infected 
MDMs in normoxia but this result does not reach statistical significance.  HIF-1α chemical inhibition 
causes a dose-dependent decrease in MMP-1 protein secretion in M.tb-infected MDMs incubated in 
hypoxic conditions.  Bars represent mean (+/- SD) of conditions in triplicate and are representative of 
at least 2 independent experiments.  **p<0.01, *p<0.05  
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HIF-1α western blot demonstrated almost complete knockdown of HIF-1α protein in M.tb 
infected MDMs in normoxia and significant, although not complete knockdown in hypoxia 
(Figure 53B).  Consistent with the gene expression data, transfection of MDMs with non-
targeting siRNA had no impact on HIF-1α levels.   
Next, I assessed whether inhibiting HIF-1α using HIF-1α siRNA affected MMP-1 activity.    
HIF-1α siRNA caused a significant decrease in MMP-1 expression at the level of both gene 
expression and protein secretion.  In normoxia, although a decline in MMP-1 mRNA levels 
was seen, this result did not reach statistical significance (Figure 54A).  There was however a 
significant decrease in MMP-1 protein seen in normoxia in cells treated with HIF-1α siRNA 
(Figure 54B; p<0.01).  In hypoxia, HIF-1α inhibition with HIF-1α siRNA caused a highly 
significant decrease in MMP-1 activity at the level of gene expression and protein secretion 
(p<0.001).   
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Figure 53:  HIF-1α knockdown and effect on HIF-1α in M.tb-infected MDMs incubated in normoxia 
and hypoxia.  MDMs were transiently transfected with either NT or HIF-1α siRNA (25nM).  Cells 
were infected with M.tb (MOI=1) and incubated in either normoxia (21% O2) or hypoxia (1% O2, 
hypoxia workstation).  (A)  HIF-1α siRNA but not NT siRNA causes a significant decrease in HIF-1α 
gene expression in M.tb-infected MDMs in normoxia and hypoxia at 4 hrs post-infection (p<0.001).  
(B)  HIF-1α western blot at 8 hrs post-infection shows HIF-1α siRNA causes complete knockdown of 
HIF-1α protein in M.tb-infected MDMs in normoxia.  A marked decrease occurs in hypoxia.  No 
change in HIF-1α protein is seen with NT siRNA. Bars represent mean (+/- SD) of conditions in 
triplicate and are representative of at least 2 independent experiments.  Representative western 
blot from 2 independent experiments  
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Figure 54:  Effect of HIF-1α siRNA on MMP-1 gene expression and protein secretion.  MDMs were 
transfected with either HIF-1α siRNA or NT siRNA (25nM).  Cells were infected with M.tb (MOI=1) 
and incubated in normoxia (21% O2) or hypoxia (1% O2).  MMP-1 gene expression was analysed 24 
hrs post-infection and MMP-1 protein secretion at 48 hrs by Luminex.  (A)  HIF-1α siRNA causes a 
significant decrease in MMP-1 gene expression from M.tb-infected MDMs in hypoxia (p<0.001).  (B)  
HIF-1α knockdown significantly decreases MMP-1 protein secretion in M.tb-infected cells in both 
normoxia and hypoxia (p<0.01).  No change in MMP-1 gene expression or protein secretion is seen 
with NT siRNA.  Bars represent mean (+/- SD) of conditions in triplicate and are representative of at 
least 2 independent experiments.   
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HIF-1α siRNA decreases MMP-1 secretion in A549 stimulated with CoMTb in 
hypoxia 
I was interested to investigate whether HIF-1α siRNA might influence MMP-1 activity in 
respiratory epithelial cells given the findings described in chapter 5 and the results of HIF-1 
western blotting.  Previous work done by our group has demonstrated successful 
transfection of A549 and NHBE cells using Fugene 6 and Dharmacon smartpool siRNA.  I 
therefore transfected A549 cells with HIF-1α using our previously validated protocol and 
subsequently stimulated them with CoMTb (1:5 concentration).  HIF-1α siRNA caused a 44% 
decrease in MMP-1 protein secretion compared to control, non-transfected cells or NT 
siRNA (Figure 55).  It would have been important to demonstrate evidence of HIF-1α 
knockdown, as I had done with my experiments with MDMs, but this was not possible to 
due to time constraints.  These experiments would have also been improved by assessed 
the effect of HIF-1α siRNA on MMP-1 gene expression. 
Collectively the results of the chemical inhibitor and RNA interference experiments 
demonstrate evidence of HIF-1α signalling pathways driving MMP-1 activity during TB 
infection. 
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Figure 55:  Effect of HIF-1α siRNA on MMP-1 secretion in A549 cells.  A549 cells were transfected 
with either HIF-1α siRNA or NT siRNA.  Cells were stimulated with CoMTb (1:5) and incubated in 
either normoxia (21% O2) or hypoxia (1% O2).  Supernatants were harvested at 48hrs post CoMTb 
stimulation and measured by ELISA.  HIF-1α siRNA induces a 44% decrease in MMP-1 protein 
secretion (p<0.001) compared to untransfected cells in cells incubated in hypoxia.  HIF-1α siRNA has 
no effect on cells incubated at 21% O2.  Bars represent mean (+/- SD) of conditions in triplicate and 
are representative of at least 2 independent experiments.  
  Normoxia                 Hypoxia 
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Lung biopsies from patients with TB demonstrate increased HIF-1α 
immunoreactivity compared to controls 
The finding of M.tb infection promoting HIF-1α stabilisation in vitro then led me to 
investigate whether this finding was also present in vivo.  Analysis was performed by 
Professor Francesco Mauri and Dr Tyler Lloyd within the Department of Histopathology, 
Imperial College NHS Trust.  Initial optimisation of the technique was first performed on a 
positive control sample from a patient with ovarian cancer and then adapted for lung tissue.  
Immunohistochemistry from six control samples demonstrated no evidence of HIF-1α 
staining (Figure 56A).  By contrast, samples from all six patients with a confirmed diagnosis 
of pulmonary M.tb demonstrated positive staining for HIF-1α within and around TB 
granulomas (Figure 56B). Of note, HIF-1α staining was seen within macrophages and 
multinucleated giant cells (Figure 57).  
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Figure 56:  HIF-1α immunohistochemistry.  Immunohistochemistry was performed on lung biopsy 
samples from 6 controls and 6 patients with a confirmed microbiological diagnosis of TB.  (A)  
Samples from control patients, 2 representative images are shown, do not demonstrate 
immunoreactivity for HIF-1α.  (B)  TB patients demonstrate positive immunohistochemical staining 
for HIF-1α within TB granulomas (brown). No HIF-1α staining is seen in regions of caseous necrosis.  
Granulomas from 4 individual patients are shown (i-iv).  Magnification x100 
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Figure 57:  HIF-1α localisation in human TB granulomas.  (A)  Positive HIF-1α staining is prominent 
within macrophages and multinucleated giant cells (arrows).  (B)  High powered images of 
multinucleated giant cell from image A. 
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Discussion 
 
 
My results demonstrate a pivotal role of HIF-1α-dependent signalling pathways in driving 
MMP-1 expression during M.tb infection.  I have shown for the first time that M.tb infection 
causes HIF-1α stabilisation even in normoxia.  In addition, my results demonstrate that HIF-
1α inhibition decreases MMP-1 gene expression and protein secretion.  Finally, 
immunohistochemistry reveals evidence of HIF-1α in patient samples.   
 
HIF stabilisation due to infective organisms has been described in several studies [195, 196] 
but this is the first time that M.tb-driven HIF-1α stabilisation has been described.  I found 
that HIF-1α stabilisation occurred following infection with both M.tb and BCG indicating that 
HIF activation might be a generalised feature of mycobacterial diseases.  It would have been 
interesting to investigate HIF stabilisation during other mycobacterial infections to assess 
this further.  Additionally, it would be interesting to assess if HIF levels differed in clinical 
strains compared to laboratory strains.  I performed this experiment twice and although 
subtle, on each occasion the amount of HIF-1α appeared slightly less in BCG compared to 
M.tb infection.  Cells were infected with equivalent optical densities of TB cultures but it 
would have been useful to perform colony counting to ensure that CFU’s were equal 
between the two conditions.  Additionally, measurement of HIF-1α protein levels by ELISA 
(R&D) might have been useful.  I had intended to stimulate the cells with both ESAT-6 and 
CFP-10 but the marginal difference in HIF-1α between M.tb and BCG and subsequent 
bacterial contamination of ESAT-6 and CFP-10 cultures meant I did not pursue this line of 
investigation.   
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My investigation of chemokines, cytokines and growth factors responses during M.tb 
infection and in response to DMOG pre-incubation reveal  factors that might be driving HIF 
accumulation (Appendix 2)  Of note, the cytokines IL-1β and TNFα and have all been shown 
to be key drivers of HIF-1α stabilisation in other infections and inflammatory conditions 
[80].  Interestingly, although TNF-α increases in response to M.tb infection, no significant 
change occurs with DMOG indicating that TNFα is not responsible for the increased HIF-1α 
stabilisation (Figure49A).  The results of the Luminex 30-plex examined the effect of DMOG 
on key cytokines, chemokines and growth factors in M.tb-infected MDMs but this analysis 
requires repetition using cells incubated in hypoxia.  Additionally, analysis of respiratory 
epithelial cells should be performed to assess M.tb networking effects. The different 
responses in MMP-3 and MMP-7 secretion in M.tb-infected MDMs (Figure 36 and 37) in 
response to DMOG and 1% O2 for example, might be driven by altered cytokine and 
chemokine profiles 
 
I have shown that hypoxia and HIF-1α-dependent pathways regulate MMP-1 gene 
expression and protein secretion.  My results are consistent with data from the hypoxic 
rheumatoid synovium where hypoxia and HIF-1α have been shown to regulate MMP-driven 
tissue destruction in hypoxic fibroblasts [174, 197].  The advantage of assessment of the 
rheumatoid synovium is the ability to directly measure pO2 levels to confirm the presence of 
hypoxia from cells taken from this region.  It would be useful to evaluate if HIF-1α responses 
in alveolar macrophages, which might be considered comparatively hypoxic, differed to 
peripheral blood MDMs in response to M.tb infection.   
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I found no significant evidence of HIF-2α activity during my investigations.  This contrasts 
with studies in osteoarthritic cartilage destruction where HIF-2 regulated MMP activity 
[198].  My experiments did not include a positive control for HIF-2α which might have 
improved the experiment but overall, I did not find any significant evidence of HIF-2α 
activity during M.tb infection in either normoxia or hypoxia.  One possible explanation for 
this is the level of hypoxia used.  Fang et al. for example, examined HIF-1 and HIF-2 activity 
in primary MDMs using O2 levels of 0.1%  [199].  Improvements to my assessment of HIF-2α 
activity would have included using alternative HIF-2α antibodies and measurement of HIF-
2α mRNA levels in response to M.tb infection in normoxia and hypoxia.   
My investigation of regulation of HIF-1α during M.tb infection focussed principally on the 
prolyl hydroxylases.  The PHDs have been shown  be key regulators of HIF-1α-mediated 
neutrophil survival in response to hypoxia [88].  Of note, PHD3 is strongly induced in 
response to infective and inflammatory stimuli and is essential for hypoxic regulation of 
neutrophilic regulation of inflammation in humans and mice [200].  My investigation of PHD 
activity was performed in human monocyte-derived macrophages and demonstrated 
changes in PHD activity in response to both M.tb infection and to hypoxia compared to 
control cells. These findings demonstrate changes in the PHD’s protein levels but do not 
specifically address which features of M.tb infection might be driving HIF-1α accumulation.  
Maximal induction of the PHDs occurs 24 hrs post-infection and indicates that the PHD 
response might occur in response to M.tb-induced HIF-1α stabilisation.  Since HIF-1α 
degradation is principally controlled by the PHDs, inhibition of the individual PHDs and 
examining the effect on HIF-1α stabilisation might provide further insights into the 
mechanism by which this occurs. 
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My study did not investigate the effect of HIF-1α inhibition on NFκB and given the inter-
dependent role of these two transcription factors, it is likely that HIF-1α siRNA would have 
affected NFκB activity.  Future experiments would include measuring NFκB activity in M.tb 
infected MDMs treated with HIF-1α siRNA focussing on the individual NFκB subunits. 
 
Examination of patient lung specimens showed evidence of HIF-1α expression in samples 
from TB patients.  HIF-1α localised to macrophages and multinucleated giant cells, immune 
cells also known to be key sources of MMPs [46, 201].  My finding contrasts with HIF 
immunoreactivity in other infections where HIF-1α is found predominantly in neutrophils 
[202].   
 
Collectively, my data demonstrates evidence of HIF-1α activation in vitro and in vivo during 
M.tb infection.  My work is complimented by two recent studies which demonstrate 
evidence of HIF-1 activation in response to TB infection. Whole-blood gene expression 
profiling shows that HIF-1 is up-regulated in TB patients compared to controls but not 
compared to patients with sarcoidosis[203].  In the zebrafish model of TB infection, 
expression of the HIF-1 target gene PHD3, is seen in response to early infection in 
leucocytes.  Furthermore, stabilisation of HIF-1α signalling with DMOG causes decreased 
Mm burden [110].    Manipulation of the HIF pathway therefore represents a potential 
target for future therapeutics against TB. 
 
In conclusion, I have shown that M.tb-infection causes HIF-1α stabilisation even in the 
absence of hypoxia and HIF-1α signalling pathways regulate MMP-1 activity in TB infection. 
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CHAPTER 7:  CONCLUSIONS 
In this first detailed study of hypoxia in human tuberculosis, I have demonstrated the 
presence of severe hypoxia within areas of lung consolidation and around pulmonary 
cavities. Hypoxia increases gene expression and secretion of MMP-1, a key collagenase that 
causes tissue destruction and immunopathology in pulmonary TB. In addition, M.tb 
infection directly drives HIF-1α accumulation, which is further increased in hypoxia to 
synergistically activate immunopathogenic signalling pathways.  
 
My clinical study demonstrated hypoxia in human TB using [18F]FMISO PET-CT scanning for 
the first time in patients with an infectious disease. Hypoxia has not previously been found 
in man although reported in diverse animal models of TB, all of which have somewhat 
different pathology to human disease [106-108]. Until now, the investigation of hypoxia and 
TB has focussed primarily on pathogen responses to oxygen restriction, controlled by the 
two-component regulation system dosR/dosS (or dosR regulon) [204-206]. Direct 
assessment of hypoxia in vivo typically involves the utilization of polagraphic oxygen 
electrodes which can provide absolute measurements of tissue oxygenation at the sampling 
location. However, this procedure is technically demanding and suffers from a number of 
limitations including invasiveness, high susceptibility to sampling errors and the fact that 
only easily accessible locations can be interrogated [207]. [18F]FMISO PET-CT scans define 
regions of hypoxia without the need for invasive probes, as previously shown in tumour 
biology [151, 208] and cerebral ischaemia [209, 210].  Since high tracer uptake, as quantified 
by standardized uptake value (SUV) or TBR, may represent high tracer delivery to a region of 
interest rather than tracer trapping under hypoxic conditions, I determined the influx rate of 
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[18F]FMISO into the trapped tissue compartment (Ki) so as to more specifically identify 
tissue hypoxia. The maximum TB lesion Ki value (0.005 min-1) is equal to the highest Ki value 
in an [18F]FMISO study of head and neck cancer by Wang et al [167], which puts the degree 
of hypoxia in this study into context.  My protocol included the measurement of [18F]FMISO 
levels in peripheral blood, thus providing an internal control for any possible movement 
artefact. In addition, the finding of stable or increasing Ki values in lung lesions compared to 
blood values, which declined over time, further supports the finding of tracer trapping 
demonstrated by Ki measurements. My data reveals that heterogeneity exists both within 
individual TB lesions and between lesions, consistent with the emerging concept of multiple 
TB microenvironments existing within a single patient [168]. 
 
The finding of hypoxia within lung lesions directed my cellular experiments. MMP-1 gene 
expression and secretion were significantly increased and was functionally active in M.tb-
infected human macrophages in hypoxia compared to normoxia and there was no 
compensatory increase in the inhibitor TIMP-1. Thus, hypoxia is a further driver to the pro-
inflammatory tissue destructive phenotype characteristic of TB, where disease is more due 
to host response than the direct effects of mycobacteria. Consistent with this, hypoxia had 
no effect on mycobacterial growth in my experiments. 
 
Hypoxia-dependent, monocyte driven up-regulation of MMP-1 gene expression in human 
respiratory epithelial cells required the transcription factor NF-κB. NF-κB and HIF-1α interact 
to regulate innate immunity and inflammation.  NF-κB critically regulates MMP activity in TB 
infection of the central nervous system [211] but has not been investigated in the context of 
hypoxia-driven MMP expression in TB infection. NF-κB is both directly affected by hypoxia 
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and modulates HIF-1α expression as well as being regulated by prolyl hydroxylases.  The 
precise nature of the interaction between HIF-1α, prolyl hydroxylases and NF-κB in TB 
requires further interrogation and is currently being investigated by the JSF group. 
 
M.tb caused significant accumulation of HIF-1α in direct infection and via a networking 
effect even in the absence of hypoxia, with a synergistic increase in HIF-1α expression in 
hypoxia or following treatment with DMOG. To my knowledge, this is the first time that 
hypoxia-independent HIF-1α stabilization has been observed in any mycobacterial infection, 
although such an effect has been reported in other specific infections [195, 196, 212].   
 
I have now shown expression of HIF-1α within TB granulomas localizing the activity to the 
host inflammatory response and in particular to epithelioid macrophages and multi-nucleate 
giant cells, which we have previously shown are key in secretion of a number of MMPs [183, 
201]. I have demonstrated using both the chemical inhibitor LW6 and targeted siRNA that HIF-1α 
regulates MMP-1 expression in TB. Consistent with my data in macrophages and respiratory 
epithelial cells in TB, hypoxia and HIF-1α have been reported to regulate MMP-driven tissue 
destruction in hypoxic fibroblasts within rheumatoid synovium [174].  
 
In summary, I show for the first time that human TB lesions are severely hypoxic. Hypoxia increases 
MMP-1 gene expression and secretion during M.tb infection, and M.tb infection independently 
increases HIF-1α activity even under conditions of normoxia. Taken together, my data suggests that 
M.tb drives a HIF-1α-dependent proinflammatory tissue destructive cascade that may lead to 
cavitation and promote disease transmission, representing a potential future therapeutic target in 
the era of increasing drug resistant TB. 
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CHAPTER 8: FUTURE WORK 
My study was able to confirm the presence of severe hypoxia during M.tb infection but 
since only a single scan was performed, was not able to assess if the extent of hypoxia 
changed over time or in response to treatment.  Future studies might include follow-up 
scans after commencing treatment e.g. 8 weeks to see if this impacted on the extent of 
hypoxia.  Such a study ideally would involve scanning patients who were treatment naïve 
with repeat scans being correlated to clinical and microbiological response.   
 
 [18F]FMISO PET-CT scans demonstrated severe hypoxia within active tuberculosis infection 
but the technique currently does not allow the quantification of level of oxygen within these 
lesions.  It is quite possible that hypoxia exists within TB lesions that cannot be detected by 
[18F]FMISO, i.e. greater than 2% O2 but less than the 9-14% found in normal healthy lung 
tissue.  Findings from some of patients demonstrated uptake of tracer within axillary lymph 
nodes (patients 2, 3 and 5) indicating that severe hypoxia might exist within lymph nodes.  
At present, it is not possible to confirm this finding using [18F]FMISO PET-CT scan as the 
method has not been validated for lymph node disease.  One possible way to overcome this 
would be to directly insert a pO2 Eppendorf into accessible lymph nodes to measure tissue 
pO2.  The advantage of this method is that the probe might also be able to assess areas of 
relative hypoxia i.e. 2-10% pO2. 
 
My results from both respiratory epithelial cells and macrophages revealed an unexpected 
effect of 10% oxygen on MMP-1 secretion.  Although the results did not reach statistical 
significance in NHBE cells, incubating cells at 10% oxygen consistently results in lower levels 
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of MMP-1 protein compared to cells incubated at 21% oxygen.  It is arguable that 10% 
oxygen more closely resembles physiological oxygen levels within the lungs but this would 
only be true of healthy lungs because until now, oxygen levels in M.tb infected lungs has not 
been explored.  It is possible to postulate that cellular changes occur at 10% O2, such as the 
stabilising of pH seen in my macrophage experiments, which act to reduce the tissue 
destructive effect of MMPs.  Possible future work in this area might include analysis of 
secreted chemokines and cytokines in response to varying oxygen concentrations as well 
assessing the effects on HIF and the PHDs.  It would also be interesting to measure TIMP 
levels to see if these are altered by the degree of hypoxia.  These findings might provide 
insights into how the pro-inflammatory profile of M.tb infection might be manipulated to 
lessen the tissue destructive effects of M.tb infection. 
 
The results of my study demonstrate that both HIF and NF-κB signalling pathways are 
involved in M.tb-driven MMP secretion.  Since the activity of HIF and NF-κB are intimately 
related future work should involve more in depth exploration of how their activity is 
regulated during M.tb infection.  I demonstrated that M.tb infection drives HIF-1α 
stabilisation but did not explore the effect of the M.tb infection on NF-κB activity in either 
normoxia or hypoxia.  Such investigation could be performed using Trans-Am kits to initially 
assess the effect of M.tb infection on NF-κB subunits in normoxia and hypoxia.  The effect of 
hypoxia on NF-κB could be further evaluated by examining the effect on NFκB gene 
expression.  Further investigation would include assessing the effect of HIF-1α inhibition on 
NF-κB expression using siRNA and conversely exploring if NF-κB inhibition affects HIF-1α 
activity during M.tb infection. 
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My investigation of the activity of the prolyl hydroxylases during M.tb infection and in 
response to hypoxia (1% O2) revealed a number of interesting findings.  I found differences 
between control MDMs and M.tb-infected cells in normoxia and augmented changes in 
hypoxia.  In particular, PHD 2 protein increased significantly.   My findings contrast with the 
effect of hypoxia in neutrophils where PHD 3 activity has been shown to critically regulate 
neutrophil function [200].  Furthermore, my results contrast with changes in PHD expression 
in pro-inflammatory macrophages where PHD3-encoding EGLN3 gene is specifically 
expressed by in vitro-generated proinflammatory M1(GM-CSF) human macrophages at the 
mRNA and protein level [213].   In order to explore these responses further, PHD mRNA 
kinetics should be measured to examine the effect of M.tb infection and hypoxia on PHD 
gene expression.  This could then be investigated further by inhibition of the PHDs using 
both chemical inhibitors and siRNA to assess the effect of specific PHD inhibition on MMP 
activity. 
 
The finding of severe hypoxia during active TB infection and augmentation of the host 
proinflammatory response to M.tb infection has implications for the other host immune 
cells.  Work by other members of the JSF group has already commenced examining the 
effect of hypoxia on neutrophils and apoptosis during M.tb infection.  Preliminary data I was 
involved with also indicates that MMP-10, a stromolysin implicated in cell migration is 
upregulated in hypoxia in M.tb-infected monocytes.  This preliminary data is included in a 
Fellowship application by the JSF group. 
 
??????????????????? ??? 
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Ultimately, the effect of hypoxia and HIF represents a potential future avenue for the 
development of new therapies and treatment strategies aimed at reducing host 
inflammatory tissue destruction.
Figure 58:  Schematic diagram of postulated mechanism by which hypoxia modulates MMP 
activity during TB infection.
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APPENDIX 1:  Abbreviations 
A549  adenocarcinoma cell line 
Ab  antibody 
BCG  Bacille Calmette-Guèrin (vaccine) 
BSA  bovine serum albumin 
CoMTb conditioned media from monocytes stimulated with M.tb 
DMOG  dimethyloxalylglycine 
ECM  extracellular matrix 
FCS  fetal calf serum 
GAS  group A streptococcus 
HBSS  Hank’s balanced salt solution 
HIF  hypoxia inducible factor 
HIV  Human Immunodeficiency Virus 
HRE  hypoxia responsive element 
HRP  horseradish peroxidise 
M.tb  Mycobacterium tuberculosis 
M-CSF  monocyte colony stimulating factor 
MDM  monocyte-derived macrophage 
MDR  multi-drug resistant 
MMP  matrix metalloproteinase 
MOI  multiplicity of infection 
M.tb  Mycobacterium tuberculosis 
NHBE  normal human bronchial epithelial cell 
OD  optical density 
PBS  phosphate-buffered saline 
PHD  prolyl hydroxylase 
RNA  ribonucleic acid 
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RT  room temperature 
RT-PCR real-time polymerase chain reaction 
SDS  sodium dodecylsulphate 
siRNA  small interfering ribonucleic acid 
TF   transcription factor 
TB  tuberculosis 
TB supp tuberculosis supernatant 
TIMP  tissue inhibitor of metalloproteinase 
TMB  tetramethylbenzidine 
uv-killed ultraviolet killed 
VHL  von Hipple Lindau protein 
XDR  extensively drug resistant 
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APPENDIX 2:  Results of 30-plex Luminex analysis 
 
MDMs pre-incubated with DMOG (0.25mM) and infected with M.tb (MOI=1). Supernatants were harvested 72 
hrs post-infection and analysed by Luminex.   Representative data from 2 independent experiments performed 
in triplicate.  *p<0.05; **p<0.01; ***p<0.001 
 215 
 
 
 
 
 
 
 
 
 
 
 
 
 216 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 217 
 
 
 
 
 
 
 
 
 218 
 
 
 
 
 
 219 
 
APPENDIX 3:  PUBLICATIONS AND PRESENTATIONS 
Presentations and awards 
 
Severe hypoxia exists within pulmonary tuberculosis lesions and augments matrix 
metalloproteinase-mediated immunopathology 
Moerida Belton*, Sara Brilha, Tim Fryer, Kuldip Nijran, Paul T. Elkington, Jon S. Friedland 
British Thoracic Society Winter Meeting 2013. Oral presentation 
Winner of BTS/BLF/BALR Early Career Investigator Prize 
 
Hypoxia Increases Matrix Metalloproteinase-Driven Immunopathology During Tuberculosis 
Infection: Evidence From In Vitro Studies And Patients With Active Pulmonary Disease 
M.Belton*, P. Elkington, K. Nijran, N. Patel, L. Tezera, T. Fryer, A. Al-Nahhas, J.S. Friedland 
American Thoracic Society 2013 International Conference, Philadelphia.  Oral presentation 
American Thoracic Society Abstract Scholarship 
British Lung Foundation Travel Award 
 
Cellular oxygen levels modulate tuberculosis immunopathology  
Moerida Belton*, Marcin Dembek, Paul Elkington, Jon S. Friedland 
British Infection Association 15th Annual Meeting 2012, Oral presentation 
Winner British Infection Association Best Original Paper 
Hypoxia modulates tuberculosis immunopathology 
Moerida Belton*, Paul Elkington, Marcin Dembek, Jon S. Friedland 
Annual Academic Trainee Event 2012, Imperial College London 
1st Prize for poster 
 
 
 
 220 
 
Tissue oxygen levels modulate tuberculosis immunopathology 
Moerida Belton*, Marcin Dembek, Paul Elkington Jon. S. Friedland 
22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2012. 
Oral presentation 
 
Hypoxia modulates tuberculosis immunopathology 
Moerida Belton*, Paul Elkington, Marcin Dembek, Jon S. Friedland 
Keystone Symposia 2012 Alberta Canada, Advances in Hypoxic Signalling: From Bench to 
Bedside.  Poster presentation 
 
Papers 
Hypoxia and HIF-1α-dependent MMP-1 secretion in human pulmonary tuberculosis 
Moerida Belton*, Sara Brilha, Roido Manavaki , Francesco Mauri, Kuldip Nijran, Young T. 
Hong, Neva Patel, Marcin Dembek, Liku Tezera, Justin Green, Rachel Moores, Franklin 
Aigbirhio, Adil Al-Nahhas, Tim Fryer, Paul T. Elkington, Jon S. Friedland 
Submitted 
 
